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OG2 is a murine IgG2b monoclonal antibody that recognises the three
mmon allelic forms of placental alkaline phosphatase (PLAP) equally
11. In addition NDOG2 recognises a second antigen of a similar
lecular weight to the PLAP subunit (67,000 Daltons) which has no
osphatase activity.
e distribution of the NDOG2 determinant in normal tissue and in the
-mmon gynaecological malignancies was assessed using an indirect
-munoperoxidase staining technique. Positive reactive staining was
in ngrmal fallopian tube, endometrial and endocervical columnar
itheliurn,thymus and lung as well as in term placentae. In addition
sitive staining was seen in 11 from 44 benign and in 36 from 56
lignant ovarian tumours. In both cases the serous histological
-owed the strongest reactive staining and primary tumours showed a
degree of staining than their secondaries. Similarly 11 from
endometrial cancers and 5 from 12 cervical cancers showed reactive
aining with ND0G2.
o enzyme linked immunosorbent assays based on NDOG2 were developed.
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asured the total protein captured by ND0G2. 44 patients were
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tained by ultrasound scanning and computer aided tomography. False
results were most frequently due to masking of
mour uptake by areas of high background activity such as the liver
d aorta. False positive results were generated by the subtraction
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Ovarian cancer is the most commonly occurring gynaecological
malignancy in the U.K. (O.P.C.S. 1983) and because of its
intra-abdominal spread presents problems, both in its early
detection and in monitoring a patient's response to therapy.
No reliable screening test exists for this disease but a
number of methods have been employed to monitor the patient's
response to therapy:
1) A 'second look' procedure (laparoscopy or laparotomy).
2) Biochemical serum markers.
3) An imaging technique such as ultrasound scanning (U.S.S.),
Xray computed tomography (C.T.) or radioimmunoscintigraphy
(R.I.S.).
Second look procedures whilst giving accurate information about
the state of the disease have a morbidity and mortality not
associated with the other two groups. In addition a second
look laparotomy can appreciably reduce the quality of life
remaining for those patients with residual disease. The
other two methods, while relatively free of side effects, do
give false positive and negative results. C.T. in particular,
but also U.S.S., suffers from relatively poor sensitivity and
specificity when applied to small, solid intra-abdominal
tumour deposits, after primary surgery. In the search for an
improved imaging technique antibodies have been used to
target radionuclides to tumour deposits (radioimmunoscinti¬
graphy). Obviously the choice of antibody is crucial. The
first ideal would be an antibody that recognises a totally
tumour specific antigen without any cross reactivity with
normal tissues.
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The second ideal would be an antibody which recognises
only one epitope. This is achieved by monoclonal
antibodies which provide a single antibody preparation
with constant specificity. This contrasts with
polyclonal antisera which can cross react unpredictably
with a variety of tissues (Lennox and Sikora 1982).
This constant specificity gives monoclonal antibodies
theoretical advantages over polyclonal antisera when
used as the basis for serum assays to monitor a
particular biochemical serum tumour marker.
Unfortunately, in the case of epithelial ovarian cancer
no truly tumour specific antigen exists although over
40 tumour associated antigens have been described
(Umbach 1984). Placental alkaline phosphatase (P.L.A.P.)
is one such antigen, and has been reported in association
with a variety of tumours including ovarian carcinoma.
Apart from term placentae P.L.A.P. has been reported in
small quantities in the epithelium of the upper female
genital tract, thymus, lung and testis (Goldstein et
al 1982, Sunderland et al 1984, Davies et al 1985).
However, in the case of ovarian cancer, production of
P.L.A.P. by placenta and testis is obviously irrelevant
and as hysterectomy is usually performed during primary
surgery this source of the enzyme is effectively removed.
Production by the thymus is minute and it is the lung
that potentially offers the greatest problem in the use
of this antigen in monitoring patients with this disease.
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This thesis describes the use of a murine monoclonal
antibody, designated ND0G2, which recognises the three
common allelic forms of placental alkaline phosphatase
(P.L.A.P.) in ovarian cancer. NDOG2 has been used in
three ways:
a) To demonstrate immunohistologically the distribution
of P.L.A.P. in normal adult organs and its presence
on ovarian and certain other gynaecological tumours.
This is described in Chapter 3.
b) As the basis of a sensitive enzyme linked immuno¬
sorbent serum assay (E.L.I.S.A.) to assess the role of
P.L.A.P. as a biochemical marker in ovarian cancer.
The development of various assays and the predictive
value of P.L.A.P. in these tumours is described in
Chapter 4.
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c) 123-iodine ( I) labelled ND0G2 has been used in
the radioimmunodetection of both primary, metastatic








This chapter describes the incidence, aetiology and
pathology of ovarian cancer and discusses the problems
in management of patients with this disease. Various
biochemical tumour markers in ovarian cancer are
described and one"such marker, placental alkaline
phosphatase (PLAP) is discussed in detail. It is
acknowledged that at least two isoenzymes of alkaline
phosphatase are present in the human placenta but the
term PLAP, as used in this thesis, refers to the heat
stable, L-phenylalanine inhibitable isoenzyme.
1.2. Ovarian Carcinoma
1.2.1. Incidence and Mortality
The incidence of ovarian carcinoma has been increasing
this century and it is now the most commonly occuring
gynaecological cancer in England and Wales. Overall it
is the sixth commonest cancer in women (Table 1.1.) with
4,317 new cases reported in 1979, giving an incidence
of 17.1/100,000 (OPCS Monitor 1983). This incidence is
increasing in women 65 years of age and over, is constant
between the ages of 45 and 64 and falling in the 16 to 44
year age group (Cancer Statistics 1981). Chart 1.1. and
Table 1.2. show the age related incidence for ovarian
cancer (all types) in 1979.
Ovarian carcinomas alone are responsible for more deaths
than cervical and endometrial carcinomas together and




There are several theories as to the aetiology of ovarian
carcinoma:
a) "Incessant Ovulation"
The term "incessant ovulation" was first coined by Fathalla
(1971). He postulated that each ovulation caused minor
trauma to the serosal (epithelial) coat of the ovary which
is then exposed to high levels of oestrogen from the
follicular fluid. Stein and Allen (1942)'had already
shown, in animal experiments, that oestrogens injected into
the ovarian capsule causes proliferation of the epithelium.
Zajicek (1978) suggested that the trauma caused by ovulation
led to inclusions of surface epithelium in the stroma of
the ovary and that these could develop into ovarian cysts
and carcinomas.
Therefore, one would expect anything that reduces the number
of ovulations to protect against the subsequent development
of ovarian carcinoma. Thus, there is an inverse relation¬
ship between the number of pregnancies and ovarian carcinoma
(Joly et al 1974, Beral et al 1978, Cassagrande et al 1979),
and the oral contraceptive has also been shown to be
protective (Cassagrande et al 1979).
This theory could explain the present increase in incidence
of ovarian carcinoma i.e. the population at present at
risk, of developing ovarian carcinoma tended to have smaller




Talcum powder is similar to, and until recently was
frequently contaminated by asbestos, a known carcinogen
for serosal epithelium. It has been suggested that
talc can migrate to the ovary via the cervical canal,
uterine cavity and fallopian tube from the vagina or
vulva where it has been introduced by condoms, caps
or deodorants (Venter and Harralde 1979) 75% of ovarian
carcinomas were shown to contain talc particles in one
series (Henderson et al 1971) although no ovarian
carcinoma has ever been induced using talc in animal
experiments.
c) Oestrogens
Oestrogens have been shown to cause ovarian epithelial
hyperplasia in animals (Stein and Allen 1942) and the
association between breast, endometrial and ovarian
carcinomas have led some workers to implicate oestrogens
as a causative factor (Wynder et al 1969). In addition
obesity, which is known to cause hyperoestrogenism by
the conversion of androstenedione to oestrone by adipose
tissue (Edman and McDonald 1978), is associated with an
increased risk of the development of ovarian carcinoma
(Cassagrande et al 1979).
d) Family History
In a few instances a strong family history can be
obtained for ovarian carcinoma (Luraine and Piver 1979,
Franceschi et al 1982, Piver 1983).
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e) Viral Infections
Childhood viral infections such as mumps, measles,
chickenpox and rubella are thought to be protective
against ovarian cancer (Newhouse et al 1972, West 1966)
but this may simply be due to a secondary effect on
ovulation rather than a protective effect of the virus
itself (Newhouse et al 1972). However, there is an
increased risk of ovarian carcinoma in patients who
have developed rubella infection between the ages of
12 and 18 when compared with those who developed the
illness before the menarche (McGowan et al 1979).
f) Coffee
Heavy coffee drinkers have been shown to have a slightly
increased risk of ovarian carcinoma (Hartage 1982).
However, this is unlikely to be a major cause of ovarian
carcinoma worldwide.
g) Association with other conditions
Carcinoma of the ovary can be associated with certain
inerited conditions such as Peutz-Jeghers syndrome
(familial intestinal polyposis) (Dozois et al 1970).
These tumours are usually granulosa cell tumours and
have a distinctive pattern suggesting that a mutant gene
is responsible for both conditions (Scully 1970).
h) Conclusions
The true aetiology of ovarian cancer is uncertain, however,
ovulation with the formation of inclusions of surface
epithelium in the stroma of the ovary gives a starting
point for the development of ovarian epithelial tumours.
However, not every woman who ovulates develops ovarian
cancer and the protective effect of pregnancy is out of
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all proportion to the number of ovulations prevented.
It is likely, therefore, that there is some external
carcinogen. Talc has been a favourite candidate for
many years, although the fact that it does not induce
ovarian cancers in animal models must cast doubt on its
role. Possible contamination with asbestos may have
caused some ovarian cancers in the past. It should also
be noted that talc while chemically similar to asbestos
exists as rounded and not pointed particles, and so does
not have "asbestos" irritant effect on epithelial cells.
The effect of oestrogen, unopposed by progestogens, on
the inclusion cysts would seem to be a more likely
cause for malignant change, but the evidence for this
is not conclusive.
1.2.3 Normal embryological development of the
gynaecological organs
The fallopian tube, uterus and cervix all arise from the
paramesonephric (Mullerian) duct. This structure appears
as an invagination of the coelomic mesothelium into the
mesenchyme on the lateral surface of the upper part of
the urogenital ridge at six weeks gestation. The parameso¬
nephric ducts are bilateral and, as they pass caudally,
fuse to form the primitive uterus and cervix, the unfused
portions forming the fallopian tubes. The walls of these
structures are formed from the surrounding mesenchyme but
the epithelium of the fallopian tube, endometrium and
cervical columnar epithelium is derived from the mullerian
duct epithelium (Janowski and Paramanandhan 1973).
The caudal tip of the fused mullerian ducts will form the
upper two-thirds of the vagina; the lower third and vulva
are formed from the urogenital sinus (Craigmyle and
Presley 1979).
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The ovaries arise as an area of thickening of the mesoderm
of the genital ridges and are covered by a layer of
coelomic mesothelium known as the germinal epithelium
(Willis 1958). This latter is a misnomer as the germ cells
arise from the area of the yolk sac and migrate to the
ovary. The germinal epithelium becomes the serosa of the
ovary and the ovarian stroma develops from the mesoderm of
the genital ridges (Craigmyle and Thomas 1979).
Thus, the ovarian serosa, fallopian tube, endometrial and
cervical columnar epithelium all arise from the same area
embryologically and are all of mesodermal origin, whereas
the cervical and vaginal squamous epithelium is thought to
migrate cephalad from the urogenital sinus and are
eclodermal in origin.
1.2.4 Pathology, mode of metastases and presentation of
epithelial ovarian cancer
Epithelial ovarian carcinoma make up 80-90% of all ovarian
malignancies. Sex cord/stroma and germ cell tumours make
up the remaining 10-20% but these tumour groups tend to
respond well to therapy and it is the epithelial cancers
that contribute to the high mortality associated with
this disease.
Epithelial tumours are so called because they arise from
the serosal coat of the ovary which itself is derived from
the germinal epithelium (Janovski and Paramanandhan 1973).
There are three common types of epithelial ovarian tumours.
Serous tumours have a cell type similar to fallopian tube
epithelium, mucinous tumour cells are similar to cervical
columnar epithelium and endometroid tumour cells have a
similar pattern to that of endometrium.
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Ovarian cancer spreads predominantly by the shedding of
cells by the primary tumour. The pumping action of the
diaphragm causes free floating tumour cells to move from
the pelvis through the peritoneal cavity with a particular
propensity for collecting in the omentum (Pemberton 1940)
and right subdiaphragmatic area (the Leinorenal ligament
tends to stop cells reaching the left hemidiaphragm)
(Bagley and Piver 1983).
Lymphatic spread to the pelvic (Musumeci 199a) and aortic
nodes (Knapp and Friedman 1974) is relatively common and
in the latter case can be present in those patients who
would otherwise be classified as having Stage 1 disease
only.
Bloodborne spread is mainly to liver and lung, occurring
by definition in only late (Stage 4) disease.
Because of this propensity for intra-abdominal metastasis
a patient with ovarian carcinoma frequently presents with
advanced disease, the symptoms of early and even moderately
advanced disease tending to be non-specific and vague.
The most common presenting symptoms are abdominal distension
and bloating (44%) non-specific digestive abnormalities
(38%) pelvic discomfort (33%) and abnormal vaginal bleeding
(13%) (Piver 1976). Many of these symptoms e.g. obvious
abdominal distenstion are only present with advanced disease.
1.2.5 Problems in the manaqment of patients with ovarian
cancer
i) Screening
The ideal way of managing patients with this disease is
to diagnose the tumour before it has metastasised. A
number of screening tests have been devised:
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a) Routine vaginal examination
It has been estimated that only 1 in 10,000 tumours will
be detected in this manner and it is sobering to realise
that a tumour of 1cm diameter would contain in the region
of 1 billion cancer cells. Tumours of this size are
virtually impossible to palpate. 95% of ovarian malignancies
however are 5cm or more in diameter and the finding of an
ovarian mass of this size warrants further investigation,
particularly if there is also a contralateral ovarian mass.
b) Culdocentesis
The instillation, aspiration and cytological examination of
saline from the pouch of Douglas has been proposed as a
screening test for this disease (Funkhaiser et al 1975)
but the results have been disappointing and the procedure
is unacceptable to a large number of women.
c) Imaging techniques
Ultrasound scanning (U.S.S.) and computerised axial
tomography (C.T.) have both been postulated as imaging
techniques.
C.T. is expensive (C.T. scanners cost upwards of £500,000),
time consuming, carries a radiation hazard and presents
certain difficulties in interpretation of images both in
the obese and very thin patient. In addition previous
pelvic surgery can also confuse the issue. U.S.S. is less
time consuming and does not have the other disadvantages
of C.T., but will not detect solid masses of less than 2cm
diameter. In addition, the differentiation between benign
ovarian tumours, loops of bowel, hydrosalpinges and
endometriosis from ovarian cancer is difficult, depending
very much on the skill of the individual operator.
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Radioimmunoscintigraphy offers potential in the detection
of small intra-abdominal tumours and this will be
discussed later in this thesis.
d) Laparoscopy and Laparotomy
These are unacceptable screening methods but have a role
in the management of patients with established ovarian
cancer.
ii) Management
The ideal scheme of treatment for a patient with
epithelial ovarian cancer includes:
a) A thorough and adequate staging procedure (the FIGO
classification for staging ovarian carcinomas is summarised
in Table 1.3). This will involve, where appropriate,
cytological examination of any ascites or of peritoneal
washings and scrapings, from the subdiaphragm; histological
examination of omentum and, if there is no obvious extra
ovarian spread, of peritoneal biopsies and of the para¬
aortic nodes.
b) Cytoreductive surgery, including total abdominal
hysterectomy, bilateral salpingo-oophorectomy and
omentectomy, aiming to remove if possible all macroscopic
tumour. In the event that this is not feasible then to
leave deposits of less than 2cm diameter (Piver 1983).
c) Chemotherapy or radiotherapy for all patients with
greater than Stage la(i) tumours.
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The problem then arises as to how to monitor the patient's
response to therapy. Ovarian cancer predominatnly
metastasises intra-abdominally and it is difficult to
detect small tumour deposits by physical examination alone.
Standard imaging techniques such as C.T. and U.S.S. have
limitations when applied to small solid intra-abdominal
tumour deposits. Therefore a 'second look' procedure is
performed, in some centres, on patients who are apparently
in remission after a course of treatment and in whom a
decision needs to be made about the need for further
chemotherapy.
Over the last 10-20 years possible biochemical tumour
markers, and more recently, radioimmunoscintigraphy have
been investigated to try and obviate the need for a second
look operation in these patients.
1.2.6 Tumour Markers in Epithelial Ovarian Cancer
A tumour marker can be defined as any identifiable
change in a body component indicitative of the presence of
cancer. Thus abnormal Papanicolaou smears could be
considered to be tumour markers for cervical carcinoma.
In the case of ovarian cancers biochemical tumour markers
have been used. An ideal markervould have to be produced
by the ovarian tumour in its earliest growth phase in
quantities to be easily measurable, would have a short
biological half life, decrease with successful treatment
and would accurately predict recurrence before this was
clinically demonstrable. Although in gynaecological practice
Beta subunit H.C.G. and alphafoetoprotein have proved
useful markers in trophoblastic neoplasia and embryonal
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sinus tumours respectively, no similar markers exist for
epithelial ovarian cancer. Indeed over 40 potential
tumour markers have been described (Umbach 1984) but none
have proved particularly useful in the management of this
disease.
Tumour markers can be divided into carcinoplacental fetal
or tumour associated antigens, and miscellaneous tumour
markers. P.L.A.P. is, in this classification, a carcino¬
placental antigen, but it will be considered separately
after describing other tumour markers most frequently used
in the management of patients with ovarian cancer.
1) Carcinoplacental Antigens;
Human Chorionic Gonadotrophin (H.C.G.)
This was first recognised as a tumour marker for tropho¬
blastic disease in 1956 (Coppelson 1981) and it is in
this group of tumours that it still has its greatest
use. H.C.G. has proved useful in the management of some
ovarian germ cell tumours such as choriocarcinoma,
embryonal carcinoma and some malignant teratomas
(Newlands 1982, Piver 1983). In epithelial ovarian
cancers it has variously been reported in association with
5-50% of cases (Stone et al 1977, Morrow and Townsend
1981, Coppleson 1981). It has been reported as being
most common in serous cystadenocarcinoma (Morrow and
Townsend 1981) but levels of H.C.G. only appear elevated
in patients with gross disease (Barker 1980) and rapidly
return to normal after the start of therapy even when
there is marked residual tumour (Stone et al 1977).
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Human Placental Lactogen (H.P.L.)
H.P.L. has been described in association with both germ
cell and epithelial ovarian cancers (Caspar et al 1984).
However, although up to 75% of patients with primary
epithelial ovarian cancers have elevated serum H.P.L.
this serum marker does not rise with early recurrent
disease (Samaan et al 1976) but can become elevated in
end stage disease (Crowther et al 1979).
Placental Proteins
Alpha macroglobulin has been reported to be elevated in
the sera of a large percentage of ovarian cancer patients
by some workers (Malkin et al 1978, Sawada et al 1982) but
others (Damber et al 1976) have failed to detect it in
these patients.
Raised serum B-l glycoprotein levels have been reported
only in a small percentage of patients with advanced
epithelial ovarian carcinomas (Tatarinov 1978, Crowther et
al 1979).
The placental specific proteins numbered 5 and 11 have been
demonstrated in association with a large number of ovarian
cancers but their clinical value has yet to be evaluated
(Coppleson 1981, Inaba et al 1982).
Bjorkland Isoenzyme or Tissue Polyseptide Antigen (T.P.A.)
T.P.A., a polyseptide of 22,500 molecular weight, is found
in normal placentae and in association with 46% of cancers
of all types including ovary. Transient raised serum
levels are noted in 22% of patients with infectious diseases,
25% of patients with non malignant diseases and 5% of the
normal population (Bjorkland 1976). Its value as a tumour
marker in ovarian cancer has not been evaluated.
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Fetal Antigens
1) Carcinoembryonic Antigen (C.E.A.)
This membrane bound glycoprotein was initially reported in
association with adenocarcinoma of the colon (Gold and
Freeman 1965). It has subsequently been found in associa¬
tion with a variety of cancers including ovary (Khoo and
McKay 1974) but is also raised in a variety of non
malignant diseases and in cigarette smokers (Hansen et al
1974). It has proven to be a very popular tumour marker
for ovarian carcinomas with an association reported between
13.4% (Stone et al 1977) and 65% (Khoo et al 1979). C.E.A.
has been variously reported as being most commonly elevated
in association with both serous cystadenocarcinomas and
poorly differentiated tumours (Khoo and McKay 1976) and
also with mucinous cystadenocarcinomas (Morrow and Townsend
1981, Coppleson 1981). The incidence of elevated C.E.A.
levels has been shown to rise with advancing stage of the
disease (Khoo and McKay 1974, Di Saia et al 1975, Van Nagell
et al 1975) but some workers (Barker 1980) suggest that it
is only elevated in patients who are in the terminal stages
of their disease. Conversely Khoo and McKay (1976) suggest
that C.E.A. falls during the terminal illness.
All these workers have used polyclonal antisera to C.E.A. as
a basis for their assays, which will therefore recognise a
number of different antigenic determinants. As C.E.A. and
a variety of other normally occurring glycoproteins e.g.
biliary glycoprotein and a glycoprotein found in the washings
of normal colon, share common epitopes (Lennox and Sikora
1982) it is not surprising that there is such a variation
in results obtained from one group of workers to another.
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Khoo and McKay (1976) found C.E.A. to be a useful tumour
marker for "gynaecological malignancies" predicting
tumour recurrence by up to 10 weeks before it was
detectable clinically, but false positives and negatives
have been reported (Khoo et al 1979, Caspar et al 1984).
Other workers have not shared this enthusiasm (Stone et
al 1977, Barker 1980, Samaan et al 1976) perhaps
reflecting the problems in using polyclonal antisera
alluded to earlier.
2) Alpha Foetoprotein (A.F.P.)
This is the main foetal plasma protein and its first
reported tumour association was with hepatoma (Abelev
1963). It is a good tumour marker for ovarian endodermal
sinus tumours (Sell et al 1976) and is also found in
embryonal cell carcinomas. A.F.P. is additionally
associated with other germ cell tumours containing yolk
sac elements (Van Nagell et al 1981) but it is not a
reliable marker in this last group. However, A.F.P.
is only rarely found in association with epithelial
ovarian carcinoma (Stanhope et al 1979, Smith and Oi 1984).
3) Other Foetal Antigens
Apha 1 antitrypsin, transferrin, prealbumin, foetal
ferritin, Beta oncofoetoprotein and foetal sulphoglyco-
protein have all been described in association, to
varying degrees with ovarian cancers, but have not




Tumour associated antigens are predominantly membrane bound
glycoproteins, which are, at least in theory, only found in
association with malignancies; however, as is discussed
below, this is not always the case.
1) Ovarian Cystadenocarcinoma associated antigen (O.C.A.A.)
This antigen is found in association with both serous and
mucinous cystadenocardnomas as well as carcinomas of breast,
cervix and colon and has not so far been detected in normal
adult tissue (Bhattacharya and Barlow 1973, 1975, 1979). It
is elevated in the sera of 66% of patients with Stage 2 and
3 disease and 80% of patients with Stage 4 disease but was
not detected in the single patient with Stage 1 disease
(Piver et al 1979) however in 70% of these patients
O.C.A.A. accurately predicted the clinical course of the
disease (Bhattacharya and Barlow 1979).
2) Ovarian Cancer Antigen (O.C.A.)
O.C.A. is found at all stages of the disease in the sera
of 65% of patients with serous or mucinous cystadenocarcinomas
and in 54% of those with endometrial tumours. It is also
found in 10% of normal controls (Knauf and Urbach 1978, 1980).
A longitudinal study is required to assess it s usefulness
in clinical practice.
3) C.A. 125
This antigen was originally thought to be totally specific
for ovarian carcinoma (Bast et al 1981), it has since however
been detected in normal adult endometrium, fallopian tube
epithelium, cervical columnar epithelium and in association
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with non-specific inflammation (Kabawat et al 1983, Niloff
et al 1984). It now appears that all carcinomas arising
from tissues derived from the mullerian duct also express
this antigen (Niloff et al 1984). 82% of patients with
ovarian epithelial carcinoma have raised serum levels and
in 93% of these serial serum levels of C.A. 125 proved to
be accurate in predicting the course of the disease, serum
C.A. 125 is also elevated in 6% of the population.
Interestingly C.A. 125 has many properties similar to
P.L.A.P. in both its distribution in gynaecological malig¬
nancies, normal tissue and structure. However, it is a
distinct antigen (Davies et al 1985, Bast et al 1985).
4) Carbohydrate Antigen C.A. 50
This antigen was initially recognised in colorectal adeno¬
carcinoma cells. It has subsequently been found in a
variety of epithelial tumours including 40% of epithelial
ovarian carcinomas (advanced Stage 3 and 4 tumours only),
(Holmgren et al 1984). Its value as a tumour marker has
yet to be decided.
5) Human Milk Fat Globule 2 (H.M.F.G.2) Antigen
This antigen is found in all normal secretory epithelium
but is present in much higher concentrations in certain
cancers, including ovarian carcinoma. Immunohistological
examination of ovarian cancer tissue, using the H.M.F.G.2
monoclonal antibody, has shown heterogeneity of expression
of this antibody within individual tumours (Hammersmith
Oncology Group 1984). A radioimmunoassay has demonstrated
elevated levels of H.M.F.G.2 antigen in the serum of 53%
of patients with advanced breast cancer, in five from six
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patients with active ovarian cancer but also in 16.6% of
control sera (Burchell et al 1984). The H.M.F.G.2 antibody-





This hormone has proven to be of no clinical use in the
management of epithelial cancers (Stanhope et al 1979).
Oestrogens
These are only of use in monitoring patients with granulosa
cell tumours (Aakvaag 1975).
A.C.T.H., A.D.H., Parathormone
These hormones have a role in monitoring patients with that
extremely rare group of hormone producing tumours (Norris
1975, Muggia et al 1975).
2) Enzymes
Lactate Dehydrogenase (L.D.H.)
Cancer cells have increased glycolysis and so patients with
carcinoma should have a raised serum level of this enzyme.
L.D.H. is therefore a non-specific tumour marker and some
workers have found that a high proportion of ovarian cancer
patients have raised serum levels (Awais 1973 and 1978).
Burrows (1980) however failed to detect any significant
increase in serum levels of this enzyme in cancer patients
when compared to controls. L.D.H. has also been reported in
association with dysgerminoma (Friedman et al 1984) and
endodermal sinus tumour (Takeuchi et al 1979).
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Glycosyltransferases
The glycosylation of proteins is different in cancer cells
than in normal cells (Rostenberg et al 1978). The
glycosyltransferase, galactosyltransferase, has been shown
to be a good tumour marker by some, being elevated in all
cases of ovarian carcinoma and predicting recurrence of the
disease up to 7 months before it was clinically obvious
(Chatterjee et al 1980). Other workers have found elevated
galactosyltransferase levels in between 32 and 64% of
patients with ovarian tumours (Gaudichon et al 1983,
Waalkes 1982).
Alpha-L-fucosidase
Alpha-L-fucosidase is involved in the metabolic pathway of
the deoxyhexose, L fucose (6 deoxyl-L-galactose). This
sugar is widely distributed in human tissues and is an
important component of the oligosaccharides responsible for
blood group specificity. Although levels of alpha-L-
fucosidase have been described as being higher in ovarian
cancer tissue when compared to normal ovary (Chatterjee et
al 1979), serum levels of this enzyme are significantly
reduced in patients with ovarian cancer (Bhattacharya and
Barlow 1979). The reasons for this are unclear and further
work is needed to ascribe a role for this enzyme, as a
tumour marker, in patients with this disease.
Plasminogen Activator
This enzyme is released by ovarian tumour cells in culture





This is a breakdown product of collagen and has been
detected in raised amounts in urine of patients with
advanced disease or metastases, sometimes before clinical
recognition (Coppleson 1981).
Fibrin Degration Products (F.D.P.) and Erythrocyte
Sedimentation Rate (E.S.R.)
Anstey and Blythe (1978) demonstrated elevated F.D.P. in
virtually 100% of patients with ovarian cancer. However
both F.D.P. and E.S.R. are elevated in a large number of
not necessarily malignant conditions and therefore cannot
be considered to be useful tumour markers.
Cyclic Guanosine 3'5' Phosphate (Cyclic G.M.P.)
Serum levels of cyclic G.M.P. have been reported to be
elevated in 90% of patients with ovarian cancer, but is
also elevated in a variety of other conditions (Turner
et al 1980 ).
1.3 Placental Alkaline Phosphatase
I shall consider the structure, function, intracellular
site and methods for distinguishing between the different
isoenzymes of P.L.A.P. before discussing it's distribution
in both health and disease.
1.3.1 The structure of Placental Alkaline Phosphatase
Placental alkaline phosphatase (P.L.A.P.) is a dimer with
each subunit having a molecular weight of 74,000 Daltons
(Stinson and Seargeant 1981). Alkaline phosphatase is a
glycoprotein; carbohydrate, mainly glucosamine galactosamine,
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hexosamine and sialic acid, makes up 15-30%, by weight,
of the molecule (McComb 1979) and there are approximately
1000 aminoacids per subunit (Nozawa and Fishman 1982).
The configuration of aminoacids at the active site however





Phosphate binds, as shown, to the first serine molecule
(Whittaker et al 1976).
The P.L.A.P. molecule contains 4 zinc atoms, two of which
are structural and hence firmly bound, the other two atoms
are loosely bound and are needed for catalytic activity
(Fishman 1974).
A high molecular weight (750,000 Daltons) form of P.L.A.P.
has recently been described(Ahu Hassan et al 1984). So
far this has only been detected in term placentae.
1.3.2 Reactions catalysed by P.L.A.P.
All alkaline phosphatase isoenzymes catalyse the same
reactions namely hydrolysis and phosphate transfer (Gutman
1959). This enzyme catalyses the hydrolysis of the P-O-C bond
(Gutman 1959), P-F bond (Fernley and Walker 1967), P-O-P
bond (Fernley and Bisaz 1968), P-S bond (Neuman 1968) and
the P-N bond (Fernley 1971) of a variety of monophosphate
esters to yield inorganic phosphate and the corresponding
sugar, alcohol or phenol etc.. The reaction proceeds in
two phases (1) after the formation of the enzyme-substrate
complex, hydrolysis of the substrate generates a phosphoryl-
enzyme and product; (2) the phosphoryl-enzyme dissociates
to give inorganic phosphate and enzyme (Fishman 1974).
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Alkaline phosphatase has been thought to be the same as
2+
two other enzymes, namely Ca ATPase and inorganic
pyrophosphatase. Although ATP is a substrate for both
enzymes (Eaton 1967, Moss 1969) Fishman (1974) demonstra¬
ted by aminoacid inhibition, that they are different
enzymes. Inorganic pyrophosphatase, while sharing many
properties with alkaline phosphatase, is inhibited whereas
the latter is activated by magnesium (Cathala and Brunei
1973).
1.3.3 Intracellular site of P.L.A.P.
Alkaline phosphatase activity has been demonstrated by
electron microscopy, on the plasma membrane lining the
microvilli in kidney proximal tubule (Goldfisher et al
1964), intestine (Hugon and Borgers 1966) and term
placental syncytiotrophoblast (Hulstaert et al 1973), in
this latter case P.L.A.P. was also demonstrated on the
basal surface of the syncytiotrophoblast. Tokumitsu et al
1981, demonstrated alkaline phosphatase intracellularly
in a variety of non malignant cells, associated predomin¬
antly with the endoplasmic reticulum, golgi apparatus,
mitochondrion and in the perinuclear space. Both the
cytoplasmic and membrane alkaline phosphatases had identical
properties suggesting the former is simply en route from
its site of production to the cell membrane. A similar
situation has been reported in ovarian tumours (Johnson
et al 1984).
1.3.4 The function of P.L.A.P.
A precise role has yet to be attributed to any of the
isoenzymes of alkaline phosphatase. However, as they are
located, in the main, in organs involved in absorbtion
and/or excretion and are membrane bound, they may well
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participate in the active transportation of substances
across the cell membrane (Kabat and Furth 1940, McComb
1979). A role for alkaline phosphatase in the regulation
of cell membrane dimensions was postulated by Fishman and
Lin (1973). Nozawa and Fishman (1982) finding phosphoryl
histone products to be a substrate for this enzyme, suggest
a role in gene regulation.
1.3.5 Differentiation between the various isoenzymes of
alkaline phosphatase
There are three isoenzymes of alkaline phosphatase. The
alkaline phosphatase found in liver, bone, kidney and
placenta before 10 weeks gestation have many similar
properties and are referred to as the tissue non-specific
isoenzyme (Nozawa and Fishman 1982). Alkaline phosphatase
present in intestine and term placentae, respectively make
up the other two isoenzymes.
Isoenzymes are a group of enzymes having the same function
but different structures, it is therefore possible to
distinguish between them using immunological methods. The
various isoenzymes also have different physical and biochem¬
ical properties and these are discussed below:
a) Urea and Heat Stability
There is a close association between inactivation of the
various isoenzymes of alkaline phosphatase by urea and
heat (Fennelly et al 1969).
The placental isoenzyme is the most heat stable and resis¬
tant to urea denaturation followed by the intestinal and
tissue non-specific isoenzymes (Birkett et al 1967,
Butterworth and Moss 1967) (Table 1.4).
30
Heat stability varies with pH; both the intestinal and
tissue non-specific enzymes being most stable at pH 7
(Moss et al 1972).
b) Specific Inhibitors
A variety of substances, mainly aminoacids, have been
described that selectively inhibit the action of one or
more isoenzymes. Bodansky (1939) was the first to use
a specific inhibitor (bile acids) to distinguish between
tissue non-specific and intestinal isoenzymes. Since
then a variety of inhibitors have been describ ed
including L-phenylalanine (Ghosh and Fishman 1966 and
1968, Fernley and Walker 1970), L-Leucine (Nakayama 1970,
Wei and Doellgast 1981), L-tryptophan (Lin and Fishman
1971), L-homoarginine (Lin and Fishman 1972), Levamisole
(Van Belle 1972, Borgers 1973), L-Leucyl-glycyl-glycine and
L-phenylglycyl-glycine (Nozawa and Fishman 1982); these
inhibitors are only effective as the L-isomer and their
effect on the various isoenzymes of alkaline phosphatase
is summarised in Table 1.5.
The mechanism of inhibition has been postulated as either
1) the formation of a poor dissociable enzyme-inhibitor-
substrate complex (Fishman and Ghosh 1967); or
2) preventing the breakdown of the phosphoryl-enzyme
intermediate formed at the end of the first phase of
the reaction to enzyme and inorganic phosphate (Fernley
and Walker 1969, Byers et al 1972).
Effect of pH
Alkaline phosphatase is distinguishable by its high
(alkaline) pH optimum from acid phosphatase. At pH 6
the alkaline phosphatase starts to split into monomers
due to the dissociation of zinc, by pH 4 all the enzyme
is monomeric (Applebury 1969). This trend can be
reversed at pH 5-6 by the addition of excess zinc or
cobalt, but below pH 5 the enzyme cannot be reactivated
(Harkness 1968).




pH optima 10.1-10.2 10.1-10.2 10.7
However, all the isoenzymes are active at physiological pH.
Electrophoretic Mobility
P.L.A.P. was first distinguished as a separate isoenzyme
using starch gel electrophoresis (Boyer 1961). Prior to
this the high levels of alkaline phosphatase in pregnancy
serum were thought to derive from fetal or maternal bone
or maternal liver. P.L.A.P. was found to occupy an inter¬
mediate position between the tissue non-specific (fast) and
intestinal (slow) isoenzymes on electrophoretic migration.
Since 1961 a number of other media support have been used
in electrophoresis i.e. cellulose acetate membrane,
polycrylamide and agar gells. These media have various
properties and have all been used to differentiate the
various isoenzymes of alkaline phosphatase (Nozawa and
Fishman 1982).
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In order to overcome problems with diffuse or overlapping
bands of the various isoenzymes some workers have used
specific inhibitors, urea denaturation or heat to exclude
one or more isoenzyme (Fennelly 1969, Green et al 1972).
Alternatively the molecular weight and negative charge of
the placental and tissue non-specific isoenzymes can be
reduced by splitting sialic acid from the molecule, using
neuraminidase, which will therefore separate these from
the intestinal isoenzyme which does not contain sialic
acid (Fishman 1974).
Electrophoresis has also been used to distinguish between
the various forms and variants of P.L.A.P., starch gel
proving to be the most useful matrix in this respect
(Inglish et al 1973, Fishman 1974). The more recent
technique of isoelectric focusing on a polyacrylamide gel
has also proved useful (Stinson and Seargeant 1981).
Affinity Chromatography
This is a method primarily to purify proteins but can also
be used to distinguish between the various isoenzymes of
alkaline phosphatase using their variable lectin binding
affinity, the intestinal isoenzyme is totally unbound,
whereas the tissue non-specific isoenzyme shows variable
binding (Trepanier et al 1976, Nozawa and Fishman 1982).
Immunology
The three isoenzymes of alkaline phosphatase were first
recognised to be antigenically distinct by Boyer in 1963,
but whilst antisera raised against the tissue non-specific
isoenzyme does not cross react with either of the other two-
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isoenzymes (Sussman et al 1968), both intestinal and
placental alkaline phosphatase appear to share at least
one epitope (Doellgast et al 1976, Lehman et al 1976).
This similarity causes difficulties in distinguishing
between these two isoenzymes using polyclonal antisera
even after appropriate absorbtion procedures (Haiji et
al 1979).
Monoclonal antibodies, which recognise a single antigenic
site, will reliably distinguish between P.L.A.P. and
intestinal alkaline phosphatase provided the site recog¬
nised is not shared and a number of such antibodies have
been described (Slaughter et al 1981, Millan et al 1982
a & b, McLaughlin et al 1983, Sunderland et al 1984).
SUMMARY
P.L.A.P. is a heat stable isoenzyme of alkaline phosphatase
which is resistant to urea denaturation and is character¬
ised by its inhibition by the L-isomers of phenylalanine
tryptophane, levamisole, phenylglycylglycine and leucyl
glycylglycine. It has a high optimal pH of 10.7, interme¬
diate electrophoretic mobility and a high lectin binding
affinity. However, the difference between the various
isoenzymes is often only one of degree. P.L.A.P. and
intestinal alkaline phosphatase in particular share many
physical and biochemical properties as well as having
antigenic similarities. This can lead to difficulties in
distinguishing between these two isoenzymes particularly
where one is present at a much higher concentration than
the other. Monoclonal antibodies to P.L.A.P. have proven
to be very sensitive tools in the detection of P.L.A.P..
Their practical applications are discussed in Chapter 2.
1.3.6 Evolution of P.L.A.P.
It is clear from their physical, biochemical and
immunological properties that there are three alkaline
phosphatase isoenzymes i.e. tissue non-specific (liver,
kidney, bone), intestinal and placental. Further
evidence for this classification comes from the study
of the aminoacid sequence of the various isoenzymes.
Liver, bone and kidney alkaline phosphatases all have an
identical peptide map which is distinct from those of
the other two isoenzymes (Seargeant and Stinson 1979).
Therefore, as all three groups have a different structure
they must be coded for by three separate genes, one for
the tissue non-specific isoenzyme, one for intestinal
alkaline phosphatase and one for P.L.A.P..
By studying the immunological properties of alkaline
phosphatase from various animal groups a plan of the
evolution of the three human isoenzymes can be postulated
(fig 1.2). An enzyme identical to the human tissue non¬
specific isoenzyme is found in fish, amphibians, reptiles
birds and mammals (Goldstein and Harris 1979, Nozawa and
Fishman 1982) suggesting that this enzyme is an early
evolutionary product. The intestinal isoenzyme is only
found in mammals (Nozawa and Fishman 1982) and shares
close immunological properties with P.L.A.P. suggesting
a common origin (Lehman 1976). An enzyme with close
properties to P.L.A.P. first appears in higher mammals
and certain primates, but is less heat stable and
L-phenylalanine sensitive (Rogers 1982); "Human" P.L.A.P.
is only found in man, chimpanzee and the orang-utan
(Doellgast et al 1979).
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1.37 Types of P.L.A.P. in Health and Disease
a) In Human Placenta
At present P.L.A.P. is the most polymorphic human enzyme
known. P.L.A.P. was first recognised as a distinct enzyme
by Boyer (1961) who was also able to identify four
phenotypes which he named A, AB, B and D in descending
order of electrophoretic mobility. He also suggested that
these three common phenotypes might be genetically determined
as their frequencies in the population were such as would be
predicted by the Hardy Weinberg Law on a 1 allele hypothesis.
Robson and Harris (1965) showed that human P.L.A.P. classi¬
fied into at least six phenotypes based on electrophoretic
mobility at varying pH's. These they called F, FI, I, SI,
FS and S. They postulated that Boyer's type 'A' phenotype
was composed of the F, FI and I forms, the 'AB' phenotype
was composed of the FS and SI forms and the 'B' phenotype
was equivalent to the S form.
They suggested that there were three alleles coding for these
forms and that they were a mixture of homozygotes (F, S, I)
and heterozygotes (FI, SI, FS), (Table 1.6). The homozygous
form was found to have one component on electrophoresis .and
the heterozygote had three components, two equivalent to
the corresponding homozygotes and the third in an intermediate
position equivalent to a hybrid substance. These six pheno¬
types are known as the common forms and are found in 98% of
human placentae. However in the remaining 2% the P.L.A.P.
expressed is a rare variant, the slow moving D band in
Boyer's original paper is thought to be composed of a number
of rare variants. Harris et al (1967) identified nine rare
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variants which were classified according to their electro-
phoretic mobilities. They postulated that there needed to be
three common and six rare alleles at an autosomal locus to
code for these forms. The potential combination of common
forms and rare variants from a total of nine alleles would
equal 35 (six common, 29 rare). Donald and Robson (1974)
looked at 5,000 placentae and discovered a further 10 of
these rare variants but also found an additional 19 new
rare variants whose phenotype was such that they could not be
coded for by the original six rare alleles. They concluded
that a total of 18 alleles (three common, 15 rare) were
needed to include all the phenotypes found. This gives a
possible total of 126 different forms and variants, however
only six common forms and 38 rare variants have been described.
In view of the large number of alleles present the old F, S,
I nomenclature was abandoned in favour of a numerical classi¬
fication where the alleles are numbered 1-18. Thus, S is
equivalent to 1, F = 2, 1=3 and so on, this remains the
standard method for classifying the various forms and
variants of P.L.A.P. present in human placentae. There are,
however, an increasing number of monoclonal antibodies
recognising different epitopes of P.L.A.P. being produced
(Slaughter et al 1981, Millan et al 1982a, McLaughlin et
al 1983) and these are beginning to be usfed to distinguish
between the different types of P.L.A.P. present both in
malignant and non-malignant tissues (Slaughter et al 1983,
Millan and Stigbrand 1983, McLaughlin and Johnson 1984,
Sunderland 1984).
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b) In Malignant and Non-Malignant Tumours
At present the classification of the various forms of
P.L.A.P. found in tissues other than placenta is confused
and is undoubtedly an over-simplification of the true
state of affairs. Four different forms of alkaline phos¬
phatase have been described in association with various
malignancies, usually taking their name from the patient in
whom they were first recognised, of these four only three
have some P.L.A.P. like characteristics, the fourth the
non-regan isoenzyme has identical properties to the isoenzyme
found in early pregnancy (i.e. the tissue non-specific form)
it will be described for completeness but will not be
referred to again.
1) Regan Isoenzyme
This isoenzyme was originally found in association with a
lung carcinoma in a patient called Peter Regan, from whom
it takes its name (W H Fishman 1968). The regan isoenzyme
has identical electrophoretic mobility to the F phenotype
of P.L.A.P., is sensitive to L-phenylalanine, resistant
to L-homoarginine inhibition, has identical heat stability,
enzyme kinetics and immunological properties as P.L.A.P.
(Stolbach et al 1969). Further evidence that the regan
isoenzyme is similar to the common forms of P.L.A.P. comes
from a study of the subunit molecular weight, isoelectric
points, aminoterminal sequences and peptide mapping (Greene
and Sussman 1973).
2) Naqao Isoenzyme
This isoenzyme was first reported in a patient (Mr Nagao)
with pleuritis carcinomatosa. It has the same immunological
properties and the same heat and urea stability as the
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common forms of P.L.A.P.; however it is markedly more
sensitive to both L-Leucine and ethyl-enediamine tetra-
acetic acid (E.H.T.A.) and is slightly more sensitive to
L-phenylalanine. The nagao iso-enzyme has a much slower
electrophoretic mobility than the S, I and F phenotypes and
this coupled with its L-Leucine sensitivity has led some
workers to suggest that the nagao isoenzyme is the re-
expression of the rare 'D' variant of P.L.A.P. by cancer
cells (Inglis et al 1973). However, Doellgast and Wei (1981)
identified three immunoreactive sites on the 'D' variant
and nagao isoenzyme, only one of which was common to both,
suggesting a close relationship but different structure.
3) Warnock variant (Regan variant, Kasahara variant)
This variant was first identified in a group of patients with
hepatocellular carcinoma and is heat stable and L-phenylalanine
sensitive with a faster electrophoretic mobility than either
the liver or placental isoenzyme (Warnock and Reisman 1969).
It has been thoroughly investigated and found to share
properties with both P.L.A.P. (i.e. L-phenylalanine and
neuraminidase sensitivity, L-homoarginine resistant, urea
stability, molecular weight and antigenicity) and the liver
isoenzyme (i.e. pH optimum and phosphate sensitivity). It
differed from both in its electrophoretic mobility, L-Leucine
and E.D.T.A. sensitivity and was marginally less heat stable
than P.L.A.P. (Higashino et al 1972).
It is probable that this variant is a hybrid isoenzyme
composed of subunits of P.L.A.P. and intestinal alkaline
phosphatase as the Warnock variant reacts with antisera
against P.L.A.P. and the intestinal isoenzyme but not liver
alkaline phosphatase (Higashino et al 1974 & 1975).
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Non Regan Isoenzyme .
The majority of alkaline phosphatase secreting tumours
produce this enzyme (Nozawa and Fishman 1982); it was
first described in a patient with lung cancer (Timperley
1968) and is identical to the isoenzyme found in human
placentae from 6-10 weeks gestation (L Fishman et al
1976, Sakyam et al 1979).
The properties of these various isoenzymes are
summarised in Table 1.7.
1.3.8 Expression of P.L.A.P. in Health
For many years P.L.A.P. was thought to be found only in
the serum of pregnant women. This view changed with the
discovery of a P.L.A.P. like enzyme in the serum of a
patient with lung carcinoma (Fishman et al 1968). Stolbach
et al (1966) and Usategui-Gomez (1974) found P.L.A.P. in
the serum of healthy non-pregnant individuals and Fishman
and Nathanson (1971) found P.L.A.P. in the serum of
patients with blood group 0 blood.
P.L.A.P. has been described in:
a) Placenta
Placental alkaline phosphatase first appears in pregnancy
serum at about 10 weeks gestation and shows an exponetial
rise to a peak at 37-40 weeks gestation (Fishman et al
1972). The serum levels of P.L.A.P. havenot, however,
been shown to be of use in the detection of placental
insufficiency (Fishman et al 1972, Marshall and Parisi
1975, McLaughlin et al 1983). After 16 weeks gestation
all the alkaline phosphatase in the human placenta is of
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the placental isoenzyme (Nozawa and Fishman 1982) and
is found on the outer cell membrane of the syncytio-
trophoblast covering the chorionic villi, (Dempo et al
1979). There is no P.L.A.P. in the villous stroma
(Dempo et al 1979).
P.L.A.P. is found in one of its six common forms in
98% of placentae and as one of at least 38 rare variants
in the remaining 2% (Donald and Robson 1974).
b) Endometrium
Several workers have reported trace amounts of P.L.A.P.
in normal endometrial epithelium (Malkin et al 1979,
Nozawa et al 1980). 21.9% of cases showed P.L.A.P. in
surface epithelium using histochemical methods based on
heat stability and aminoacid inhibition (Nozawa et al
1980). Other workers however (Goldstein et al 1980) have
not detected P.L.A.P. in endometrium.
c) Cervix
Malkin et al (1979), Nozawa et al (1980) and Goldstein et
al (1980 and 1982) have all detected P.L.A.P. in cervical
columnar epithelium. Goldstein et al (1980) estimated
that 18% of the alkaline phosphatase activity in cervical
columnar epithelium and mucus was due to P.L.A.P.. The
isoenzyme has properties similar to the 'Regan isoenzyme1
and is L-Leucine resistant (Goldstein 1982). However,
small quantities of an L-Leucine sensitive form of
P.L.A.P. have also been detected in normal cervix
(McLaughlin et al 1984).
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d) Testis
Chang et al (1978) and Goldstein et al (1982) have both
demonstrated P.L.A.P. in normal testis. This isoenzyme
was shown to be L-Leucine sensitive and it was postulated
that this was the 'Nagao isoenzyme', (Goldstein et al
1982). McLaughlin et al (1984) have confirmed this
finding but also detected trace quantities of one of the
common forms of P.L.A.P.
e) Thymus
The form of P.L.A.P. found in this organ was also
L-Leucine sensitive (Goldstein 1982).
f) Lung
Trace quantities of an L-Leucine resistant form of
P.L.A.P. have been detected in normal lung (Goldstein et
al 1982) as well as varying amounts of an L-Leucine
sensitive form (McLaughlin et al 1984). It is interesting
to note that raised serum P.L.A.P. of up to ten times the
normal, non-smoking range has been recorded in cigarette
smokers. The levels did not correlate with the number
of cigarettes smoked a day (Maslow et al 1983, Tonik
et al 1983). However, a form of P.L.A.P. recognised by
one monoclonal antibody (McLaughlin et al 1983) does not
appear to be present in the serum of smokers, although
this antibody does recognise P.L.A.P. present in normal
lung (McLaughlin et al 1984).
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1.3.9 Expression of P.L.A.P. in Disease
a) Non malignant disease associated with elevated serum
P.L.A.P.
Nathanson and Fishman (1971) reported raised serum P.L.A.P.
in patients with non malignant as well as malignant disease.
They used heat stability and polyclonal antisera to
differentiate between P.L.A.P. and the intestinal and
tissue non-specific isoenzymes. Elevated serum P.L.A.P.
was found in:
1) Alcoholic cirrhosis 2 from 8 cases
2) Ulcerative colitis 2 from 4 cases
3). Diverticulitis 1 from 1 case
4) Peripheral vascular disease 3 from 7 cases
5) Hydronephrosis 1 from 2 cases
Cigarette smoking at that time was not recognised as a
cause of raised P.L.A.P. and so this might explain some
or all of the elevated levels (particularly those with
peripheral vascular disease) and cross reactivity between
placental and intestinal isoenzymes may explain elevated
levels in those patients with intestinal disorders.
b) P.L.A.P. and Malignancy
Although P.L.A.P. has been described in association with a
large number of tumours (Table 1.8) it should be noted
that cigarette smoking, now recognised as a cause of
elevated P.L.A.P. (Maslow et al 1982) was not taken into
account in all of these papers.
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P.L.A.P. has been used as a tumour marker with varying
degrees of success. Thus, although raised serum
P.L.A.P. has been described in association with breast
carcinoma in between 14% and 21% of cases (Nathanson
and Fishman 1971, Cadeau et al 1974 and Wada et al
1979) McDicken et al (1983) could not detect elevated
serum P.L.A.P. in cases where immunohistology of the
tumours had been positive (7 positive out of 7 cases).
This latter finding was confirmed by McLaughlin et al
(1983). Non Regan isoenzyme has also been demonstrated
in association with this tumour (Miyayama et al 1976).
It is possible that although the tumour type produces
P.L.A.P. (as shown histologically), the serum levels
are too low to detect (McDicken et al 1983). The
elevated serum levels in early studies could all have
been due to cigarette smoking.
However, in the case of seminoma, P.L.A.P. has been
demonstrated immunohistologically on resected specimens
(Wahren et al 1979) and approximately 60% of such
patients with active disease have elevated P.L.A.P.
levels (Lange et al 1982). Other workers have found
P.L.A.P. to be a useful tumour marker in this group of
patients (Jepsson et al 1983).
1.3.10 P.L.A.P. in Genital Cancer
a) Ovarian Carcinoma
P.L.A.P. was first recognised in association with ovarian
cancer by Stolbach et al in 1969. This finding has
subsequently been confirmed by many workers, often
without distinguishing the form of P.L.A.P. expressed.
Between 22% and 39% of patients with ovarian cancer
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have elevated serum levels of this enzyme (Nathanson
and Fishman 1971, Stolbach et al 1976, Malkin et al
1978, Van Nagell 1981). Fishman et al (1975) used
inhibition with L-Leucine to distinguish between the
types of P.L.A.P. present and found that while ascitic
fluid P.L.A.P. was, in 82% of cases, the L-Leucine
sensitive form, this was only present in serum in 35%
of these cases. An L-Leucine sensitive form of P.L.A.P.
was also detected in tumour tissue extracts but again
this was not necessarily reflected in serum P.L.A.P.
levels (Benham et al 1979).
Various groups (Cadeau et al 1974, Kellen et al 1976 and
Haije et al 1979) have found a P.L.A.P. like enzyme
to accurately reflect tumour load. Haije et al using
an enzyme linked immunosorbent assay based on polyclonal
antisera, stress the usefulness of 1carcinoplacental
alkaline phosphatase' as a tumour marker, finding it
elevated in 40% of patients, predominantly those with
serous and endometroid cystadenocarcinomas and that it
accurately predicted the course of the disease in 86%
of patients. McLaughlin et al (1983) have also found
elevated serum P.L.A.P. using an enzyme immunoassay
based on a monoclonal antibody, in 35% of patients with
ovarian cancer. However, Doellgast and Holmesley (1984)
while finding elevated serum P.L.A.P. in patients with
ovarian cancer did not find it to be a useful tumour
marker although they found that a high preoperative
level suggested a poor prognosis. Burrows (1980) failed
to detect significantly raised serum P.L.A.P. in any
patient with ovarian cancer.
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P.L.A.P. has been used as part of a 'battery' of other
tumour markers and although there is an increased pick up
rate for at least one marker, the practical value of this
mode of follow up is questionable (Fishman et al 1975,
Stolbach et al 1976).
b) Cervical Carcinoma
Nathanson and Fishman (1971) found raised serum P.L.A.P.
in association with this tumour in 22% of cases and
this finding has been confirmed by others (Van Nagell
1981). Nonetheless P.L.A.P. would not appear to be of
use as a tumour marker in this type of cancer. Cadeau et
al (1974) found 17% of patients with active disease to
have raised serum levels but also found elevated levels
in 25% of cases who were in remission and other workers
found that the incidence of raised serum P.L.A.P. is in
indirect proportion to the stage of the tumour (Kellen et
al 1976, Malkin et al 1978).
c) Endometrial Cancer
Cadeau et al (1974) found elevated P.L.A.P. in the sera
of 12% of patients with endometrial carcinoma. Van Nagell
et al (1981) confirmed this observation but some workers
have failed to detect raised serum P.L.A.P. in such
patients (Nathanson and Fishman 1971). Variable amounts
of P.L.A.P. were found in endometrial carcinoma tissue
extracts in 29 from 33 cases (Doellgast and Holmesley 1984)
and Nozawa et al (1981) histochemically demonstrated
P.L.A.P. in 7 from 42 cases of this tumour.
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As with cervical carcinoma P.L.A.P. has not been
thought to be a useful tumour marker here, Kellen et
al (1976) only found elevated serum P.L.A.P. levels in
Stage la tumour and could not detect it in the serum
of any patient with later stage disease.
d) Seminoma Tumour of the Testis
Wahren et al (1979) detected elevated serum P.L.A.P. in
the preoperative serum samples in 10 out of 19 patients
with active seminoma. Similar figures were obtained in
two subsequent larger studies (Lange et al 1982, Jeppsson
et al 1983). In all three studies serial serum P.L.A.P.
measurements were of value in monitoring the course of
the disease in between 60% and 75% of patients studied.
None of these studies considered the effect of cigarette
smoking in elevating serum P.L.A.P. (Maslow et al 1983)
and it is of interest to note that in two of these studies
between 13% (Jeppsson et al 1983) and 35% (Lange et al
1982) of patients in complete remission also had elevated
serum P.L.A.P. levels.
1 4
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NUMBERS OF NEW CASES OF THE TEN COMMONEST FEMALE
CANCERS (1979)
Cancer Type Number Percentageof whole
Breast 20,648 22%
Skin (excl. melanoma) 9,154 10%








Figures for carcinoma of the cervix excludes in-situ
lesions.
TABLE 1.2














Table 1.3 F.I.G.O. Stage-grouping for primary carcinoma
of the ovary
Stage 1 Growth limited to the ovaries
la Growth limited to one ovary; no ascites
(i) No tumour on external surface, capsule
intact
(ii) Tumour on external surface and/or capsule
breached
lb Growth limited to both ovaries; no ascites
(i) & (ii) as for Stage la
lc Growth limited to one or both ovaries with
malignant ascites or cells in peritoneal washings
Stage 2 Growth invading one or both ovaries with pelvic
extension
2a Extension and/or metastases to uterus and/or tubes
2b Extension to other pelvic organs
2c Stage 2a or 2b tumour with malignant ascites or
cells in peritoneal washings
Stage 3 Growth involving one or both ovaries with intra¬
peritoneal metastases outside the pelvis and/or
retroperitoneal nodes. Metastasis to the surface
of the liver is also Stage 3 disease.
Stage 4 Growth involving one or both ovaries with distant
metastases. If pleural effusion is present there
must be positive cytology to allot a case to
Stage 4. Parenchymal liver metastases equals
Stage 4.
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Intestinal ++ - ++
Placental +++ +++ +/-
- = None
+ - +++ = Degree of stability/denaturation





L-phenylalanine 31 0.8 1.1




Levamisole 0.03 6.8 1.7
L-Leucine 13.1 3.6 5.7
(from Goldstein et al 1982)
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TABLE 1.6
PHENOTYPE, GENOTYPE AND ELECTROPHORECTIC MOTILITY OF THE
6 COMMON FORMS OF P.L.A.P.
Phenotype ElectrophorecticMotility Genotype
SS Slow P1S P1S
SF Intermediate P1S Plf
SI Intermediate P1S Pi1
II Intermediate Pi1 Pi1
FI Fast Plf Pi1









Earlyfeta placentafrom 6-10weeks gestation
Hybridtoiso¬ enzymecomposed ofintestinal andD-variant subunits
Termplacenta (10-16weeks onwards) (S,I,F)




































































% Expressing „p^AjP^ Reference
33% 1
14% 1
100% (1 patient) 2
14% 1
10% 1









100% (1 patient) 1
60% 5
15% 1
* Refers to tumour type with 10 or more cases studied.
References
1 = Nathanson and Fishman 1971
2 = Jacoby and Bagshawe 1971
3 = Warnock and Reisman 1969
4 - Higashino et al 1972





A monoclonal antibody is a defined chemical entity
recognising a single antigenic determinant, which can be
reliably and easily reproduced. Polyclonal antisera
however, are undefined mixtures of antibodies which
recognise a variety of epitopes and whose composition
varies from batch to batch produced. The production of
such antisera requires prolonged animal immunisation
schedules and time consuming purification procedures
whereas monoclonal cell lines may be grown up simply
in cell culture.
Any antibody, be it monoclonal or derived from polyclonal
antisera, can potentially recognise a number of different
antigens, provided they all carry the relevant epitope.
However, whereas cross reactivity can be accurately
predicted in the case of a monoclonal antibody, this is
not so in a variable mixture of antibodies. Unfortunately,
this very purity of a monoclonal antibody may prevent it
from recognising its antigen should a change of environ¬
ment (e.g. formalin fixation) alter its epitope, a
situation less likely to occur with polyclonal antisera
which recognise many epitopes and are therefore partially
self correcting.
This chapter describes the theory of production and
discusses the potential uses of monoclonal antibodies
with particular reference to the clinical applications
of the ND0G2 antibody used in this thesis.
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2.2 Production of Monoclonal Antibodies
2.2.1 Theory of production of monoclonal antibodies
The basis of -the monoclonal technique is that one
B-lymphocyte, in response to a given antigenic stimulus,
will only produce one antibody. If this lymphocyte can be
cloned then the resultant cell line will produce a pure
antibody of single specificity. Unfortunately, lymphocytes
will not survive for long in cell culture. However, myeloma
cell lines will grow in culture and although there are many
that will produce an antibody of their own there are some
that are non secretors e.g. the N.S.I, cell line. The method
of fusing a lymphocyte with such a myeloma cell line was
first described by Kohler and Milstein in 1975 and the
resultant tetraploid hybrid cell is able to grow in cell
culture medium and will produce a single antibody.
The myeloma cell lines used have certain genetic deficiencies
which do not allow them to grow under certain conditions.
These cell lines are unable to incorporate externally
supplied hypoxanthine or thymidine as they lack the
appropriate salvage pathway. Thus, when the endogenous
synthesis of D.N.A. precursors is blocked with methotrexate
or aminopterin, then these cells die even in the presence of
hypoxanthine or thymidine. Lymphoid spleen cells do possess
the salvage pathway but will not survive in cell culture.
Therefore only the hybrid cells will survive in a culture
medium containing H.A.T. (hypoxanthine, aminopterin and
thymidine), the growth of these cells is encouraged by the
presence of non fused spleen eells referred to as feeder
cells.
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The hybrid cells are individually isolated by dilution so
that the resultant colonies are all derived from a single
cell i.e. are clones. The steps in the production of
monoclonal antibodies are summarised in fig 2.1 (Milstein
1982).
2.2.2 Problems in the production of monoclonal antibodies
(Bastin et al 1982)
These usually stem from infection of one sort or another.
Bacterial, yeast or fungal infections are usually obvious
and are due to imperfect aseptic technique, contamination
of cell culture media or from fungal spores in the
atmosphere. Mycoplasma infections on the other hand are
more insidious, often presenting as failure of the hybrid
colonies to grow or the cessation of antibody production.
Mycoplasma may be introduced with the myeloma cell line
which can continue to grow, albeit more slowly, while
infected.
Some clones grow poorly in low cell density cultures, the
addition of extra feeder cells and 2 mercapto-ethanol
-4
(10 M) + 20% fetal cell serum helps to overcome this
problem.
Overgrowth by non secreting clones will cause the cessation
of antibody production by hybrid cells. The culture should,
therefore, have been cloned earlier.
2.2.3 Production of monoclonal antibodies to trophoblast
antigens
The NDOG2 cell line was produced by Sunderland et al in
1981 and it is from this cell line that all the ND0G2
antibody used in the experiments in this thesis is
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derived. I was not involved in the production of this cell
line nor have I been responsible for the production of any-
monoclonal antibody cell lines. However, the methods
described below are those currently used by the University
of Bristol, Department of Obstetrics and Gynaecology in the
production of monoclonal antibodies to trophoblast antigens.
Preparation of trophoblast membrane extract for use in
the immunisation of mice
This method was adapted from that originally described by
Smith et al (1974) and Standing and Williams (1978).
A term placenta was obtained from the Central Delivery Suite
within 30 minutes of delivery and the cotyledons cut into
small pieces. The amnion, chorion, blood vessels and
umbilical cord were discarded. The cut cotyledons were
washed in 2L 0.1M Ca Cl2 and 1L P.B.S., shredded in a mincer
and suspended in 350ml of 0.15M NaCl. This suspension was
stirred for 30 minutes at 4°C to separate the chorionic villi
from the bulk of the placental tissue. The mixture was
sieved, the fluid collected and centrifuged at 3000 r.p.m.
for 10 minutes and finally at 18,000 r.p.m. for 30 minutes.
The pellet containing trophoblast membrane was saved and
resuspended in 100ml per 500gm wet weight of placenta of
2% Tween 40 in 0.15M NaCl, 0.01M Tris/HCl pH 7.4, homogenised
and stirred for 1 hour at 4°C. 20ml of 32% sucrose in 0.01M
Tris/HCl pH 8.0 were loaded under 15ml aliquots of the
preparation and centrifuged at 18,000 r.p.m. for 2 hours to
remove serum proteins. The membranous band was removed from
the surface of the sucrose, washed in 0.01M Tris/HCl (pH 8.0)
and stored at -20°C until used.
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Mouse Immunisation Schedule
4-5 week old B alb/c mice were immunised by the subcutaneous
injection of 50ug of trophoblast membrane preparation, in
complete Freunds adjuvant, into the abdominal wall on two
occasions four weeks apart. Two weeks after the second
injection a further 50ug of trophoblast membrane preparation
in lOOul of P.B.S. was injected into the tail vein and the
mouse sacrificed three days later.
Fusion of mouse spleen cells with N.S.I, mouse myeloma cells
a) Reagents
1) RPM I 1640 (Flow) is a cell culture medium which is
supplied with or without a 20mmol Hepes buffer.
2) Fetal calf serum (Gibco) (F.C.S.) is heat inactivated and
virus free. It is used in RPM I 1640 at a 10% dilution.
3) Glu/P/S is a 200mM solution of L-glutamine (Flow) in
lOOmls, to which 1,000,000 units of Benzyl Penicillin
(Glaxo) and lgm of Streptomicin (Glaxo) have been added.
5ml of glu/P/S is added to every 500ml RPM I 1640 used.
4) H.M.T. supplement consists of 20ml of a 0.01M hypoxanthine,
1.6ml of 0.001M methotrexate, 3.2ml of 0.01M thymidine and
0.6ml of 0.01M glycine. 1 x H.M.T. is 1.25ml of H.M.T. added
to ]00ml of cell culture medium. It is sterilisedby filtration.
b) Method
The fusion was performed in an undirectional laminar flow
microbiological safety cabinet.
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The spleen was removed from the dead immunised mouse and
fragmented to form a single cell suspension in 5ml RPM I
1640 Hepes + F.C.S. + glu/P/S. This suspension was added
to 5ml RPM I 1640 Hepes + F.C.S.. In order to estimate the
number of cells in this suspension lOOul was made into a
1 in 50 dilution with 0.85% NH^Cl to lyse any red blood
cells. 500ul of this solution was mixed with an equal
volume of 2% Trypan Blue in P.B.S. to stain any dead cells
and an aliquot transferred to a counting chamber. There
g
were usually between 2 and 2.5 x 10 cells in the original
solution. The initial suspension was centrifuged at
1000 r.p.m. for 5 minutes, the supernatant discarded and
the cells resuspended in 5ml RPM I 1640 Hepes + F.C.S..
N.S.I, myeloma cells were grown up in RPM I 1640 Hepes +
F.C.S. + glu/P/S for 24-48 hours and a volume containing
10% the number of spleen cells was centrifuged at 1000 r.p.m.
for 5 minutes and resuspended in 5ml RPM I 1640 Hepes
+ F.C.S..
The two suspensions were mixed for 5 minutes at 37°C, centri¬
fuged at 1000 r.p.m. for 5 minutes, the supernatant was
discarded and 800ul of sterile 50% polyethyleneglycol in
RPM I 1640 Hepes added over 1 minute. The solution was
stirred at 37^C and fusion between spleen cells at the
lymphoblast stage and N.S.I . cells occurs. 10ml of RPM I
1640 Hepes was added dropwise over 5 minutes to dilute the
polyethyleneglycol and stop it clumping. The solution was
centrifuged at 1000 r.p.m. for 5 minutes and the cells
suspended in 4ml of RPM I 1640 Hepes + F.C.S. + glu/P/S
+ 1 x H.M.T., which was divided equally among 8 universal
containers of 8ml RPM I 1640 Hepes + F.C.S. + glu/P/S + 1
x H.M.T.. 250ul of these solutions were added to each well
of 8 96 well plates (Flow), which were sealed and incubated
in a moist atmosphere containing 5% CO2 at 37°C for 10-12 days.
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Cloning
10-12 days after fusion culture supernatants were tested
immunohistologically for antibody binding to trophoblast
membrane. Positive supernatants were checked against
normal human liver and kidney. Cultures secreting antibody
not absorbed by these tissues were diluted using RPM I 1640
H.T. medium into microtitre plates at 10-20 cells/well with
5
2.5 x 10 mouse thymocyte feeder cells. After growth and
reassay cells were rediuted in RPM I 1640 into microtitre
plates at 1-5 cells per well with thymocyte feeders. The
process was repeated until wells containing single active
clones were obtained. The cells were pooled, recloned and
grown up as a single cell line. In order to ensure
successful cloning cells were diluted into microtitre plates
to give an average of one to two clones per well and super¬
natants checked for antibody to trophoblast membrane.
2.3 The ND0G2 monoclonal antibody
ND0G2 is a class lgG2b antibody and was produced using a
technique similar to that described in 2.1.3 (Sunderland
et al 1981). Indirect evidence that ND0G2 recognises a
P.L.A.P. determinant comes from the immunohistological
examination of human placentae. Positive reactive staining
with NDOG2 first appears on placentae of gestational age
10-16 weeks and is present on all placentae of greater than
16 weeks gestation. Positive reactive staining was
recorded on all of 50 term placentae examined and this
distribution is identical to that of P.L.A.P.. The immuno¬
histological technique employed and the distribution of
reactive staining with ND0G2 in both malignant and non
malignant tissues is described in detail in Chapter 3.
Bowel, liver and kidney do not show any reactive staining
with this antibody, evidence that ND0G2 does not cross




Antibody specificity was demonstrated using serial dilutions
of ND0G2 and 3 control antibodies whose properties are
described in Table 3.1, in a solid phase enzyme immunoassay
(McLaughlin et al 1983) which is described in detail in
Chapter 4. Multiwell plates were coated with rabbit anti-
mouse immunoglobulin, washed and incubated with serial
dilutions of the appropriate monoclonal antibody. The
wells were washed and incubated with 50ug/well of purified
P.L.A.P., supplied by Dr R Sutcliffe (University of Glasgow).
After a final wash a colourmetric reaction for alkaline
phosphatase was demonstrated using paranitrophenol
phosphate; only the wells containing ND0G2 showed any evidence
of alkaline phosphatase activity (fig 2.2). Similar experi¬
ments using pregnancy serum in the second incubation again
showed ND0G2 to specifically find a heat stable phosphatase
activity.
Dr J L Millan of the Umea University, Stockholm supplied
independant confirmation that ND0G2 only recognises the
placental isoenzyme of alkaline phosphatase and that it
recognises the 3 common allelic forms of P.L.A.P. equally
well.
2.4 Potential uses of monoclonal antibodies
2.4.1 Immunohistology
Methods available
Immunohistological examination of tissues can be performed
using monoclonal or polyclonal antibodies. The antigen
binding region of a monoclonal antibody lacks the variability
present in polyclonal antibodies and is therefore highly
specific. A further advantage of monoclonal antibodies over
polyclonal antisera is that limitless supplies of exactly
the same antibody can be easily produced (Mason et al 1982).
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There are three main methods of immunohistology (Kurman 1984).
1) Indirect immunoperoxidase technique
The sections are incubated with the primary antibody (e.g.
of mouse origin) and then with a peroxidase conjugated
immunoglobulin directed against the primary antibody (e.g. a
rabbit anti mouse immunoglobulin). The reaction product is
visualised by the addition of diaminobenzide (D.A.B.) and
hydrogen peroxide (H^C^)-
2) Peroxidase anti-peroxidase (P.A.P.)
This method depends on an excess of rabbit anti mouse
immunoglobulin which links the primary mouse antibody to
the mouse antibody in the P.A.P. complex, which is a soluble
antigen-antibody complex composed of peroxidase and a mouse
antibody to peroxidase. The reaction is visualised by the
addition of D.A.B. and • This method has increased
sensitivity over the indirect peroxidase method but mouse
P.A.P. is not widely available from commercial sources due
to the difficulty in producing large volumes of polyclonal
antibody in mice (Mason et al 1982).
3) Biotin-Avidin method (Hsu et al 1981)
Avidin, an egg white glycoprotein, has a very high affinity
for the vitamin biotin. Biotin is co-valently bound to
peroxidase molecules allowing peroxidase to bind avidin.
The complex is linked to the primary antibody by a
biotinylated antiprimary immunoglobulin and the reaction
product visualised by the addition of D.A.B. and
The biotin-avidin method is the most sensitive of the
three methods and reduces the risk of non-specific staining.
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4) Immunofluorescence
Immunofluorescence can be used as an alternative to
immunoenzymatic methods of demonstrating antigen/antibody
reaction. It is easy to use but does not allow simultaneous
visualisation of the morphology of the section. In addition
fluorescently labelled sections tend to fade on storage and
non-specific background staining is common especially if the
antibodies are over conjugated (Mason et al 1982).
Limitations of Immunohistological labelling (Mason et al 1982)
1) Limited sensitivity
If the sought antigen is only produced in limited amounts or
has a very short half life then it may not be detectable.
Also if the antigen has been denatured by the fixative
(particularly Zenker-type fixatives and to a lesser extent
10% formalin and Bouins) then a false negative reaction may
be obtained. This can be a particular problem with paraffin
embedded tissues and so cryostat sections are frequently
used, but there is still a risk of destruction of the
antigen when the sections are fixed prior to staining.
Acetone has been shown to be the best fixative in these
circumstances (Gomori 1952, Dempo et al 1980).
2) Background staining
There is much less of a problem with monoclonal as opposed
to polyclonal antibodies, but nonetheless still occurs. It
can be recognised by the use of appropriate controls and
thereby differentiated from the presence of cellular antigen
in the extracellular environment, e.g. in gland secretions.
67
The Histochemical method of detecting Alkaline Phosphatase
Histochemical techniques of tissue staining can be applied
in the case of alkaline phosphatase. This method depends
on the substrate alphanapthyl acid phosphate being split by
alkaline phosphatase and-the product being visualised by
fast blue BBN (Sasaki and Fishman 1973) or fast red violet
L.B. salt (Nozawa et al 1980) as opposed to an antibody
recognising a specific determinant. This method requires
the presence of the enzyme in an active form and therefore
appropriate aminoacid inhibitors are usually used to
differentiate between the various, isoenzymes.
2.4.2 Serum Assay
Enzyme linked immunosorbent assays (E.L.I.S.A.) and radio¬
immunoassays (R.I.A.) are the two methods in common usage
employing antibodies in serum assays. Both depend on the
adsorption of either antigen or antibody to a solid phase,
which is a result of hydrophobic interactions between non
polar protein substances and the non polar plastic matrix
(Clark and Engval 1980). The solid phase may be particles
of cellulose or polyacrylamide but, as these require centri-
fuging in the washing steps, preformed material such as
beads, tubes, discs or microplates are more conveniently
used. Polystyrene is the most commonly used solid phase
as it can be coated easily and reproducibly.
E.L.I.S.A.
A variety of assays exist (Voller et al 1976).
A) Competitive method
i) Specific antibody is attached to the solid phase which
is then washed.
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ii) A test solution thought to contain antigen is then
added. It is either mixed with enzyme-labelled antigen
or enzyme-labelled antigen is added after a short time.
Plates are then incubated and then washed.
iii) Enzyme substrate is added. The colour change is
inversely proportional to the amount of antigen present
in the test sample.
B) Double Antibody Sandwich Method
i) As (A).
ii) The test solution is incubated with the sensitised
solid phase and then washed.
iii) Enzyme-labelled specific antibody to the antigen is
then incubated with the solid phase and then washed.
iv) Enzyme substrate is added. The colour change is
proportional to the amount of antigen in the test solution.
C) Modified Double Antibody Sandwich Method
i ) As (B) .
ii ) As (B).
iii) Specific antibody, produced from a different species
than the antibody in step (i) is added, incubated and
washed.
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iv) Enzyme labelled anti immunoglobulin is then added,
incubated and washed. This anti immunoglobulin is
reactive to the antibody in step (iii) but not to that in
step (i).
v) Enzyme substrate is added and the colour change is
proportional to the amount of antigen in the test sample.
D) Inhibition E.L.I.S.A,
i) The relevant antigen is attached to the solid phase and
then washed.
ii) The test solution is mixed with a reference antiserum
containing specific antibody and this mixture is incubated
with the sensitised solid phase, which is then washed. If
this antibody is enzyme labelled then step (iii) is not
required.
iii) Enzyme labelled anti immunoglobulin (reactive with
antibody in (ii) is added, incubated and washed.
iv) Enzyme substrate is added. The amount of antigen present
in the test sample is indirectly proportional to the colour
change.
In these assays the product of the enzyme causes a colour
change which can be measured using a spectrophotometer. Two
enzymes are commonly used, alkaline phosphatase and
peroxidase. The substrate for alkaline phosphatase is
paranitrophenyl phosphate, the reaction is stopped with
concentrated NaOH and the resultant stable yellow product
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measured photometrically at 405nm. The best substrate
for peroxidase is O-phenylenediamine (O.P.D.), the reaction
can be stopped with 2M E^SO^ and read at 492nm. O.P.D. has
been reported as being mutagenic and should be used with
care.
Where alkaline phosphatase is the antigen to be measured
in serum then enzyme labelled antibodies are not necessary
to develop a colour reaction (McLaughlin et al 1983).
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R.I.A. makes use of the radionuclide Iodine-125 ( I) in
place of enzyme labelled antibodies/antigens, but other¬
wise the various methods are similar.
There are a number of problems associated with E.L.I.S.A.
(Clark and Engvall 1980):
1) As the antibody (or antigen) is only physically
adsorbed to the solid phase and not co-valently bound
then the protein can be lost in washes and incubation
thereby lowering the precision and sensitivity of the
assay, particularly in competitive assays.
2) The adsorbed protein may become denatured thereby
loosing some binding capacity.
3) The binding of protein to the solid phase is non¬
specific and therefore either the test antigen, in
competitive and sandwich assays, or the second antibody
can also bind. This can be minimised by blocking the
remaining sites on the solid phase after step (1) with




Paul Ehrlich, in the early part of this century, first
proposed the idea of using antitumour antibodies to
selectively target toxic substances to tumour cells
(Himmelwiet 1960). However, it was not until 1929 that
tumours were shown to be antigenically distinct from
non malignant tumours (Witebsky 1929), and their ability
to take up foreign proteins and dyes non-specifically
was demonstrated by Duran-Reynals (1939). Pressman and
Keighley (1948) used a radiolabelled antibody in animal
experiments to visualise the kidney. Bale et al (1957)
and Pressman (1957) demonstrated radiolabelled antibody
uptake by transplanted rodent tumours and tumour
antibodies were shown to cross react with normal tissues
by Day (1964). In the early 1970's human tumours
transplanted in hamsters were visualised using radiolabelled
anti H.C.G. (Quinones 1971) and anti C.E.A. (Goldenberg et
al 1974, Primus et al 1973). Both these antibodies were
only partly purified, by using affinity purified
antibodies, again in animal experiments, Mach (1974)
obtained superior tumour visualisation. All these
experiments demonstrated a raised concentration of anti-
tumour antibody, when compared with a non-specific
antibody in the relevant tumour.
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Radioimmunodetection of tumour deposits
A large number of human cancers have been investigated
using radioimmunoscintigraphy (R.I.S.), these include
breast (Rainsbury et al 1983, Epenetos et al 1982), colon
(Goldenberg et al 1980, Farrands et al 1982, Epenetos et
al 1982, Chatal et al 1984), islet cell tumour of the
pancreas (Fairweather et al 1982), melanoma (Larson et
al 1984), ovary (Goldenberg 1980, Van Nagell et al 1980,
Halsall et al 1981, Epenetos et al 1982 and 1984),
osteosarcoma (Perkins et al 1984), prostate (Deland and
Goldenberg 1984, Zimmer et al 1982), testis - germ cell
tumours (Halsall et al 1981) and thyroid (Shepherd et al
1984)l R.I.S. is usually performed after intravenous
injection of the labelled antibody but intralymphatic
injection has also proved to be useful and this will
be discussed separately. Intracavity injection of radio-
labelled antibodies has been used therapeutically but not
diagnostically (Hammersmith Oncology Group 1984).
Choice of Antibody
Antibodies have been raised to a variety of tumour antigens,
some of these such as C.E.A. (Goldenberg et al 1978) and
human milk fat globule memrane antigen (Epenetos et al
1982) are present on normal human tissues and could lead
to production of false positive results. Other antibodies
raised against tumour tissue e.g. anti P 97 (Larson et al
1984) and 17-1 A (Chatal et al 1984) tend to be more
tumour specific.
Among the types of antibody which have been used are:
1) Unpurified polyclonal antisera which were used in
some early animal experiments but gave poor results and
were consequently abandoned.
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2) Affinity purified antibodies which have the disadvantage
that several antigenic sites may be recognised and have
therefore the potential for unpredictable cross reactions
with other antigens.
3) Monoclonal antibodies. These, in theory, should be
superior to (2) as their specificity and affinity are
precisely determined. Initial reports suggested that
this may be so (Ballou et al 1979, Moshakis et al 1981).
However, since then a number of workers have not, in
practice, found any superiority for monoclonal antibodies
(Fairweather et al 1982, Begent 1983, Jeppsson et al 1984).
4) Fab and FCab'^ fragments of antibodies are produced
by papain or pepsin digestion of whole antibodies, and
in consequence neither bear the antigenic Fc receptor
and therefore do not bind with complement or cells bearing
Fc receptors. They, therefore, do not form immune
complexes as readily as whole antibodies and should
consequently produce less background activity. In practice
however, immune reactions still occur (Vinocur 1984) and
while F(ab')2 fragments give optimal background ratios
for earlier imaging, intact antibodies tend to give the
best tumour images (Khow et al 1984). Nonetheless
tumour deposits as small as 1.5cm have been successfully
visualised using labelled Ftab'^ fragments (Romanelli-
Beardsley et al 1983) and Fab fragments (Larson et al
1984).
The Choice of Radionuclide
The ideal radionuclide for radioiinmunoscintigraphy would:
a) Bind easily to the appropriate antibody without
reducing its specific activity;
b) Not dissociate from the antibody when injected
intravenously;
c) Be rapidly excreted without accumulating in any
organ when the radiopharmaceutical is broken down by
the reticulo-endothelial system;
d) Be a pure gamma emittor with an energy range suitable
for the modern gamma camera;
e) Have a sufficiently long half life to give the
antibody time to reach and bind to the appropriate tumour
antigen but not so long that it may present a hazard to
the patient's health.
In practice the ideal radionuclide does not exist. However,
several have been successfully used in radioimmunoscinti-
graphy, the most common of which are the three isotopes of
iodine - 131i (Hoffer et al 1974, Goldenberg et al 1980),
(Epenetos et al 1982) and 123i (Schlumberger et al
1982). In addition Ill-Indium (^^In) (Fairweather et al
Q Q rn
1983, Slack 1984) and 99-Technecium ( Tc) (Wong et al
1982) have been successfully used. The properties of
these various isotopes are summarised in Table 2.1.
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12^I and"1-11!]! are the most suitable radionuclides in that
they have the best energy ranges for the modern gamma
131
camera and both are pure ^mma emittors. I with its
high energy range and combined beta and gamma emission
QQm 195
gives poor quality images. Tc and I have respec¬
tively too short a half life and too low an energy
emission to be of use when labelled to antibodies in
humans.
I OO
I was the radionuclide used in this thesis as blocking
agents, such as potassium iodide or potassium perchlorate
can be used to reduce uptake of the free radionuclide by
normal organs; no such blocking agents exist for i;L1In.
12 3 111
I is cheaper than In but because of its short half
life and limited production by Harwell, radioimaging is
limited to one day of the week.
Comparison of R.I.S. with other imaging techniques
R.I.S. is likely to have its biggest impact in the
detection of intra-abdominal tumour deposits. The two
most commonly used imaging techniques in these cases are
Xray computed tomography (C.T.) and ultrasound scanning
(U.S.S.) both of these have relatively poor sensitivity
for small solid metastases, particularly after primary
surgery (Piver 1983).
R.I.S. is at least as good as conventional imaging
techniques for abdominal tumours (Begent 1984) and gives
more information than C.T. as to whether the deposits
are viable or necrotic (Begent 1983). It may be as good
as C.T. in cases of lung metastases (Begent 1983) although
other workers (Halsall et al 1981) have found C.T.
superior in these cases.
Several studies exist reporting R.I.S. detection of
intra-abdominal deposits not detected by C.T. and U.S.S.
(Van Nagell et al 1980); C.T., angiography and intravenous
pyelography (Goldenberg et al 1980); C.T. and angiography
alone (Fairweather et al 1982) or C.T. and lymphangiography
(Halsall et al 1981).
While in animal experiments the smallest tumour deposit
detected was only 1mm in diameter (Epenetos et al 1984)
in humans this ranges from 1.5cm (Fairweather et al 1982,
Larson et al 1983) to 2cm (Silva et al 1980, Van Nagell
et al 1980, Halsall et al 1981).
Problems associated with R.I.S.
Allergic Reactions
There is always a risk of the development of allergic
reactions when a foreign protein is injected. This would
not appear to be a great problem. Sfakianakis and Deland
(1982) only reported 2 reactions in over 400 examinations,
in 50 of which repeat injections (up to 3 times) were
given without side effects. In this case only small
quantities 150-250ug of antibody were used. However,
the development of human anti mouse antibody (H.A.M.A.) has
been reported even with Fab fragments but tends to occur
only when large amounts of antibody are used - up to
20mg in one series (Larson et al 1983). The presence of
H.A.M.A. causes more rapid clearance of the labelled
antibody with a subsequent lower uptake by the tumour and
is most easily avoided by using low (less than 400ug)
doses of antibody per study (Vinocur 1984). Nonetheless,
it is sensible precaution to perform skin testing before
the injection of repeat doses of antibody.
Specificity
Tumours, because of the increased permeability of their
capillaries, tend to absorb more foreign protein from the
circulation than normal tissues (Duran-Reynals 1939). It
is, therefore, important to demonstrate an antibodies
specificity in vivo, this is usually performed by using
9^mTc labelled human serum albumin (Goldenberg et al 1978)
or a labelled non-specific antibody (Van Nagell 1980). The
uptake by the tumour of the radiolabelled antibody is
however low, being reported between 0.1-7% of the injected
dose (Mach et al 1980, Caroll et al 1984).
High background activity
There is usually only a small percentage of the injected
radiopharmaceutical that localises to the tumour and
because of this there is a high background activity. This
is particularly a problem in the liver where up to 40% of
the whole body radioactivity is present 24 hours after the
initial injection of ^^"^In (Rainsbury et al 1983) and can
lead to false positives in this organ (Begent 1983).
Iodine can be absorbed by an incompletely blocked thyroid
gland, gastric mucosa and by scars (Goldenberg et al 1980,
Mach et al 1980).
A variety of antibodies raised to highly tumour restricted
antigens exist (Larson et al 1983, Farrands et al 1982).
However others e.g. human milk fat globule membrane antigen
are present, in smaller quantities, on normal secretory
epithelium as well (Epenetos et al 1982) and can therefore
contribute to high background activity. Immune complexes
between circulating antibody and antigen e.g. H.C.G.,
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(Goldenberg et al 1980) or C.E.A. (Mach et al 1980)
might be expected to collect in the liver and give rise
to false positives. This, in fact, happens infrequently
and when it does gives rise to a picture of diffuse
"involvement" but not discrete nodules. No case of serum
sickness has been reported secondary to these complexes.
A number of different methods have been suggested to
enhance the visualisation of areas of increased activity,
although these are often identifiable, even in liver,
eithout the need for enhancement (Romanelli-Beardsley
1983).
The first method of enhancement was that of subtraction
using ^mTc labelled human serum albumin to give the
blood pool picture. By subtracting this image from that
obtained with the labelled antibody a clearer picture of
areas of increased activityv^s obtained (Goldenberg et al
131
1978). This is not an ideal method as the I image is
9 9m
larger than that of Tc and does not have the same
uniformity of response (Begent 1983) and a number of
artefacts have been generated using this method (Green et
al 1984). A better method of subtraction involves
subtracting the early (post injection) image, giving the
blood pool picture, from a later image which will
represent tumour uptake of the radiopharmaceutical as
well as blood pool. However, accurate repositioning of
the patient for each image is essential to avoid the
generation of artefacts (Carroll et al 1984).
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Liposomally entrapped second antibodies (L.E.S.A.) have
been used to increase the clearance of the first antibody
from the blood pool without affecting clearance from the
tumour (Begent et al 1982). The second antibody is
raised against the first antibody species type and does
give improved images, however, as L.E.S.A. is cleared by
the reticulo-endothelial system high liver background
images may be generated. Antibody fragments, as discussed
earlier, are cleared from the circulation more rapidly
than whole antibody and give less background activity.
Better imaging techniques such as singlephoton emission
tomography, may in the future lead to improved images
(Perkins et al 1984).
False negative results
These have been variously reported as between 10%
(Goldenberg et al 1980) and 60% (Mach et al 1980).
One of the main limiting factors seems to be the size of
the tumour deposit, the smallest metastasis detectable
being between 1.5cm (Vinocur 1984) and 2cm (Silva et al
1980, Van Nagell et al 1980).
In the case of boney metastases R.I.S. seems to be best
in detecting early deposits (Rainsbury et al 1983) older,
larger metastases detected by Xray or conventional bone
scans are not visualised (Rainsbury et al 1983, Deland
and Goldenberg 1984).
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The blood brain barrier results in the poor visualisation
of cerebral metastases but nonetheless it is possible to
detect some intracranial tumour deposits by R.I.S.
(Farrands et al 1982, Richardson et al 1984).
Radioimmunoscintigraphy in Ovarian Tumours
In both germ cell and epithelial tumours of the ovary anti
alphafoetoprotein has been successfully used in the
detection of metastases (Kim et al 1980, Halsall et al
1981). Other antibodies used for R.I.S. in epithelial
ovarian cancers include anti C.E.A. (Goldenberg et al
1980), an affinity purified antibody to C.E.A., which
successfully detected all the primary tumour sites but only
67% of the metastatic sites by R.I.S.. Nodules of less
than 1cm diameter were the main cause of these false
negatives. Many of these patients had high serum C.E.A.
levels but this did not lessen the sensitivity of the
investigation. Similar findings were reported by Van Nagell
et al (1980) who also successfully imaged 1 from 5 benign
ovarian cysts; again plasma levels of C.E.A. were not an
indicator of how successful the procedure would be.
A monoclonal antibody to human milk fat globule membrane
123
antigen designated H.M.F.G^ labelled with I, has been
used in R.I.S. of ovarian cancers. This antigen is found
on all normal human secretory epithelial cells but is
present in much larger quantities in various malignant
tumours including ovary (Epenetos et al 1982). In this
study over 70% of tumour deposits were detected by
radioimmunoscintigraphy, those that were not visualised
included abdominal, chest and lumbar spine tumours. Tumour
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uptake was between 0.2 and 2.6% of the injected dose with
radiolocalisation occurring between 10 minutes and 18
hours from the time of injection (Epenetos et al 1984).
Using the same antibody in a prospective preoperative
trial good correlation between R.I.S. and operative
findings was obtained in 17 from 18 cases but uptake of
the labelled antibody was also reported in benign ovarian
cysts and uterine fibroids (Granowska et al 1984).
R.I.S. using antibodies to P.L.A.P.
Apart from ND0G2 a variety of monoclonal antibodies to
P.L.A.P. are being used in the radioimmunodetection of
ovarian cancer deposits e.g. the H317 and H6/72 monoclonal
antibodies (Advances in the application of monoclonal
antibodies in Clinical Oncology, Royal Postgraduate Medical
School 1985). However, no substantive series has yet
been publised. Part of this thesis explores the use of
radiolabelled NDOG2 in the radiolocalisation of ovarian
cancer deposits.
Lymphography using Radiolabelled Antibodies
This was first used to locate nodes involved with Hodgkins
Lymphoma (Order et al 1975). Involved nodes were demonstra¬
ted but the possibility of false positive results due to
the concentration of a foreign antibody by the lymphatics,
was raised. Deland et al (1979) used intralymphatic injec-1
131
tion of I anti C.E.A. to detect axillary node involve¬
ment by breast cancer, however, a high false positive rate
was recorded which the authors suggested was due to the
presence of C.E.A. in nodes draining the tumour site.
But this could equally well have been due to non-specific
Qo
uptake by the lymph nodes. Begent (1984) suggested that
blockage of lymphatics by tumour could limit the usefulness
of this procedure.
However, one advantage of radioimmuolymphography has over
intravenous injection of labelled antibody is the minimal
binding of antibody to antigen in the circulation or on
normal tissue. Weinstein et al (1983) in animal experiments
demonstrated a fourfold increase in uptake of labelled
antibody by lymph node metastases when an intralymphatic
route was used in preference to intravenous injection. This
suggests that the low uptake of labelled antibody by tumour
previously recorded is not due to saturation of antigenic
sites but to low concentrations of available antibody in the
circulation (Begent 1984). Large intravenous doses of
antibody have been used (up to 20mg) in R.I.S. of colonic and
ovarian cancer but these have not improved the quality of the
images (Larson personal communication).
2.4.4 Immunotherapy
This can take the form of a non-specific boost to the
patient's immune system or as antibody directed therapy
to the tumour.
1) Non-specific immuotherapy
The rationale for this form of therapy is to reverse the
immune depression that can exist with many tumours or that
results from conventional therapy - surgery, chemotherapy
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or radiotherapy; in addition it may be possible to increase
the immunogenicity of the tumour cells themselves (Freedman
et al 1983). The agents used include Bacille Calmette-
Guerin (B.C.G.) (Hudson et al 1976), autologous tumour
extracts and corynebacterium parvum (Gudson et al 1983),
and virus modified tumour cell extracts (Freedman et al
1983). The benefit of this form of therapy is debatable
(Hamblin 1982).
2 ) Antibody directed therapy
Chlorambucil, linked to antibody, was an early form of
antibody directed therapy. This was not successful as
the complex was not stable when given to the patient
(Rubens and Dulbecco 1974).
Toxin conjugated antibodies would appear to be an ideal
chemotherapeutic agent. Toxins postulated for use
include ricin (Krolik et al 1982) or diptheria toxin
(Moolten et al 1975). R'icin, in particular, appears an
attractive toxin to use in vivo. It consists of a toxic
polypeptide ('A1 chain) coupled to a cell binding
polypeptide ('B' chain) (Olsnes and Phil 1973). The 'A'
chain by action on the ribosome, kills the cell by
inhibiting protein synthesis (Olsnes and Phil 1984) but
'A' chain on its own cannot enter the cell and is therefore
harmless (Neville and Youle 1982). 'A' chain ricin has
been successfully linked to antibodies (Uhr and Vitella
1983, Seon et al 1983) and has been used to eliminate
leukaemia cells in animals (Uhr and Vitella 1983) and
from marrow in man, prior to autologous transplantation
(Seon et al 1983). Similarly, antibodies linked to magnetite
containing polystyrene microspheres have been used to
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eliminate neuroblastoma cells from marrow, by passing the
suspension through a magnetic field, prior to autologous
transplantation (Treleaven et al 1984) and complement
fixing monoclonal antibody used to "cleanse" bone marrow,
in vitro, of breast cancer cells (Buckman et al 1982).
While toxin conjugated antibody therapy may have a place
in the treatment of leukaemias, therapy of solid tumours,
such as ovarian carcinoma, present a number of problems
i) Penetration of the tumour mass may not be adequate as
many solid tumours are relatively avascular at their centres.
ii) Ensuring that the antibody used recognises tumour
cells alone. If the antigen is also expressed by normal
tissues then the specificity of antibody directed.therapy
is lost. Unfortunately, no truly tumour specific antigen
exists in the case of ovarian cancer, although some
e.g. C.A. 125 (Bast et al 1981) are only weakly expressed
by certain normal tissues (Kabawat et al 1983, Niloff et al
1984).
iii) Expression of the antigen within the tumour is not
always homogenous (Hammersmith Oncology Group 1984).
Thus even if the cells expressing that particular antigen
are destroyed a population of tumour cells will be
unaffected, multiply and ultimately kill the patient.
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iv) It has become apparent from experience obtained with
R.I.S. that only a small percentage of the injected antibody
will localise to the tumour (Epenetos et al 1982, 1984;
Carroll et al 1984). As this is unlikely to be due to
saturation of the available antigenic sites (Begent 1984)
a higher dose of antibody could be given. However, this
would increase the risk of an allergic reaction (Vinocur
1984) and lead to the development of antibodies which would
tend to render this form of therapy less effective
(Larson et al 1983, Vinocur 1984).
v) Antigenic modulation; cells exposed to an antibody can
undergo change (modulation) so that they no longer express
that antigen. This would not be a problem if every cell
that comes into contact with a toxin conjugated antibody
is destroyed, however a better form of therapy might
involve the use of antibody fragments which appear not to
induce modulation (Glennie and Stevenson 1982).
Antibody directed Radiotherapy
The treatment of patients with ovarian cancer by means of
radioactive colloids is not new. Intra-abdominal instilla-
32
tion of P has proven to be as effective as other forms of
therapy and has few side effects (Penzer et al 1978).
However, homogenous distribution throughout the peritoneal
cavity cannot be guaranteed, particularly if adhesions are
present. The retroperitoneal tissues such as the para¬
aortic nodes receive no treatment and these can be involved
even when no other extra ovarian spread is apparent (Piver
et al 1978). Therapy with radionuclide linked antibodies
would help to overcome the lack of homogeneity of expression
of the antigen, by the tumour, as any cell within a few
millimetres of a cell, with beta partical emitting
radionuclide attached, would be destroyed. In addition
administration of the antibody into a restricted space
such as a pleural, pericardial or peritoneal cavity
results in a much higher uptake of the antibody, by the
tumour than would be anticipated by an intravenous
injection (Hammersmith Oncology Group 1984).
The most obvious radionuclide to use in this situation is
131
I, predominantly a beta emitter, which can be easily
linked to proteins. There is a risk of loss of activity
by the antibody when iodinated and from radioactivity of
the radionuclide. Different monoclonal antibodies have
131
been successfully iodinated with high doses of I by
both the chloramine T (Ferens et al 1984) and iodogen
methods (Hammersmith Oncology Group 1984) without
significant loss of activity.
Three patients, one with an advanced ovarian carcinoma
I O I
have been treated by intracavity instillation of I
H.M.F.G«2 antibody and remissions induced (Hammersmith
Oncology Group 1984).
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2.5 Tables, Charts and Figures
Fig 2.1 Usual steps involved in the derivation and
cloning of antibody producing hybrid cells
Immunised animal
Spleen cells j
(Die in tissue culture
J
Myeloma cell line
(Grow in tissue culture
but die in H.M.T.)
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Fig 2.2 Demonstration of NDOG2 specificity
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CHAPTER 3




Immunohistology was performed, using an indirect immuno-
peroxidase technique on frozen sections of normal and
malignant tissues in order to assess the distribution of
the ND0G2 determinant in healthy organs and in gynaecolo¬
gical cancer. Histochemistry, using specific aminoacid
inhibitors of the various isoenzymes of alkaline phosphatase
was performed in certain tissues, to confirm that ND0G2
was recognising P.L.A.P..
Frozen sections were used in preference to formalin fixed,
wax embedded tissue as it has been the Department's previous
experience that conventional methods of fixation result in
the partial denaturation of the ND0G2 determinant
(Sunderland et al 1984).
3.2 Methods
3.2.1. Tissue collection and storage
Tissue from normal gynaecological organs and tumours was
obtained fresh at the time of operation. Normal endometrium
was sampled by dilation and curettage from patients under¬
going laparoscopy for sterilisation or investigation of
subfertility. Postmenopausal endometrium was obtained
from patients undergoing diagnostic curettage for post¬
menopausal bleeding in which subsequent histological
examination showed no evidence of malignancy. Specimens
of cervix, myometrium and fallopian tube were obtained
from hysterectomy specimens, where no underlying malignancy
was present.
Placental tissue was obtained, fresh, either at delivery or
from therapeutic termination of pregnancy depending on the
gestational age of the pregnancy.
Small pieces of tissue of 5mm diameter were snap frozen on
aluminium foil floating in liquid nitrogen, within 2 hours
of delivery or operation and stored/ in cyrotubes, at -70°C
or in liquid nitrogen until used.
Other specimens of normal tissue were obtained from post
mortem examination material, within 8 hours of death and
similarly stored.
3.2.2 Immunohistoloqy
Frozen sections of 6u thickness were cut and mounted on four
well, teflon coated slides, air dried for 1 hour and fixed
in acetone for 10 minutes at room temperature. One section
from each block was fixed in 10% formol saline, stained with
Mayers haematoxylin (Gurr) and 1% eosin (Gurr) and mounted
in D.P.X. (B.D.H.). This section acted as a reference.
The other sections were washed in 0.15M NaCl, 0.05M Tris HC1
pH 7.4 (T.B.S.) for 2 minutes. 50ul of ND0G2 (2 wells per
slide) or an appropriate positive or negative control (1 well
per slide) (Table 3.1) were applied to each section and
incubated for 45 minutes at room temperature in a moist
atmosphere. They were then washed twice, for 2 minutes in
T.B.S. and similarly incubated with 50ul of peroxidase
conjugated rabbit anti mouse immunoglobulin (Dako) at 1/50
dilution in T.B.S. with 10% normal human serum for 30 minutes
A further washing was performed and the sections incubated,
in a fume cupboard, with 50ul of diaminobenzide tetra HC1
(Sigma) at 0.5mg/ml in T.B.S., with 0.0075% H-C^ (Analar)
for 8 minutes. They were then washed in excess water,
- counterstained with Mayers haematoxylin and mounted in D.P.X.
A positive control antibody was used to indicate the
antigenic integrity of the tissues and the technical
validity of the experiment. Antibodies which were used
were W6/32, BMH 1 and TROMA 1. The negative control
antibodies, NDOG4, BMH5 and MRC 0X6 were used to identify
any non-specific binding of antibodies (see Table 3.1
for reactions and sources of these antibodies). This
was negligible except for cervical columnar epithelial
secretions and to a lesser extent colonic epithelium,
which could be eliminated by the inclusion of normal
human serum (10-50%) in the first incubation buffer.
This had no effect on the specificity of ND0G2 as assessed
on placental sections. A small population of cells with
endogenous peroxidase activity were identified in the
thymus and in the lamina propria of duodenum and colon.
The morphology position and staining intensity of these
cells obviously distinguished them from specifically
staining tissue. Endogenous peroxidase activity was also
noted in erythrocytes.
3.2.3 Histochemistry
Frozen sections of 6i^ thickness were cut and air dried
for 1 hour at room temperature. No fixative was -applied.
Napthyl A.S. M.X. phosphoric acid (2mgm) (Sigma) was
dissolved in 0.2ml dimethylformamide and 9.8ml of 0.1M
Tris HC1 pH 8.0 added. lOmgm of Fast Blue (Gurr) was
added, the sample divided into 1ml aliquots and 1ml of
the appropriate inhibitor added to each, centrifuged at
12,000 r.p.m. in a Beckman microfuge for 2 minutes and
applied to the tissue sections. The sections were
incubated for 15 minutes at room temperature, washed in
excess tap water and mounted in glycerin jelly.
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ImM Levamisole was used to inhibit tissue non-specific
alkaline phosphatase and 2mM L-phenlalanyl glyclyglycine
used to inhibit P.L.A.P..
3.3 Results
3.3.1 Immunohistoloqy of normal tissues
Serial sections of duodenum, liver and kidney were cut and
stained either histochemically or by the indirect immuno-
peroxidase technique with ND0G2. There was no reactive
staining with ND0G2, in any of these tissues but alkaline
phosphatase activity was demonstrable histochemically on
duodenal epithelium, liver sinusoids and kidney tubules.
The ND0G2 antibody does not therefore cross react with
these isoenzymes. In addition, no reactive staining could
be demonstrated in any of the normal tissues listed in
Table 3.2.
However, the following normal tissues did show positive
reactive staining with ND0G2:-
a) Placenta
Reactive staining with the ND0G2 antibody could be demonstra¬
ted in placentae from 10 weeks gestational age. This
staining was initially prominent around multinucleate
syncytial buds but later spread to 'cover uniformly the
villous syncytiotrophoblast plasma membrane (fig 3.1).
There was slight staining of the syncytiotrophoblast
basement membrane in the second and third trimester. The
non-villous forms of trophoblast in the placental bed bound
either none or very low quantities of ND0G2. Term chorionic
membrane showed up to 50% of cytotrophoblast cells stained
with ND0G2 and these were concentrated on the fetal aspect
of the chorionic cytotrophoblast layer. NDOG2 showed
reactive staining with all of the 50 term placentae examined.
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b) Cervix
10 specimens of normal, healthy cervix were examined.
There was some non-specific staining of endocervical
gland secretions. This was reduced by the incorporation
of normal human serum in the monoclonal antibody
incubation, revealing specific NDOG2 binding to the
luminal epithelial surface (Fig. 3.2) and some specific
staining of gland secretions with ND0G2. The squamous
epithelium of the ectocervix was consistently negative.
c) Endometrium
Samples of endometrium from 22 women in their reproductive
years and from 3 women who were postmenopausal were
examined. 13 samples were from the proliferative phase of
the menstrual cycle, 8 were in the secretory phase and 1
patient was premenstrual. Reactive staining with ND0G2
was looked for on surface (Fig. 3.3) and glandular (Fig. 3.4)
epithelium.' Positive staining was always seen on at least
some cells of the surface epithelium although it was
sometimes absent from glandular epithelium in the same
specimen (Table 3.3). Only a few glands were cut in
longitudinal sections, but in those that were, some cells
were always positive. There was reactive staining on the
cell membrane with the strongest reaction occurring on
the luminal surface of the cell in both epithelial types
examined. The functional glandular epithelium showed a
greater degree of reactive staining than the reserve cells
but there was otherwise no obvious difference between
cells expressing the NDOG2 determinant and those that did
not.
96
21 from 22 specimens of premenopausal endometrium showed
positive reactive staining with ND0G2. In 15 of these
both glandular and surface epithelium was present but in
6 only glandular epithelium was seen. The negative
specimen contained glandular epithelium (in cross section)
alone.
Surface epithelium was present and positive in 15 sections,
glandular epithelium was positive in 13 from 22 sections
(Table 3.3). There was no variation in expression of the
ND0G2 determinant throughout the cycle (Table 3.4) and the
stromal tissue was consistently negative.
Reactive staining with ND0G2 was found in all 3 specimens
of postmenopausal endometrium in both surface and glandular
epithelium (Table 3.3).
d) Fallopian Tube
In all 4 samples studied there was reactive staining with
ND0G2 on the luminal surface and of virtually all the
epithelial cells (Fig. 3.5).
e) Lung
There was marked variation in reactive staining amongst the
6 specimens examined. In 3 specimens no staining was seen
but in the remaining 3, specific staining presented as a
linear streak on a single epithelial surface (Fig. 3.6) as
opposed to circumscribing the cell, as might be expected
from a typical cell membrane antigen. This pattern of
expression may be consistent with enzyme secretion.
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F) Thymus
The thymus gave the only example of cellular reactivity
in normal tissues. A minor subpopulation of reticular
cells in the thymic medulla gave a positive reaction
which was diffuse throughout the cell, probably indicating
cytoplasmic localisation of antigen. These cells comprised
less than 1% of the cells in the thymus and were of
typical reticular morphology, having a large pale staining
nucleus and long cytoplasmic processes (Fig. 3.7).
3.3.2 Immunohistology of gynaecological tumour tissue
Ovarian Tumours
100 ovarian tumours were examined immunohistologically for
the expression of the NDOG2 determinant, of these 44 were
benign tumours and 56 malignant tumours.
Serial sections of one serous cystadenocarcinoma were
stained by the immunoperoxidase technique with ND0G2 and
histochemically for the enzyme alkaline phosphatase. The
alkaline phosphatase reaction was intensely positive on
precisely the same subpopulation of epithelial cells as
bound detectable ND0G2 antibody. This enzyme activity was
totally inhibited by 2mM L-phenylalanylglycylcine while
ImM levamisole gave only a marginal diminution in staining.
These inhibiting properties are characteristic of the
placental isoenzyme of alkaline phosphatase (Goldstein et
al 1982). Stromal tissue showed a lesser amount of
alkaline phosphatase activity localised on blood vessel
endothelium which was inhibitable completely by ImM
Levamisole but not 2mM L-phenylalanylglycylglycine i.e. a
typical inhibiting pattern of the tissue non-specific
isoenzyme. ND0G2 did not bind to any stromal tissue.
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25% of all benign tumours (Table 3,5) and 64% of malignant
tumours (Table 3.6) showed variable degrees of reactive
staining with ND0G2 but in no specimen examined were 100%
of cells positive. In all specimens of primary ovarian
cancers and benign cystadenomas examined, staining was
present on the epithelial cell membrane (fig. 3.8 & 3.9);
but secondary tumours, when positive, showed uniform
distribution of staining throughout the cell. In both
benign and malignant tumours it was the serous cystaden¬
omas and cystadenocarcinomas that predominantly expressed
P.L.A.P. (47% and 81% respectively). There was much
variation in the degree of staining within each histolo¬
gical grade of tumour; however, when both primary and
secondary tumour tissue was available from the same patient,
the primary tumour usually showed the greater degree of
reactive staining (Table 3.7 and gis 3.9 and 3.10). In
all specimens the stromal tissue did not show specific
reactive staining with ND0G2.
Endometrial Carcinoma
Specimens of endometrial cancer tissue were obtained from
17 patients. Of these, 2 were adenosquamous tumours and
the remainder adenocarcinomas. The effect of histological
type, stage and differentiation on the degree of staining
was assesed. Both adenosquamous carcinomas were negative
but 11 from 15 adenocarcinomas were positive. Intense
reactive staining was seen on the cell surface of malignant
cells with no intracellular or stromal staining (fig 3.11).
The degree of staining was unaffected by stage or differ¬
entiation of the tumour (Tables 3.8 and 3.9 respectively).
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Cervical Carcinoma
12 squamous carcinomas of the cervix were examined, only
5 tumours showed reactive staining and this was, on the
whole, scanty with 3 tumours showing reactive staining in
less than 1% of the total number of cells and 2 with 1-25%
of cells positive. The remaining 7 tumours were all negative.
Again staining was confined to the cell membrane (fig 3.12).
Other Gynaecological Malignancies
3 uterine sarcomas and 5 vulval carcinomas all failed to
show reactive staining with NDOG2.
3.4 Conclusions and Discussion •
Fresh frozen tissue was used both for immunohistological and
histochemical examination, as formalin fixed, wax embedded
tissues appear to loose the ND0G2 determinant. Positive
reactive staining with ND0G2 was demonstrated in normal
fallopian tube, endometrial and endocervical columnar
epithelium, thymus, lung and placentae from 10 weeks gesta¬
tion to term. Although, as far as I am aware, P.L.A.P. has
not previously been described in association with fallopian
tube epithelium, this distribution is the same as that
described in the literature for P.L.A.P. (Fishman et al
1972, Nozawa et al 1980, Goldstein et al 1982). It has
already been shown that ND0G2 fixes a P.L.A.P. determinant
(section 2.3) and the absence of reactive staining on
duodenum, kidney and liver is evidence that ND0G2 does not
cross react with the other alkaline phosphatase isoenzymes.
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Virtually all the specimens of endometrium examined showed
positive reactive staining with NDOG2 and this was more
marked on surface than glandular epithelium (Table 3.3)
and this was unaffected by the stage of the menstrual
cycle (Table 3.4). This is a much greater expression of
P.L.A.P. by this tissue than has been previously described
(Nozawa et al 1980) and suggests a greater sensitivity
for immunohistology over those methods relying on the
L-phenylalanine sensitivity of P.L.A.P. or heat stability.
No reactive staining with NDOG2 was demonstrated on the
single specimen of testis examined although P.L.A.P. was
described in association with this organ (Chang 1978)
however the form of P.L.A.P. expressed is usually the rare
'D' variant (Goldstein et al 1982) a form not recognised
by NDOG2.
Endocervical columnar endometrial and fallopian tube
epithelia are all derived from the paramesonephric duct
and all three express P.L.A.P.. Although no specimen of
the rare fallopian tube carcinoma were available for
study, both endometrial and cervical carcinomas express
this enzyme. This suggests that there is an inbred
inherence for tissues derived from similar regions
embryologically and their tumours to express a particular
antigen, in this case P.L.A.P., and that this is not due
to a malignancy-induced change from the bone-liver-kidney
isoenzyme to P.L.A.P. as suggested by Nozawa et al (1981).
Although P.L.A.P. has been described in association with
both endometrial and cervical cancer (Cadeau et al 1974,
Kellen et al 1976) its expression by endometrial cancer
does not appear to be affected by the stage of the tumour
(Table 3.8) or the degree of differentiation (Table 3.9)
as suggested by Kellen et al (1976).
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In a similar vein all epithelial ovarian cancers derive
from the so called germinal epithelium of the ovary which
arises, embryologically, close to the paramesonephric duct,
and a high proportion (64%) of such cancers studied showed
positive reactive staining with ND0G2. Histochemistry
performed on serial sections of tumour showed P.L.A.P.
activity on the same subpopulation of cells as those with
ND0G2. Serous cystadenocarcinomas showed a greater degree
of specific staining than any other histological type
studied (Table 3.6) and a similar distribution was seen
when benign tumours were studied (Table 3.5). The histo¬
logical grade of the tumour did not affect the degree of
reactive staining with ND0G2, however the primary tumour
usually showed a higher percentage of cells positive than
did metastases from the same patient (Table 3.7).
Although P.L.A.P. is not tumour specific it is expressed
by relatively few normal tissues and of these some
(fallopian tube, endometrium and cervix) are usually
removed at primary surgery for ovarian cancer. Expression
of P.L.A.P. by thymus is minute and in any case tends to
be intracellular and obviously expression by placentae is
irrelevant when P.L.A.P. is considered as a tumour marker
in ovarian cancer. The presence of P.L.A.P. in lung is
potentially problematical, and as can be seen in Chapter 4
caused problems in interpreting raised serum P.L.A.P.
levels in cigarette smokers. The reduced expression of
this enzyme by tumour metastases was disappointing and
could affect the sensitivity of P.L.A.P. as a tumour marker.
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3.5 Tables, Charts and Figures
Legend for Figures
Positive reactive staining with NDOG2, using an indirect
immunoperoxidase technique, counterstained with haematoxylin
is demonstrated on frozen sections of the following tissues.
Fig 3.1 Term placenta.
Fig 3.2 Normal cervix.
Fig 3.3 Surface endometrial epithelium.
Fig 3.4 Glandular endometrial epithelium.
Fig 3.5 Fallopian tube epithelium.
Fig 3.6 Normal lung.
Fig 3.7 Normal thymus.
Fig 3.8 Ovarian serous cystadenoma showing grade 3
reactive staining.
Fig 3.9 Primary ovarian serous cystadenocarcinoma,
showing grade 4 reactive staining.
Fig 3.10 Omental secondary from the tumour in Fig 3.9
showing grade 2 reactive staining.
Fig 3.11 Primary endometrial adenocarcinoma showing
grade 4 reactive staining.
Fig 3.12 Primary cervical squamous carcinoma showing
grade 1 reactive staining.
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Negative Grade1 Grade2 Grade3 Grade4
5 1 7
0 0
3 2 2 1
0
1 0 0 0 0




Table 3.5 Degree of staining with NDOG2 compared with
histological type of benign ovarian tumours
(includes fimbrial cysts)
Histological Type
Degree of staining Total
Neg G1 G2 G3 G4
Serous cystadenoma 9 1 1 5 1 17
Mucinous cystadenoma 8 - 1 - - 9
Fibroma 5 - - - - 5
Dermoid cyst 5 - - - - 5
Fimbrial cyst - 1 1 - - 1
Chocolate cyst 1 - - - - 1
Theca granulosa cyst 1 - - - - 1
Cystadenomafibroma 1 - - - 1 2
Follicular cyst 1 - - - - 1
Thecalutein cyst 1 - - - - ■ 1
Thecoma 1 — — — — 1





= Less than 1% of cells positive
= 1-25% of cells positive
= 25-75% of cells positive
= 75-100% of cells positive

























































































































































































Table 3.8 The degree of staining with NDOG2 compared with




Neg 1 2 3 4




Table 3.9 The effect of differentiation on the degree of




Neg 1 2 3 4
Well differentiated 2 1 2
Moderately
differentiated








A serum assay measuring the presence and levels of a
tumour marker which gave an accurate indication of the
course of the disease would be very useful in the
management of patients with ovarian cancer. This chapter
describes the use of the ND0G2 antibody as a basis for
such an assay.
ND0G2 recognises the enzyme P.L.A.P. and there are two
basic ways of using antibodies to determine the levels of
an enzyme:
1) Through the amount of enzymatic activity specifically
bound by the antibody.
2) Through the amount of protein specifically bound by
the antibody.
Assay 1 followed the first option whereas assays 2 and 3
attempted to measure the total protein bound. Enzyme
linked immunosorbant assays (E.L.I.S.A.) were used in
option 2 and not radioimmunoassays because of the proven
sensitivity and convenience of the E.L.I.S.A. technique.
The discrepancies noted between option 1 and 2 may be due
to the presence of inactive enzyme protein (measured in 2
but not in 1) or cross reaction of ND0G2 with some other
serum protein. Attempts to distinguish between these were




109 healthy female blood donors acted as controls for this
study, 66 of these were non-smokers (mean age 39.4 years).
The mean age of the 43 cigarette smokers was 35.4 years.
Patients
a) With benign ovarian tumours
Preoperative serum samples were obtained from 6 non-smoking
patients (mean age 52.4 years) whose tumours subsequently
showed positive reactive staining with NDOG2.
b) With ovarian cancer
Serum samples were available from 52 patients with ovarian
cancer. 44 patients (mean age 51 years) were followed up
for between 4 and 26 months (mean 9.8 months); during this
time 27 (61%) either died of their disease or developed a
clinically obvious recurrence. Only 5 patients were
cigarette smokers. Serum samples were collected at monthly
intervals whilst the patient was undergoing chemotherapy
and thereafter at 3 monthly intervals. All samples were
spun down within 2 hours of collection and stored at
-20°C until use.
4.3 General Principles in running E.L.I.S.A.
4.3.1 Buffers used
a) Carbonate coating buffer - 1.59g Na2C02 (Analar) and
2.93g NaHCO^ (Analar) were made up to 1L in distilled 1^0
(Analar) pH 9.6. This was stored at room temperature and
was replaced every 2 weeks. 0.2g sodium azide was added
to prevent bacterial growth.
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b) P.B.S./Tween. This consists of reconstituted P.B.S.
(oxoid) in distilled water to which 0.05% (volume by-
volume) Tween 20 was added.
c) Tris/citrate buffer consisting of 50mM Tris (Sigma)
and lOmM citric acid (Sigma) pH 7.4 was used to store the
trophoblast membrane extract (T.M.E.) used in assay 1.
0.05% Tween 20 was added for use in all washes in assay 1.
d) P.B.S. +0.5% (weight by volume) bovine serum albumin
(R.I.A. grade Sigma) with 2mMol Hepes pH 7.4 was the
buffer used to dilute standard P.L.A.P. (Sigma) and
antibodies used in assays 2 and 3 (unless otherwise stated).
4.3.2 Blocking step
This was performed in assays 2 and 3 which used purified
ND0G2, after coating with the first layer protein (P.L.A.P.
or NDOG2 depending on the assay), using 10% (volume by
volume) foetal calf serum (F.C.S.) in P.B.S. to block any
remaining sites on the wells. This step was performed
at room temperature over 2 hours. As lOOul of F.C.S.
was used per well, evaporation was not a source of error
and by incubation at room temperature adsorbtion of F.C.S.
to the plates proceeds more rapidly allowing the assay to
be completed that day.
This step was omitted from assay 1 where the F.C.S.
present in NDOG2 supernatant would perform the same
role.
4.3.3 Incubations
With the exception of the blocking step and incubation
with the appropriate substrate all other incubations were
performed at 4°C. This ensured a constant temperature
regardless of the season, for the reaction and ensures
the protein remained stable. The substrate used in assay 1,
paranitrophenyl phosphate (P.N.P.) was incubated overnight
at 37°C while orthophenyldiamine (O.P.D.) was incubated
at room temperature for 20 minutes.
4.3.4 Substrates
O.P.D. was made up freshly immediately prior to use.
24.3ml of 0.1M citric acid and 25.7ml of 0.2M Na2HP04,
2 H2O pH 5.0 were added to 50ml distilled water. O.P.D.
was added in the ratio of lmgm O.P.D. to 2.5ml of buffer,
and an appropriate volume of substrate solution made up
depending on the number of plates used. 4ul of 30% H202
were added to every 10ml of solution immediately before
lOOul of the whole was added to each well. The reaction
proceeded for 20 minutes and was stopped with 50ul 2.5M
H2SO4. The plates were read at 492nM on a titerteck
multiskan spectrophotometer (Flow).
P.N.P. was made up in a 0.2M diethanolamine buffer. lOOul
was added to each well and the plates incubated overnight
at 37°C. The reaction was stopped with 3M NaOH and the
optical density read at 405nM.
4.3.5. Micro titrewell plates
These were Flow multiwell disposotray 96 U shaped non
sterile well plates (Cat. No. 76/364/05) with flexible
formed (non sterile) plate covers (Cat. No. 76/406/05).
The edges of these plates were trimmed before they would
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fit into the spectrophotometer. The plates were kept
covered during all incubations at 4°C and room tempera¬
ture and sealed when incubated at 37°C.
4.3.6 Purification of the ND0G2 antibody
Whilst assay 1 relied on Rabbit anti mouse immunoglobulin
to attach ND0G2 antibody, from spent supernatant, to the
microlitre wells; in assays 2 and 3 purified ND0G2 anti¬
body was adsorbed directly. ND0G2 was purified using
Protein A affinity chromatography and sephacryl S300
column chromatography.
ND0G2 antibody was produced by bulk culture of the cell line
in R.P.M.I. 1640 with 2% F.C.S. (tg.p.s.).
a) Affinity Chromatography
An 8.5ml affinity column had previously been made by
swelling protein A sepharose CL4B in P.B.S. (lgm will give
3.5ml of swollen gel with a capacity of 25mgm of protein
per ml of swollen gel). Protein A interacts with the Fc
portion of certain immunoglobulins including subclass
lgG2b and will therefore remove these from a mixture of
proteins.
The prepared column was first eluted with 50ml of 0.1M
glycine/HCl pH 3.0 and then washed with a similar volume
of P.B.S.. This step removed any immunoglobulin that might
already be attached to the column and any sodium azide
used to preserve the column when stored. All washes,
elution steps and running the supernatant were performed
under gravity. A convenient volume of supernatant, usually
500-600ml, was run through the column overnight; the rate
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of flow was adjusted by varying the height between the
column outlet and supernatant. The fractions of effluent
were stored after each step and an aliquot run on
electrophoresis, to check for ND0G2, at the end of the
purification process.
After running the supernatant, the column was washed with
50ml each of P.B.S., P.B.S. + 6% NaCl and more P.B.S.
prior to elution with 0.1M glycine/HCl pH 3.0. 1ml fractions
were collected and read in a spectrophotometer, previously
blanked with 0.1M glycine/HCl buffer, at 280nM. Protein
was eluted between fractions 3 and 9 inclusive, which were
immediately neutralised with concentrated Tris (pH6.8)
and the samples pooled.
b) Sephacryl S300 column chromatography
A previously loaded 1.5cm x 74.5cm column containing
365.5ml of swollen sephacryl S300 was prepared prior to
running the eluate. All air bubbles were excluded from
the system and the column washed with 500ml P.B.S. pumped
from top to bottom at 25ml per hour.
The eluate was pumped into the column, followed by P.B.S.
and 5ml fractions collected. The optical density of
each fraction was read in a spectrophotometer, previously
blanked with P.B.S., at 280nM. An elevated O.D. was
recorded between fraction 43 and 47 inclusive. These
samples were pooled.
118
c) Calculation of amount of protein collected
Immunoglobulins give an absorbance of 1.4 (at 280° A) at
a concentration of lmg/ml. .*,mg of immunoglobulin =
sum of P.P. x No. of mis of pooled sample
1.4
In this example mg of NDOG2 = 0.148 x 24 _ ^ 54mgm1.4
.*. We have 2.54mgm in 24ml or a concentration of
0.106mg/ml of ND0G2.
d) Concentrating NDOG2
In this thesis purified NDOG2 has been used in 3 ways:
a) In serum assays 2 and 3;
b) In making the NDOG2 column;
c) In R.I.S..
for a & b ND0G2 was concentrated to 3.5mg/ml and for c to
2.6mg/ml. The method was the same for both.
ND0G2 was concentrated using an amnicon filtration unit.
A PM 30 ultrafiltration membrane which allows substances
of molecular weight of less than 30,000 to pass and which
can withstand pressures of up to 751b/sq. in. was used.
NDOG2 was loaded and the unit placed on a magnetic stirrer
to stop aggregation of protein on the membrane. A filtra¬
tion pressure of 251b/sq. in. of Nitrogen was used and the
filtrate collected, as a precaution, in case the membrane
ruptured. The volume that the preparation was to be
concentrated down to was calculated using the formula:
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Final volume =
Concentration of ND0G2 in sample
Concentration of NDOG2 desired x volume of samPle
The antibody was stored at -20°C until use.
e) Electrophoresis
The purity of the antibody in each batch was demonstrated
by polyacrylamide gel electrophoresis of a small sample
which was compared to that of a standard ND0G2 preparation
of known purity. The method of gel electrophoresis is
described in section 4.4.4.
4.4 Serum Assay 1
4.4.1 Introduction
This assay is based on a method initially described by
McLaughlin et al (1983) for use with a similar monoclonal
antibody. The ND0G2 is bound to the microlitre plate wells
by means of a rabbit anti mouse (R.A.M.) immunoglobulin.
ND0G2 will bind any P.L.A.P. which in turn catalyses the
hydrolysis of paranitrophenyl phosphate and the resultant
colour change is measured by means of a spectrophotometer
(fig 4.12).
Term placentae are a convenient source of P.L.A.P. and a
method of extracting this and calculation of its activity
is described before the assay method. Placentae may
contain other alkaline phosphatases but as ND0G2 binds
P.L.A.P. alone only this isoenzyme can be measured.
This assay depends on the enzyme activity of the antigen
being measured, the other two assays do not.
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4.4.2 Preparation of Trophoblast Membrane Extract (T.M.E.)
This method was adapted from that originally described by
Smith et al (1974) and Standring and Williams (1978).
A term placenta was obtained from the Central Delivery Suite
wihin 30 minutes of delivery, and the cotyledons cut into
small pieces. The amnion, chorion blood vessels and umbilical
cord were discarded. The cut cotyledons were transferred to
a sieve and washed with 21 0.1M CaCl2 (Analar) and 11 P.B.S.
(Oxoid), shredded in a mincer and suspended in 350ml of
0.15M NaCl (Analar). This suspension was stirred for 30
minutes at 4°C to separate the chorionic villi from the bulk
of placental tissue. The mixture was sieved, the fluid
collected and centrifuged at 3000 r.p.m. for 10 minutes, in
an MSE 18, at 4°C. The supernatant was recentrifuged at
9200 r.p.m. for 10 minutes and finally at 18000 r.p.m. for
90 minutes. The pellet containing trophobla st membrane was
saved and resuspended in 10ml P.B.S.. 25ml of 6% Triton X
(B.D.H.) in P.B.S. (volume by volume) was added and the
mixture transferred to a Damps Homogeniser. After homogenis-
ation (10 strokes) the solution was stirred for % hour at
4°C and then centrifuged for 90 minutes at 18000 r.p.m. at
4°C. The supernatant was transferred to a dialysis bag, which
had been boiled for 10 minutes and checked for leaks. This
was suspended in a conical flask containing 50mM Tris (Sigma),
lOmM citric acid (Sigma) pH 7.4 at 4°C.
The Tris/citrate buffer was changed 3 times over 36 hours.
The contents of the dialysis bag then contained P.L.A.P. in a
Tris/citrate buffer and were aliquoted and stored at -20°C
until use.
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4.4.3 Calculation of the activity of P.L.A.P. in the
T.M.E. preparation
The T.M.E. preparation was diluted to 1 in 30 and 1 in 100
in a 0.2mol/l diethanolamine buffer (Sigma). 0.1ml of
each dilution was added to 3ml of paranitrophenol
phosphate in the same buffer and the optical density-
read in a 1cm cuvet immediately and after 3 minutes at
405nM. The spectrophotometer had initially been blanked
with 3.1ml of substrate.
P.L.A.P. (Sigma) which contains 116U/L was reconstituted
with 3ml of buffer and was used in a similar experiment,
both neat and in a 1 in 2 dilution, as a control. The
level of activity quoted for this preparation was only
valid for up to 3 hours after reconstitution.
An International unit of alkaline phosphatase is that
amount of enzyme which will convert 1 micromole of
substrate per minute per litre of test solution under
specified conditions (30°C) and may be calculated using
the following equation:
International Units per litre (I.U./L) =
A A per 3min x 1000 x 3.1 x T.C.F.
18.75 x 0.1 x 3
Where Aa per 3 minutes = Final A (O.D. after 3 minutes) -
Initial A (O.D. at start).
T.C.F. = Temperature conversion factor.
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ImM of paranitrophenol in 1 litre absorbs 18.75 O.D. units
at 405nm (Sigma Bulletin) 1 micromole/ml will also
absorb 18.75 O.D. units. As the total volume is 3.1ml




The change of absorbance (A A) observed represents an
increase of A A x 3.1 umole paranitrophenol.
18.75
.". I.U./0.1ml = A A x 3.1
No. of minutes x 18.75
.*. If we read for 3 minutes I.U./0.1ml = A A x 3.1
3 x 18.75
.". I.U./L = A A x 3.1 x 1000 At the temperature of the
3 x 18.75 x o.l experiment.
= aA x 3.1 x 1000 x T.C.F.
3 x 18.75 x 0.1
= ^A x 551 x T.C.F.
This experiment was performed at 27°C giving a T.C.F.
of 1.13 and the T.M.E. had previously been heated to
65°C for 10 minutes.
1) At at 1/30 dilution of the T.M.E.
AA = 0.988 - 0.138 = 0.850
. . P.L.A.P. activity at 1/30 dilution =
0.85 x 551 x 1.13 = 529.14 I.U./L
Neat T.M.E. contains 15,877 I.U./L
• • *
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2) At a 1/100 dilution of the T.M.E.
A A = 0.272 - 0.222 = 0.250
.*. P.L.A.P. activity at 1/100 dilution =
0.25 x 551 x 1.13 = 155.66
.*. Neat T.M.E. contains 15,566 I.U./L
The average of these two results = 15,721 I.U./L.
A parallel control experiment was performed using a
standard sigma preparation of known activity. The results
obtained (118 I.U./L) correlated well with this prepara¬
tion's known activity (116 I.U./L).
4.4.4 Assay Method
lOOul of a 1 in 1000 dilution of a rabbit anti mouse immuno¬
globulin (DAKO) in carbonate coating buffer was added to
each well and the plates incubated overnight. The wells
were washed three times with Tris/citrate buffer, 0.05%
Tween 20, incubated for 1 hour with lOOul of a 1 in 10
dilution of spent ND0G2 supernatant and then washed three
times. lOOul of either test serum (neat or in a 1 in 10
dilution in Tris/citrate buffer) or serial dilutions of
1 in 3000 or 1 in 5000 dilution (depending on the batch
used) of T.M.E. in Tris/citrate buffer was added to each
well and incubated for 1 hour. The wells were washed 3
times and lOOul of P.N.P. added to each well; the plates
were sealed and incubated overnight at 37°C. The reaction
was stopped with 50ul of 3M NaOH and the optical density
(O.D.) read at 405nm using a Tieterteck multiskan spectro¬
photometer (Flow).
124
All samples were tested in triplicate and an average
of the O.D. taken. A standard curve was constructed
using the serial dilutions of T.M.E. from which the
quantity of P.L.A.P. in each sample of patient's serum
was obtained.
This method differs in a number of ways from that
described by McLaughlin et al (1983):
1) ND0G2 supernatant and R.A.M. were each titrated, with
other assay parameters constant, to find the lowest
concentration of each consistent with maximum sensitivity.
R.A.M. at a concentration of 1 in 1000 (as opposed to
1 in 200 (McLaughlin et al 1983)) and ND0G2 supernatant
at a concentration of 1 in 10 filled these parameters.
2) T.M.E. was used to make the standard curve as opposed
to commercially available P.L.A.P.. This titration curve
showed a linear response as did serial dilutions of
malignancy serum (fig 4.2).
3) Washes were performed using Tris/citrate buffer
+0.05% Tween 20 as opposed to P.B.S./Tween.
T.M.E. was initially stored in P.B.S. and it was noted that
its P.L.A.P. activity dropped over a period of several
months. To test the hypothesis that P.B.S. was causing
product inhibition of the enzyme, T.M.E. was diluted to
1 in 30 and 1 in 100 in Tris/citrate buffer and each
divided into 2 samples. The first samples were incubated
with P.N.P. and the O.D. measured immediately and then at
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30 second intervals for 3 minutes. The second samples
were left for 30 minutes to allow any phosphate to be
released and then its activity similarly measured, a
greater than 10 fold increase in activity was demonstrated
(fig 4.1). Thereafter, T.M.E. was stored in Tris/citrate
buffer without loss of activity.
4.4.5 Results
a) Calculation
A graph of O.D. against serial dilutions of T.M.E. was
plotted. The T.M.E. preparation was initially diluted
from the original preparation to 1 in 3000 so that each
1/10 dilution of this preparation was equivalent to
0.5 I.U. P.L.A.P. activity. The reaction proceeded in
a straight line initially, levelling off at higher
concentrations of T.M.E. (fig 4.2) where the O.D. of the
neat test serum fell on the straight portion of the graph
then this value was read off. If it occurred on the
flattened portion then the 1 in 10 dilution was read and
multiplied by a factor of 10.
b) Normal range
i) Non smokers
McLaughlin et al (1983) quote an upper limit of normal
for their assay of 0.1 I.U./L. Using this level 4 out of
66 volunteers had levels above this (2 of 0.15 I.U./L
and 2 of 0.25 I.U./L). Therefore, an upper limit of
normal for this assay was taken as 0.25 I.U./L.
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(ii) Smokers
Serum was obtained from 43 volunteers who were
cigarette smokers and all were asked how many cigarettes
a day they smoked. 17 smokers had P.L.A.P. levels of
less than 0.25 I.U./L and in 14, P.L.A.P. levels were
less than 0.1 I.U./L. The total number of cigarettes
smoked a day was correlated with serum P.L.A.P..
I-10 cigarettes 18 cases
II-20 cigarettes 16 cases
21+ cigarettes 9 cases
range 0-3.7 (mean 0.52) I.U./L
range 0-2.95 (mean 1.07) I.U./L
range 0.3.0 (mean 1.24) I.U./L
The mean levels of P.L.A.P. increased with the number of
cigarettes smoked a day but, interestingly, the person
with the highest serum level (0.37 I.U./L) only admitted
to smoking 10 cigarettes a day. As patients are often
inaccurate when admitting the number of cigarettes they
smoke, due caution should be taken in interpreting elevated
serum P.L.A.P. levels in such cases. In the event only
5 patients with ovarian cancer in this study were known
cigarette smokers.
c) Serum half life of P.L.A.P.
Serum levels of P.L.A.P. were estimated, preoperatively and
at daily intervals for 10 days after operation from a non
cigarette smoking patient who had a stage la (i) ovarian
carcinoma completely resected. The half life of P.L.A.P.
in vivo was 4 days (fig 4.3) which is in accord with that
reported in the literature (Fishman 1974).
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d) Benign ovarian tumours
Preoperative serum P.L.A.P. levels were undetectable in
5 out of 6 patients with benign ovarian tumours and
0.21 I.U./L in one (Table 4.1).
e) Ovarian carcinoma
This section attempts to answer the following questions:
i) Do preoperative serum enzymically active P.L.A.P.
levels correspond with the immunohistology of the tumour?
Preoperative serum samples were obtained from 20 patients
in whom fresh tumour tissue was available for immunohisto-
logical examination. All these patients denied cigarette
smoking and in 12 there was positive reactive staining with
NDOG2 (4 grade 4, 2 grade 3, 4 grade 2 and 2 grade 1).
Serum P.L.A.P. levels were elevated in all patients with
greater than grade 1 reactive staining with the exception
of patient 2 (Table 4.2). This patient had a stage 2c
serous cystadenocarcinoma of borderline malignancy which
showed grade 3 reactive staining but whose serum P.L.A.P.
levels were normal. Conversely a patient (No. 36) with
negative immunohistology had elevated serum P.L.A.P. and
this subsequently proved to be a good tumour marker,
accurately reflecting the course of her disease. It was
possible that an unrepresentative sample of tumour was
initially examined in this case.
The degree of reactive staining and elevated preoperative
serum P.L.A.P. showed close correlation as one would
expect. Thus, those tumours in whom over 25% of cells
expressed this antigen (grade 3 and 4 reactive staining)
and excluding the tumour of borderline malignancy, the
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range of values was between 0.45 and 8.5 I.U./L with a mean
of 4.54 I.U./L compared with a range of 0.95-2.1 I.U./L
(mean 1.59 I.U./L) in tumours with grade 2 reactive staining
and of less than 0.1 I.U./L in 9 out of 10 tumours with
less than 1% of their cells showing positive staining
(Table 4.2).
ii) Is enzymically active P.L.A.P. a good tumour marker
for ovarian cancer?
The upper limit of normal for this assay was taken as
0.25 I.U./L. The effect of lowering this to 0.1 I.U./L
in those patients in whom P.L.A.P. proved to be a poor
marker did not improve the predictive value of this assay.
24 patients were followed from before primary surgery, 17
patients were recruited shortly after surgery but all had
residual disease present and 3 were recruited while in
remission. Fresh tumour tissue was available for immuno-
histology in 27 cases. During this study 30 patients (68%)
either developed an obvious tumour recurrence or died of
their disease.
The serum levels of enzymically active P.L.A.P. rose or
fell appropriately, reflecting the course of the disease,
in 12 cases (27%) but was of poor predictive value in
the remaining 32 patients. The results of this assay are
summarised in Tables 4.3 and 4.4. In 6 out of the 12 cases
(patients 13, 20, 24, 38, 39 and 40) there were falls of
serum P.L.A.P. levels corresponding to the degree of
surgical debulking achieved, and subsequent falls in levels
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during chemotherapy. These patients remain well with
normal serum P.L.A.P. levels (e.g. fig 4.4). In the
other six cases (patients 22, 23, 25, 36 and 43) there
were initial falls in serum P.L.A.P. levels corresponding
to surgery and chemotherapy with subsequent rising levels
reflecting proven tumour recurrence (e.g. fig 4.5).
Tumour tissue was available in 11 cases, 9 of which
showed grade 2 or greater reactive staining with ND0G2.
In 23 cases serum P.L.A.P. was never elevated but in the
remaining 9 cases P.L.A.P. was elevated at some stage of
the disease. However the levels did not totally accurately
reflect the course of the disease. Four distinct patterns
were noted in these patients.
a) P.L.A.P. only rose prior to the patient's death, in
the presence of massive recurrent disease, in one case
(patient 34). No preoperative serum sample was available
from this patient but her primary tumour showed grade 2
reactive staining with NDOG2.
b) P.L.A.P. levels returned to normal levels after primary
surgery in 2 cases (patients 6 and 32), even though
residual tumour remained. Both patients primary tumours
showed grade 4 reactive staining with ND0G2 and in patient
6 the primary tumour was incompletely excised. In the
case of patient 32 while the primary tumour was excised
metastases, showing grade 2 staining, remained. Both
these patients failed to respond to chemotherapy but
serum P.L.A.P. remained in the normal range (e.g. fig 4.6).
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c) In 4 patients serum P.L.A.P. levels fell inappropri¬
ately, in 3 cases (patients 15, 19 and 44) P.L.A.P. levels
initially reflected the course of the disease but then fell
even thcugh there was continued massive tumour growth
(e.g. fig 4.7). In one case (patient 12) P.L.A.P. levels
fell following surgery even though the patient ultimately
died of her disease. Tumour tissue was available for
immunohistological examination only in patient 19, and
showed grade 4 reactive staining. This inappropriate fall
in levels of P.L.A.P. may reflect the death of the P.L.A.P.
producing cell line with chemotherapy but the continued
growth of other cell lines. Alternatively, chemotherapy
may be affecting the ability of the cell to produce
enzymically active P.L.A.P..
d) Elevated serum P.L.A.P. due to cigarette smoking was
seen in 2 cases (patients 18 and 45). Patient 18, whose
tumour showed grade 3 reactive staining was recruited
while in remission; she subsequently remained well, with
no additional therapy, although her serum P.L.A.P. levels
fluctuated (fig 4.8). Patient 45 was a heavy smoker
whose serum levels remained elevated prior to and following
surgery and chemotherapy. Both patients remain well 17
and 5 months respectively after treatment finished.
iii) Does the degree of reactive staining with ND0G2 act
as a reliable guide as to those patients who should be
followed up using this assay?
Immunohistological examination of fresh tumour tissue was
performed in 26 patients and compared with the predictive
value of this assay (Table 4.3). In the 15 cases where
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the tumour showed grade 2 or greater reactive staining
with NDOG2, in a patient who was a non smoker, this
assay was of predictive value in 9 cases. However as
described in theprevious section in 2 cases (patients
6 and 32) it did not reflect the course of the disease;
in one case (patient 34) P.L.A.P. only became elevated
with gross recurrent disease and in a further instance
(patient 19) fell inapprorpiately. Serum P.L.A.P. was
always within the normal range in one patient with a
serous cystadenocarcinoma of borderline malignancy
(patient 2).
In only one (patient 22) out of 6 cases with grade 1
reactive staining did serum P.L.A.P. levels reflect
the course of the disease as it did with one patient
with negative staining (patient 36).
Conclusions
Overall (all patients studied) enzymically active P.L.A.P.
as measured by this assay, proved to be a disappointing
tumour marker. However, in those cases where immunohis-
tological examination of tumour tissue had been performed
and grade 2 or greater reactive staining noted, then this
assay predicted the course of the disease in 60% of
cases. Nonetheless in five patients in particular
(patients 2, 6, 19, 32 and 34) where, based on the
immunohistology, this assay might reasonably be expected
to accurately reflect the course of the disease, it
failed to do so.
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There are 3 possible reasons for this:
1) The assay is not sufficiently sensitive;
2) In any one tumour there are several different cell
lines, only one of which may produce P.L.A.P.. This cell
line may be preferentially destroyed by chemotherapy, or
have a low potential for metastasis in some cases;
3) P.L.A.P. may be produced in an inactive form by certain
tumours. This may be due to chemotherapy damaging the
pathway producing P.L.A.P. resulting in inactive enzyme
fragments being produced.
To test hypotheses 1 and 3 further assays were developed
in an attempt to measure the total protein recognised by
ND0G2, independant of enzymic activity.
4.5 Serum Assay 2
4.5.1 Introduction
This modified indirect E.L.I.S.A. (Voller et al 1976) was
used to see if ND0G2 could recognise P.L.A.P., present in
human serum, when adsorbed directly to the E.L.I.S.A. wells.
4.5.2 Method
Each half of 2 E.L.I.S.A. plates were coated, in duplicate,
with lOOul/well of 24 halving dilutions of P.L.A.P. (Sigma)
(lOmgm/ml to zero) in 10% normal human serum in carbonate
buffer, overnight at 4°C. lOOul of neat (750ug/ml) 1 in 4
or 1 in 16 dilutions of ND0G2 were added to each well of
the appropriate half plate and buffer (P.B.S./B.S.A./Hepes)
alone added to the final half plate. The plates were
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incubated for 1^ hours at 4°C, washed and then incubated
for % hour with lOOul of a 1 in 200 dilution of peroxidase
conjugated rabbit anti mouse immunoglobulin (Dako) at 4°C.
The reaction was developed with O.P.D..
4.5.3 Results
There was no difference between background optical density
(that generated by the half plate incubated with P.B.S./
B.S.A./Hepes alone) and those of the other half plates,
nor was there any titration.
4.5.4 Conclusions
Because of the background problems, this assay was abandoned
in favour of assay 3.
4.6 Serum Assay 3
4.6.1 Introduction
This is a modified double sandwich E.L.I.S.A. (Voller et
al 1976). P.L.A.P. is captured from test samples by
NDOG2 directly adsorbed to microtitre plate wells. Rabbit
anti human P.L.A.P. polyclonal antiserum (Dako) is used
as second layer antibody and, as this is not supplied in a
peroxidase conjugated form, a peroxidase conjugated goat
anti rabbit immunoglobulin (Miles) was used prior to
development with O.P.D. (fig 4.13).
Rabbit anti human P.L.A.P. was used as the second layer
antibody (as opposed to first layer) to avoid blocking
its active sites with any intestinal alkaline phosphatase
present in test sera, and so that the NDOG2 determinant
on P.L.A.P. is not bound by this polyclonal antiserum.
4.6.2 Development of this assay
Experiment 1
The wells of each half of 2 E.L.I.S.A. plates were coated
with 50ul of either lOug/ml, 50ug/ml, lOOug/ml or 200ug/ml
of NDOG2, overnight at 4°C. The wells were blocked with
10% F.C.S. and 50ul of 24 serial, doubling, dilutions from
lOmg/ml P.L.A.P. (Sigma) to zero were incubated in
duplicate at 4°C for one hour. The plates were washed and
50ul of a 1 in 150 dilution of rabbit anti human P.L.A.P.
(Dako) added to each well and incubated at 4°C for ^ hour.
The plates were again washed and 50ul of a 1 in 200 dilution
of a peroxidase conjugated goat anti rabbit immunoglobulin
added, and incubated at 4°C for % hour. The plates were
developed with O.P.D..
Results (Experiment 1)
These are summarised in fig 4.9,. The wells that had been
coated with 50ul 200 ug/ml, lOOug/ml and 50ug/ml of NDOG2
gave over-range readings for too many dilutions of P.L.A.P.
to be of use but the wells coated with lOug NDOG2 gave a
favourable titration. However, the background was rather
high in this assay. This was unlikely to be due to rabbit
anti human P.L.A.P. cross reacting with bovine intestinal
alkaline phosphatase present in F.C.S. as this antibody
only cross reacts with the human form of this isoenzyme
(Dako Data Sheet). A more likely reason for this high
background, supported by the development time of only 3
minutes, was that the concentrations of second and third
layer antibody were too high.
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Experiment 2
This was performed to try and reduce background readings
and to see if a 50ul coating concentration of 20ug/ml or
5ug/ml ND0G2 would give a better titration than lOug/ml.
Experiment 1 was repeated using these concentrations of
ND0G2 to coat the wells and using the second layer anti¬
body in a 1 in 250 dilution and the third layer antibody
in a 1 in 1000 dilution.
Results (Experiment 2)
These are summarised in fig 4.10. A coating concentration
of lOug/ml ND0G2 gives the best titration and the background
optical density readings were reduced to a satisfactory 0.4.
As in assay 1, malignancy sera showed a linear titration
when used in this assay.
4.6.3 Method of Serum Assay 3 used
Microlitre wells were each coated with 50ul of lOug/ml
NDOG2 in carbonate buffer, overnight at 4°C. The wells
were blocked by incubation with lOOul of 10% F.C.S. for
2 hours at room temperature. A calibration line of 18
serial dilutions of P.L.A.P. (Sigma) from lOmg/ml to zero
was incubated in duplicate. This occupied the first 3
rows of the plate, leaving room for 30 serum samples (in
duplicate) to be tested, one of which was always from a
healthy, non smoking control. 50ul of either test serum
or standard P.L.A.P. solution was added to each well and
incubated at 4°C for 1 hour and the plates washed in
P.B.S./Tween 3 times. 50ul of rabbit anti human P.L.A.P.
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antiserum (Dako) in a 1 in 250 dilution was added to each
well and incubated at 4°C for J5 hour. The plates were
again washed 3 times and incubated for a further ^ hour
at 4°C with 50ul of a 1 in 1000 dilution of peroxidase
conjugated goat anti rabbit immunoglobulin (Miles). A
further washing step was performed and the plates
developed by incubation for 20 minutes with lOOul of
substrate solution at room temperature. The reaction was
stopped with 50ul of 2.5M H2S04 andthe plates read with
a Tieterteck Multiskan spectrophotometer at 492nM.
4.6.4 Results
a) Method of calculation
The optical densities for each serum sample tested were
averaged and converted to ug/ml with a linear regression
using least squares fit; this programme was developed by
the Department of Medical Physics, Bristol Radiotherapy
Centre, and gave a correlation coefficient of between
0.87 and 0.94.
This method proved simpler than reading the log concentra¬
tion of the test sample from a graph of optical densities
of the standard dilutions of P.L.A.P. and then converting
to ug/ml.
b) Normal range
Serum levels in the normal population varied between
0.17ug/ml and 149.44ug/ml (mean 8.76ug/ml) in non smokers
and 0.15 to 388.44ug/ml (mean 17.25ug/ml) in cigarette
smokers. There was again a tendency overall for cigarette
smokers to have higher levels of the ND0G2 determinant
(Table 4.5).
When correlated with the number of cigarettes smoked:
I-10 18 range 0.15-23.29 ug/ml (mean 3.90ug/ml)
II-20 16 range 0.17-82.29 ug/ml (mean 6.51ug/ml)
21+ 9 range 0.15-388.44ug/ml (mean 24.24ug/ml)
The possibility exists that endogenous proxidase activity,
from lysed red blood cells, may have given rise to these
elevated levels in the normal population. However, the
active sites on the plates should have been blocked with
B.S.A. and any free peroxidase removed by washing. To
test this hypothesis high normal sera were run in the
assay but the step involving incubation with peroxidase
conjugated goat anti rabbit immunoglobulin was omitted.
No significant colour change was noted in the wells
incubated with these samples demonstrating that endogenous
peroxidase activity was not a source of error.
c) Serum half life of the ND0G2 determinant
The same series of sera, in the same patient as in
section 4.4.5 (c), was studied using this assay and the
results plotted on fig 4.3. Serum levels of 19.5ug/ml
fell to 13ug/ml after 6 days and thereafter varied between
12 and 13ug/ml. There was therefore a fall of 6.5ug/ml
in 6 days giving a similar half life to assay 1 (3-4 days).
d) Benign ovarian tumours
Levels of the NDOG2 determinant were measured in the same
six patients studied in section 4.4.5 (d). Levels of the
NDOG2 determinant were low ranging between 0.44 and 0.09
ug/ml (mean 0.198ug/ml) (Table 4.1).
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e) Ovarian Cancer
The same three questions were asked of this assay as were
asked of assay 1:
i) Do preoperative levels of "the ND0G2 determinant
correspond with the degree of reactive staining with
ND0G2.
A very similar pattern to that observed with assay 1 was
found in that those tumours with the larger proportion of
their cells showing positive staining tended to have
higher serum levels (Table 4.2).
Thus, the range for those tumours with Grade 3 and 4
reactive staining was 0.35-368.22ug/ml (Mean 68.19ug/ml).
Grade 2 reactive staining was 0.14-19.5ug/ml (mean 5.11ug/ml)
Grade 1 reactive staining was 0.1-2.81ug/ml (mean 0.65ug/ml)
ii) Does the ND0G2 determinant, as measured by this assay,
act as a good tumour marker in ovarian cancer?
The same serum samples were run in this assay as in assay
1 and the results summarised in Tables 4.3 and 4.4.
Although the mean normal levels for non smokers was
8.76ug/ml, wide individual variations in levels were
noted (0.17ug/ml-149.44ug/ml) with this assay. The
significance of a single result was consequently difficult
to interpret and so each patient was assessed on an
individual basis; rising levels should correspond to
n
tumour recurrence and falling levels correspond to a
response to therapy. Using these criteria, this assay
accurately predicted the course of the disease in 20
patients. In 6 of these (patients 13, 20, 24, 38, 39
and 40) serum levels fell after treatment and did not
subsequently rise (e.g. fig 4.4). These patients all
remain well and are in remission. In 14 cases (patients
13, 6, 8, 12, 14, 21, 25, 30, 31, 32, 35, 36, 43 and 44)
levels fell after surgery and initial chemotherapy but
then subsequently rose reflecting recurrent tumour (e.g.
fig 4.5). In two of these cases (patients 6 and 32)
recurrent tumour had not been predicted by assay 1 (fig 4.6).
In a further 2 cases (patients 10 and 40) levels fell after
surgery and chemotherapy but there was an unexplained single
elevated level when the patients were in remission.
Subsequent serum levels were low and the patients remain
well. Tissue was available for immunohistological examin¬
ation in 16 of these 22 cases and showed grade 2 or greater
reactive staining in 11 cases, grade 1 staining in 2 cases
and was negative in 3 cases.
In 11 cases levels remained constant throughout the disease
but did vary at some stage in the remaining 11. Three
patterns of change were noted:
a) Levels only rose in the presence of massive recurrent
disease in two cases (patient 1 and 34). Tumour tissue
was only available from patient 34 and showed grade 2
reactive staining with NDOG2.
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b) An inappropriate fall in serum levels were noted in
7 cases (patients 5, 16, 19, 22, 23, 37 and 41). In all
of these cases serum levels had originally risen
reflecting recurrent disease but then fell even though
the tumour continued to grow.
c) False positive results were seen in the same 2 cases
(patients 18 and 45) (fig 4.8) as in assay 1, and have
been discussed earlier.
iii) Does the degree of reactive staining of the tumour
with NDOG2 act as a guide as to whom should be
followed up using this assay?
There were 15 patients whose tumours showed grade 2 or
greater reactive staining with NDOG2 and this assay
accurately predicted the course of the disease in 11
patients i.e. 73% (this figure includes patients 10 and
40 discussed in section 4.6(ii)). This assay, in common
with assay 1, failed to predict the course of the
disease in 4 patients. One of these (patient 18) was a
cigarette smoker and this gave rise to a false positive
result and another (patient 2) had a tumour of borderline
malignancy whose pre and post operative and follow up serum
levels did not vary. Both of these patients remain well.
In the case of patients 19 and 34, whose tumours showed
grade 4 and grade 2 reactive staining respectively, this
assay was not particularly useful. Patient 191s serum
levels initially reflected the progress of the disease
but then fell inappropriately shortly before her death
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Serum levels only rose in patient 34, in the presence of
gross disease. These findings may reflect a changing
cell population within the tumour.
There were 12 patients whose tumours showed less than
grade 2 reactive staining with ND0G2 and this assay
predicted the course of the disease in 41% of these.
2 cases (patients 3 and 8) showed grade 1 and 3 cases
(patients 21, 30 and 36) showed no reactive staining.
Thus, immunohistology does act as a guide as to who should
be followed up but there are exceptions. In general the
greater the degree of reactive staining, then the better
the predictive value of this assay. This can be further
improved if cigarette smokers and patients with tumours
of borderline malignancy are excluded.
4.7 Comparison of results obtained with assays 1 and 3
Overall, assay 3 accurately predicted the course of the
disease in 50% of all the patients studied whereas assay
1 was accurate in 27%, The predictive values of both
assays were improved if the tumour showed grade 2 or
greater reactive staining with NDOG2 (60% assay 1, 73%
assay 3).
The results with both assays were identical in 27 cases.
In 11 cases both assays accurately reflected the course
of the disease and in a further 12 cases there was no
change throughout the disease with either assay. In both
assays there were 2 false positive results and in one
case levels only rose with bulk disease; in a further case
levels fell inappropriately (Tables 4.3 & 4.4).
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In 7 cases, assay 3 predicted the course of the disease
when assay 1 either failed to do so (patients 3, 6, 8,
21, 30, 31 and 32) or fell inappropriately (patients 12,
15 and 44). In the case of patients 6 and 32 both assays
showed a fall after primary surgery but assay 1 failed to
show a rise in the presence of recurrent tumour (fig 4.6).
Assay 3 was of some value in a further 4 cases (patients 5,
16, 37 and 41) in that it initially predicted the course
of the disease but subsequently fell shortly before the
patient's death; in these cases assay 1 was of no predictive
value at any stage of the disease. In patient 1, assay 3
alone showed a rise but only in the presence of massive
tumour recurrence.
There were 5 cases in which both assays initially agreed
with each other in predicting the course of the disease
but then subsequently one showed an inappropriate fall.
In 3 of these (patients 12, 15 and 44) assay 3 was the
more accurate and in all 3 the fall in assay 1 was mirrored
initially by a lesser fall in assay 3. This subsequently
rose but assay 1 showed continued low levels (e.g. fig 4.7).
A change in chemotherapy correlated with this fall in one
case only (patient 44) and a change back to the original
regime did not result in a subsequent rise in assay 1.
In 2 cases (patients 22 and 23) an inappropriate fall was
seen in assay 3 whereas a continued rise was seen with
assay 1, but at a slower rate (e.g. fig 4.11). The fall in
assay 3 corresponded to change in chemotherapy in patient
23.
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4.8 Affinity Chromatography using ND0G2 - sepharose,
gel electrophoresis and immunoblotting
4.8.1 Introduction
It became clear, from the previous sections that either
assay 3 was a far more sensitive assay than assay 1 or
that ND0G2 was capable of recognising at least one other
tumour associated antigen. This latter possibility
seemed the more likely in view of the very large range of
normal levels and the different patterns seen in patients
with ovarian cancer and in particular, cases 12, 15, 22,
23 and 44, where a fall in either assay resulted in a
temporary drop or a slowing of the rate of increase of
the other assay.
In this section 2 methods of assessing what, if anything,
NDOG2 was recognising, in addition to P.L.A.P. in both
normal and malignancy serum, were employed. The first
method involved affinity chromatography with an ND0G2 -
sepharose column and gel electrophoresis, while the second
used an immunoblotting technique.
4.8.2 Cyanogen Bromide activation of Sepharose and
linking of the ND0G2 antibody
The object of this procedure is to covalently link the
ND0G2 antibody to sepharose CL4B (Sigma) and thus to
form a column for use in affinity chromatography.
A I I I I
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Method
Both Sepharose CL4B and the purified ND0G2 antibody need
to be present in an activated form before covalent
linkage can occur. The previously concentrated ND0G2
antibody is present in a P.B.S. buffer (3.5ug/ml) and
this must be changed to a carbonate buffer pH 8.4 to
activate ND0G2. This was done by gel filtration.
Sephadex G25 is swollen overnight in P.B.S. and 2, 12ml
columns packed with this slurry. P.B.S. is used in
preference to carbonate buffer (a) to clean the sephadex
and (b) because the carbonate buffer pH may change
overnight due to exposure to CO2 in the atmosphere.
12ml of a 0.1M carbonate (NaHC02/Na2CC>2) buffer pH 8.4
with 0.5ml NaCl (to stop electrostatic sticking) is run
into each column. Further carbonate buffer was added to
each column and the progressof the Dextran Blue observed.
ND0G2 and Dextran Blue should travel through the column
at the same rates, so when the Dextran Blue is at the
bottom of its column the NDOG2 fraction will be ready
to be collected. A further 4m1 of buffer was run into
the columns and the ND0G2 fraction was collected now
present in carbonate buffer. A further 4m1 of carbonate
buffer is added to this fraction, bringing the total
volume to 8ml.
Sepharose CL.4B is supplied in a slurry with thiomersylene,-
preservative and is washed in distilled 1^0, in a sintered
glass funnel connected to a Bruckner flask, to remove
this. 12ml of Sepharose CL4B was added to 10ml of distilled
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1^0 in a beaker (this produced sufficient Sepharose for
conjugation with 3 antibodies, of which ND0G2 was one)
and the pH of this solution was made up to 11.0 with 1M
NaOH. This beaker, with magnetic stirrer and a pH
electrode attached was transferred to a fume cupboard
prior to activation. lgm of cyanogen bromide (Kodak)
was weighed out in the fume cupboard and added to the
Sepharose CL4B solution. The pH, which will tend to drop,
is kept at 11.0 by the addition of further 1M NaOH. It
is vital that the pH does not fall significantly as
hydrogen cyanide gas will form at a pH of 8 or less.
When the pH remained stable at 11 the reaction had
ceased and this took 15 minutes from the time of adding
the cyanogen bromide. All spatulae etc., that had come
into contact with cyanogen bromide were washed in 1M
NaOH.
The activated Sepharose was washed with 200ml H20 followed
by 200ml carbonate buffer in the sintered glass funnel,
in the fume cupboard. This step should not take longer
than 90 seconds to stop the sepharose beads cross
linking to each other.
The activate sepharose was then added to the ND0G2
solution, sealed and mixed overnight at 4°C.
This method results in 80-90% of the protein linking to
the sepharose beads, the amount of free protein can be
estimated by measuring the solution's optical density
at 280° A and 8.9mg of NDOG2 was coupled to the beads.
Further potential binding sites on the sepharose beads were
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blocked by incubation with 20ml of 1M diethanolamine HC1
pH 8 for 2 hours at room temperature. The beads were
washed with 200ml each of carbonate buffer, 0.1M sodium
acetate, 0.5M NaCl glacial acetic acid pH 4.1, carbonate
buffer and finally P.B.S.. The beads were suspended in
20ml P.B.S. with azide and stared at 4°C until use.
4.8.3 Running the NDOG2 column
125ul of serum from ovarian cancer patients with high and
normal P.L.A.P. levels on serum assay 1 and from the normal
control were run on the NDOG2 columns. These were prepared
using 6 1ml syringes with glass wool packing their tips
and a 21 gauge needle attached to direct the filtrates into
the appropriate receiver. 3 syringes were packed to the
0.4ml mark (i.e. 3 x the load for each column) with ND0G2-
sepharose and the other 3 syringes with sepharose linked to
a contol lgGl recognising an antigen on the Ebstein-Barr
virus, these latter acted as controls to identify any non-
sepcific sticking of protein to sepharose. All columns
were washed twice with P.B.S. and checked to ensure no air
bubbles were trapped in the column.
The serum samples were centrifuged at 13,000 r.p.m. to
remove any large molecules that may block the columns.
125ul of the appropriate test sample was loaded into each
pair of columns (i.e. 1 ND0G2 and 1 control) and incubated
for 1 hour at room temperature, a further 30ul of test
sample was added to two separate occasions during this
time to aid spread of the test sample throughout the
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column. The columns were then washed with 5ml P.B.S. and
eluted using 0.05M diethylamine (D.E.A.) pH 11.5. 400ul
of D.E.A. were initially run into the column and the pH
of the filtrate measured, when this became alkaline a
further 500ul of D.E.A. was run in and the filirate
collected. 125ul (i.e. 25% of the filtrate volume) Tris
pH 8.0 was added to the filtrate to bring its pH nearer
the physiological range.
4.8.4 Polyacrylamide gel electrophoresis
a) Preparation
The protein in the filtrate must be resuspended in a
running buffer before electrophoresis can be performed.
Protein in the filtrate sample was precipitated by adding
an equal volume (i.e. 625ul) of 15% trichloracetic acid
(T.C.A.) and incubating for 30 minutes at 4°C. T.C.A.
has a minimum threshold for precipitating proteins and it
is usual to add lug/ml of bovine serum albumin (B.S.A.)
to the sample; however, as B.S.A. has a similar molecular
weight to the subunits of P.L.A.P. this was not performed.
T.C.A. will destroy the biological activity of proteins
but this is not necessary for successful electrophoresis.
After incubation the sample was centrifuged at 13000 r.p.m.
the supernatant aspirated and the pellet resuspended in
500ul acetone and again centrifuged. This process was
repeated, the supernatant aspirated and the pellet
centrifuged to dry it.
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The glass electrophoresis plates were washed and then
cleaned twice with alcohol, followed by distilled water to
remove any grease or protein from their surfaces.
Spacers were placed between the plates and the edges
sealed with vaseline. Bulldog clips held the whole
together. 60ml of a 10% polyacrylamide separating gel
consisting of:
1) 20ml acrylamide solution (30gm acrylamide and 0.8gm
methylene bisacrylamide in 100ml);
2) 15ml of 1.5M Tris HC1 pH 8.8;
3) 0.6ml of 10% S.D.S.;
4) 24.1ml H20;
5) 0.02ml Temed;
6) 0.3ml 10% ammonium persulphate (A.P.S.) - which should
be added last as this starts the reaction.
was poured between the plates to a line'lcm below the
introducer. H20 was added above this to stop the
formation of a meniscus.
A 3% stacking gel was prepared consisting of:
1) 1.5ml of acrylamide solution;
2) 3.75ml of 0.5M Tris HC1 pH 6.8;
3) 0.15ml of 10% S.D.S.;
4) 9.45ml H20;
5) 0.01ml Temed;
6) 0.15ml 10% A.P.S..
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H20 was emptied from above the set separating gel and
the stacking gel was poured in. The introducer comb
was added to form the sample wells.
The pellet was resuspended in 80ul of a gel sample
buffer (0.5M Tris HC1, 10% S.D.S., glycerol, H20 with 1%
B mercaptoethanol (M.C.E.), 0.5% bromphenol blue in a
ratio of 1:1:1:6:8:0.2 and boiled for 5 minutes. M.C.E.
will split P.L.A.P. into its subunits by breaking
disulphide bridges.
b) Running
The bottom spacer was removed and the plate put into the
electrode holder. Vaseline was again used as a seal.
Electrode buffer, 3gm Tris, 14.4gm glycine and 10ml 10%
S.D.S. in 1L H20 was added to the bottom well and all
bubbles removed from under the gel. The introducer comb
was removed after the bottom of the wells had been marked
on the plate and the upper electrode well filled. 20ul
of a mixture of proteins with known molecular weight were
added to the wells at each end of the gel and the samples
loaded into the remaining wells ensuring that they do not
overflow.
A Volkam power pack, which gives a constant current was
attached, with the positive lead to the bottom well and
negative to the top well. The gel was run at a constant
40 M.A., although the voltage varied, for 4^ hours and
all bubbles that formed were removed.
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c) Staining and destaininq
The gel was removed from the plates, the left side marked
and the gel staining with 0.1% coomassie brilliant blue in
methanol/acetic acid/water (5:1:4 by volume) overnight at
room temperature. Destaining using methanol/acetic acid/
water (1:1:8 by volume) took 48 hours at room temperature
during which time the destaining solution was changed 3
times.
d) Results
No conclusive result was obtained by affinity chromatography
due to a large amount of serum protein sticking, non-
specifically to sepharose and showing on both the NDOG2 and
control eluates. Albumin was present in relatively large
amounts in both columns and, because of its molecular weight
being very similar to that of the subunits of P.L.A.P.,
masked any P.L.A.P. present. Therefore an immunoblotting
technique was next employed.
4.8.5 Immunoblotting
a) Introduction
Polyacrylamide gel electrophoresis is a convenient method
of separating proteins but is difficult to handle and
will not allow immunostaining of protein. Nitrocellulose
membrane however, is convenient to handle and will allow
immunostaining but is not used in electrophoresis.
The method of immunoblotting described here ("Western blot")
involves the separation of proteins by polyacrylamide gel
electrophoresis and their transfer to nitrocellulose
membrane using a transblot electrophoretic transfer cell.
The presence of the ND0G2 determinant can then be recognised
by incubating with NDOG2 and then an enzyme linked second




Electrophoresis was performed used a 10% polyacylamide
gel to separate serum proteins from:
1) An apparently healthy individual with high levels of
the NDOG2 determinant as measured by assay 3;
2) Patient 6. A preoperative sample of serum and a
sample of serum taken at the time of tumour recurrence
were tested. This patient had elevated levels in both
assays preoperatively but only assay 3 predicted her
tumour recurrence;
3) Patient 52. A preoperative sample of serum was tested.
This patient's serum levels remained constantly normal
in bothassays;
4) P.L.A.P. (Sigma) at a concentration of lmg/ml. The
first well contained the standard marker protein suspension
and the next 5 wells contained lOul of the test samples
boiled in 40ul G.S.B. which were repeated in the next 5
wells.
2 pieces of 3mm blotting paper and 1 piece of nitrocellu¬
lose were cut to the size of the polyacrylamide gel (16cm
x 17.5cm) and soaked with 2 pads of "scotchbrite" in
electroblot buffer (36g Tris, 172.6g Glycine, 1200ml
methanol made up 6 litres). After electrophoresis, the
gel was rinsed in electroblot buffer for 5 minutes and
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the transblot cassette loaded, from anode to cathode,
with "scotchbrite", paper, nitrocellulose, gel, paper,
"scotchbrite" taking care to exclude all air bubbles.
The cassette was closed and transferred to the transblot
cell, containing electroblot buffer and run at 500 MA for
3 hours. Ice was packed around the outside of the cell to
prevent overheating and a magnetic stirrer ensured that
the buffer was kept circulating, to minimise any pH change
due to electrolysis.
Prior to blotting the gel was measured so that, after the
blotting step had been completed, the nitrocellulose
membrane could be cut into 2 strips. The left half
contained the marker proteins and the 5 test samples and
the right half the 5 samples alone. The right half of
the nitrocellulose membrane was transferred to a solution
of 1% B.S.A., 1% haemoglobin in P.B.S., 0.02% azide and
incubated overnight at 4°C. The lefthalf was stained for
10 minutes using an 0.5% solution of amino black in fix
solution (500ml f^O, 450ml methanol, 50ml acetic acid)
and then destained in fix solution to demonstrate the
separation of the test proteins. The polyacrylamide gel
was stained with coomassie blue as previously described
(section 4.8.4 (c)) to confirm transfer of proteins
from the gel to nitrocellulose.
The right hand half of the nitrocellullose membrane was
washed in P.B.S., 0.05% Tween 20 after the blocking step
and incubated with 15ml of NDOG2 supernatant in a plastic
bag, for 1 hour at 4°C. The membrane was then washed
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three times with P.B.S., 0.05% Tween 20 and incubated
for 30 minutes with 15ml of a 1/150 dilution of an
alkaline phosphatase conjugated sheep antimouse immuno¬
globulin (Sigma) in P.B.S., 0.5% B.S.A., 2% Hepes, at
4°C. A further four washes were performed with P.B.S.,
0.05% Tween 20 followed by one wash with T.B.S. pH 7
buffer.
Fresh substrate consisting of 15mgm of Fast Red T.R. salt
(Sigma) in 15ml of a solution containing 0.3mg Napthol
ASMX dissolved in 0.3ml diethyl formamide in 14.7ml 0.1M
Tris HC1 pH 8.2, filtered using Whatmans No. 3 filter
paper, was prepared and incubated with the nitrocellulose
membrane for 30 minutes, at room temperature, in a fume
cabinet. The membrane was then washed with T.B.S. and any
positive reactive staining showed as a red band.
Results
lOul of 'neat' test serum per well resulted in overloading
of both the gel and nitrocellulose paper with serum
proteins. The strip stained with amido black confirmed
that protein had been transferred but no meaningful
result was obtained from the strip incubated with ND0G2.
c) Experiment 2
Method
Experiment 1 was repeated but in this case lOul per well
of a 1 in 200 dilution of each test serum was run on 2
polyacrylamide gels. The blotting procedure was repeated
but the 2 cassettes used required 1.1 amps for 3 hours to
transfer protein from the gel to the nitrocellulose paper.
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4 strips of paper were therefore obtained each containing
1 row of sigma P.L.A.P. and the 4 test sera. The first
strip was stained with amido black, the second was incuba¬
ted with ND0G2 and then with an alkaline phosphatase
conjugated sheep anti mouse immunoglobulin. The third
strip was incubated with P.B.S./0.05% Tween 20 and acted
as a control; the fourth strip was incubated first with
the rabbit anti human P.L.A.P. immunoglobulin (Dako) used
in assay 3 and then with an alkaline phosphatase onjugated
goat anti sheep immunoglobulin. The colour was developed
as in experiment 1.
Results
The paper was not overloaded in this case, and both NDOG2
and the rabbit anti human P.L.A.P. antiserum recognised a
band at 67,000 Daltons in the sigma preparation. In
addition the polyclonal preparation recognised a number
of bands of lower molecular weight in this preparation.
These may have been due to P.L.A.P. degradation productions,
not recognised by NDOG2 or the presence of contaminants
in the sigma preparation recognised by the polyclonal anti¬
body alone.
The strip incubated with the polyclonal preparation also
showed a very faint band at 67,000 Daltons in the positive
(patient 6) recurrent (patient 6) and high 'normal' serum
samples.
These were not detected by ND0G2, possibly due to the low
concentrations of P.L.A.P. present in lOul of a 1 in 200
dilution of test serum. Polyclonal antisera detect a
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number of antigenic sites on any one protein, whereas a
monoclonal will detect only one. Therefore, many more
molecules of the rabbit antihuman P.L.A.P. antiserum will
attach to the P.L.A.P. molecule than ND0G2. This may
explain why although both recognise the sigma P.L.A.P.
preparation (a high concentration), only the strip incubated
with the polyclonal antiserum showed a band at 67,000
Daltons in the high and recurrent serum samples.
Experiment 3
Method
600ul of test serum from patients with:
a) High serum levels in both assays;
b) Low serum levels in both assays;
c) A 'normal' case with normal levels in assay 1 but high
levels in assay 3.
and 600ul of a preparation containing 200ug of P.L.A.P.
(sigma) in P.B.S., were all mixed for 2 hours at 4°C with
400ul of NDOG2-sepharose. The beads were separated by
centrifugation at 10,000 r.p.m. for 5 minutes and then
washed with 1ml P.B.S., three times.
The beads were transferred to a fresh tube, washed again
and then boiled with 400ul of gel sample buffer for 5
minutes. The beads were separated by centrifuging at
1000 r.p.m. for 5 minutes and the supernatant saved.
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2 10% polyacrylamide gels were prepared and loaded with
80ul/well of each sample as follows:
WELL ( 1 2 3 4 5 6
( 7 8 9 10 11 12
Markers PLAP PLAP Sample a b c Blank
AFTER INCUBATION WITH
ND0G2- SEPHAROSE
Experiment 2 was repeated but used purified ND0G2 in a
concentration of lOug/ml.
Results
i) The strip of nitrocellulose stained with amido black
showed the separation and transfer of proteins from the
test samples;
ii) The control strip showed bands equivalent to the
heavy and light chains of NDOG2 due to elution of the
antibody from sepharose;
iii) The strip incubated with rabbit anti human P.L.A.P.
immunoglobin showed a band at 67,000 Daltons, the same
molecular weight as P.L.A.P. subunits, in the sigma
P.L.A.P. sample faintly in test samples (a) and (c} and in
the sample of P.L.A.P. previously incubated with ND0G2-
sepharose. This latter showed fewer of the lower molecular
weight bands previously demonstrated in experiment 2
(4.8.5 (c)). As the 67,000 Dalton band was still visualised
in samples (a) and (c) after incubation with NDOG2-sepharose
it is unlikely that this was due to intestinal alkaline
phosphatase.
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iv) The strip incubated with ND0G2 showed bands equiva¬
lent to the heavy and light chain only. No bands were
seen with the P.L.A.P. (Sigma) samples or test sera.
This result may be due to the ND0G2-sepharose binding
only a small amount of P.L.A.P., which, while sufficient
to be detected by the polyclonal antibody, might still be
too low to be visualised using ND0G2.
4.9 Conclusions and discussions
This chapter described the development of 2 assays,
based on ND0G2, that have been used to monitor patients
with ovarian cancer. The first of these, assay 1,
measured enzymically active P.L.A.P. and the second,
assay 3, measured protein captured by ND0G2. There were
many similarities between these 2 assays:
1) The half life of the antigen(s) recognised was the
same in both assays;
2) Cigarette smoking was a cause of raised serum levels
with both assays;
3) There was a close correlation between preoperative
serum levels and the degree of reactive staining of the
ovarian carcinoma in both assays;
4) Low preoperative serum levels were recorded with both
assays in patients with benign ovarian tumours.
5) Both assays accurately predicted the course of the
disease in the same 11 cases (section 4.7).
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There were also several differences:
1) The most striking of these was the unexplained high
levels recorded with assay 3 in some healthy blood donors;
2) In 7 cases (patients 3, 6, 8, 21, 30, 31 and 32)
assay 3 accurately reflected the course of the disease
when assay 1 did not;
3) In 5 cases (patients 12, 15, 22, 23 and 44) both
assays initially agreed but then one showed an inappro¬
priate fall in the presence of residual tumour. The other
assay either briefly fell and then continued to rise
(e.g. fig 4.7) or rose at a slower rate (e.g. fig 4.11).
This latter case suggests a high initial concentration
inactive protein as active enzyme could only rise whilst
total protein (assay 3) fell under the circumstances.
These differences suggest that NDOG2 recognises active
P.L.A.P. and a second tumour associated antigen. This
second antigen has not been clearly identified but it is
obviously very closely related to P.L.A.P.. It must have
one epitope recognised by NDOG2 and at least one other
recognised by the polyclonal rabbit anti human P.L.A.P.
antiserum. This latter is known to cross react with
human intestinal alkaline phosphatase (Dako Data Sheet).
The proposed second antigen possibly has a molecular
weight identical to that of an alkaline phosphatase
subunit as a faint band at 67,000 Daltons was detected
by the polyclonal antiserum (but not NDOG2) in the high
normal serum sample (experiments 2 & 3, (4.8.5)). Incuba¬
tion of higher volumes of test serum with NDOG2-sepharose
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prior to blotting (experiment 1 (4.8.5)) still resulted in
insufficient protein being transferred to the nitrocellu¬
lose paper to be visualised using ND0G2.
The second antigen may be an inactive form of P.L.A.P. or
an inactive hybrid alkaline phosphatase molecule which would
consist of one P.L.A.P. and one intestinal alkaline
phosphatase subunit. However, it could also be a separate
serum protein, with no phosphatase activity equivalent to
the low molecular weight bands detected in the sigma
P.L.A.P. preparation (experiments 2 & 3 (4.8.5)).
The predictive value of both assays was improved when only
patients with positive immunohistology were followed up.
Even so assay 1 was only accurate in 60% of these and
assay 3 in 73%. This is possibly due to the lower
expression of the NDOG2 determinant by secondary tumour
deposits (Chapter 3).
Cigarette smoking is the major "benign" cause of elevated
serum P.L.A.P. and can therefore cause confusion in the
interpretation of both assays in such cases (e.g. fig 4.8).
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4.10 Tables, Charts and Figures
Table 4.1 Preoperative serum levels in patients with
benign ovarian tumours compared with degree






Assay 1 Assay 3




















Grade 3 0.0 I.U./L 0.21 ug/ml
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Table 4.2 Comparison of the degree of reactive staining
with ND0G2 of the primary tumour and preoperative
serum levels using assay 1 and 3 in non smoking








6 Serous Grade 4 5.6 0.35
13 Serous Grade 4 5.6 36.02
24 Serous Grade 4 2.55 3.35




Grade 3 <0.1 0.37
38 Serous Grade 3 8.5 368.22
20 Serous Grade 2 0.95 19.5
33 Serous Grade 3 2.1 0.2
35 Serous Grade 2 1.5 0.6
43 Adenocarcinoma Grade 2 <0.1 0.14
7 Adenocarcinoma Grade 1 <0.1 0.16
8 Serous Grade 1 <0.1 0.89
21 Adenocarcinoma Negative <0.1 2.81
30 Anaplastic Negative <0.1 1.51
36 Adenocarcinoma Negative 0.35 0.3
37 Serous Negative <0.1 0.41
46 Adenocarcinoma Negative <0.1 0.13
50 Mucinous Negative <0.1 0.13
52 Adenocarcinoma Negative <0.1 0.1
4 Serous Necrotic <0.1 0.11
1 6 2
Table 4.3 Comparison of the immunohistology of the tumour










Assay 1 Assay 3
6 R S Grade 4 N Y
13 W S Grade 4 Y Y
19 D S Grade 4 (Y) (Y)
24 W S Grade 4 Y Y
32 R S Grade 4 N Y
2 W S (B.M.) Grade 3 N N
10 W S Grade 3 Y Y
18 W S Grade 3 F.P. F.P.
38 W S Grade 3 Y Y
39 W S Grade 3 Y Y
20 W S Grade 2 Y Y
34 D A Grade 2 B B
35 R A Grade 2 Y Y
oin W S Grade 2 Y Y
43 R A Grade 2 Y Y
7 W A Grade 1 N N
8 R S Grade 1 N Y
11 W S Grade 1 N N
22 R S Grade 1 Y (Y)
45 W M Grade 1 F.P. F.P.
3 D S Grade 1 N Y
36 D A Negative Y Y
21 R A Negative N Y
30 D A Negative N Y
37 D S Negative N (Y)
42 R A Negative N N
4 W S Necrotic N N
R = Recurrence Y = accurately predicts
D = Death N = levels never elevated
W = Well B = levels only elevated with
S = Serous cystadenoma bulk disease
M = Mucinous cystadenoma (Y) = levels fall inappropriately
A = Adenocarcinoma F.P. = False positive
(B.M. = Borderline malignancy
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Table 4.4 The value of assays 1 and 3 in predicting the
course of the disease in those patients in






Predicts the course of
the disease?
Assay 1 Assay 3
1 R S N B
5 D S N (Y)
16 D M N (Y)
28 W S N N
31 W s N Y
41 D s N (Y)
29 W s N N
49 R A N N
48 D A N N
47 D A N N
14 R A Y N
23 D A Y (Y)
12 D S (Y) Y
15 R A (Y) Y
25 R S Y Y
44 D A (Y) Y
17 R A N N
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Table 4.5 Variation in levels of P.L.A.P. determined




<1.0 ug/ml 37/66 56% 23/44 52%
<1.5 ug/ml 45/66 68% 27/44 61%
<3.0 ug/ml 50/66 76% 29/44 65%
<4.0 ug/ml 51/66 77% 34/44 77%
<5.0 ug/ml 53/66 80% 36/44 82%
<6.0 ug/ml 54/66 82% 36/44 82%
<10.0 ug/ml 57/66 86% 39/44 89%
<15.0 ug/ml 59/66 89% 39/44 89%
< 50.0 ug/ml 62/66 94% 41/44 93%
<100.0 ug/ml 64/66 97% 42/44 95%
<200.0 ug/ml 66/66 100% 43/44 98%
<300.0 ug/ml 66/66 100% 43/44 98%
<400.0 ug/ml 66/66 100% 44/44 100%
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Demonstration of long term product inhibition of P.L.A.P.
FIG 4.2 Titration curve for T.M.E*
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Titration curves. Assay 3 with coating concentrations of
200ug, lOOug, 50ug and lOug NDOG2 per well.
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Titration curves Assay 3 with coating concentrations of 20ug,
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Ovarian cancer, with its propensity for intra-abdominal
metastasis, presents certain problems in the detection of
early tumour recurrence and in assessing a patient's
response to therapy. Conventional imaging techniques
such as ultrasound scanning (U.S.S.) and Xray computed
tomography (C.T.) have limited value in the detection of
small, solid intra-abdominal tumour deposits, particularly
after surgery. Radioimmunoscintigraphy (R.I.S.) which is
an imaging technique using radiolabelled antibodies, has
shown promise in the detection of small intra-abdominal
tumour deposits (Van Nagell et al 1978, Granowska et al
1984).
This chapter describes the use of 123-iodine labelled
ND0G2 antibody in R.I.S. of patients, primarily those with
ovarian cancer but also those with brest, testicular and
endometrial cancers. The ND0G2 determinant is present on
the three common allelic forms of P.L.A.P. and has been
demonstrated immunohistologically in over 60% of epithelial
ovarian cancers and over 50% of endometrial carcinomas.
Both testicular and breast tumours have been reported to
express P.L.A.P. (Lange et al 1982, McDicken et al 1983).
The strongest reactive staining with ND0G2 in normal tissues
was seen in fallopian tube, endometrial and endocervical
epithelium (Chapter 3), organs that, in the case of ovarian
cancer, will usually have been removed at the time of
primary surgery. Lung and thymus showed variable staining
with ND0G2 and in the latter case staining was minimal and
intracellular. Therefore, from the point of potential
uptake by normal tissue NDOG2 compares favourably with





R.I.S. was performed in 27 patients, of these 20 had known
or suspected ovarian cancer, 5 patients had metastatic
breast cancer and 1 patient, each, was imaged with an
endometrial carcinoma and a disseminated seminoma. 14
patients in the ovarian cancer group were imaged prior to
or shortly after surgery, 5 patients were imaged after a
course of, or prior to a change in, chemotherapy and the
final patient was imaged after radiotherapy.
Informed consent was obtained in all cases and any patient
with a known allergy to mice or iodine excluded from this
study. All patients received a thyroid blocking agent.
For the first 9 patients 400mg of potassium perchlorate
was given orally 2 hours before imaging, followed by 200mg
daily for the next 3 days. This proved to be only partly
123
effective in blocking thyroid uptake of 123-iodine ( I)
and so potassium iodide, in a dose of 420mg either 14 or
2 hours before imaging and 180mgm daily for 3 days after
imaging was used. This was fully effective.
Patients in the ovarian cancer group were selected because
of positive immunohistology of their tumour alone (6 patients)
elevated serum P.L.A.P. (either assay) alone (4 patients)
or both parameters (6 patients). 3 patients were imaged
without prior knowledge of the P.L.A.P. status of their
tumour and one patient was imaged whose tumour did not
apparently produce P.L.A.P. (Table 5.1).
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5 patients with breast carcinoma, in whom there was no
evidence of dDdominal or pelvic metastases were imaged.
Breast cancer does express P.L.A.P. although serum levels
may be normal (McDicken et al 1983); however the primary
aim of imaging this group of patients was to obtain a
series of scans of disease free pelvis and abdomens.
The patient with an endometrial carcinoma had both positive
immunohistology and elevated serum P.L.A.P. levels whilst
the patient with disseminated seminoma, who was also a
heavy smoker, had elevated serum P.L.A.P.. No fresh
tissue was available in this latter case.
5.2.2 Purification of NDQG2
The NDOG2 antibody used in this chapter was produced by
NDOG2 tumours growing in the peritoneal cavities of Balb/c
mice. The ascites produced by these animals was collected
and the antibody purified by Protein A sepharose affinity
chromatography and sephacryl S300 column chromatography
(section 4.3.6 (ab) and (b)). The antibody was concentra¬
ted to 2.6mg/ml (section 4.3.6. (d)), divided into lOOul
(i.e. 260ug) aliquots and stored at -20°C until use. This
preparation gave no side effects when injected into 2 rats
and 2 guinea pigs at a concentration of 70ug per animal.
5.2.3 Choice of Radionuclide
The various istopes used in R.I.S. have been discussed in
123
Chapter 2. I was used in this study because it is a pure
gamma emitter with an energy range ideally suited to the
modern gamma camera and because simple and effective methods
exist for the iodination of proteins. Although free
iodine is taken up by the thyroid gland this can be preven¬
ted as described in 5.2.1..
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5.2.4 Method of Iodination
a) Theory
Two methods of iodinating antibodies for use in R.I.S.
exist, the iodogen (Epenetos et al 1982) and the chloramine
T methods. The latter, originally described by Hunter and
Greenwood (1962), was used in this study.
Iodine will bind to the aromatic side chain of tyrosine but
also, weakly to histidine and phenylalanine, whether they are
free aminoacids or in proteins. Chloramine T, a potent
oxidising agent, converts iodine to a more reactive form and
enhances its binding capacity.
b) Method
The iodination of ND0G2 was performed in the 'sterile' room
of the Radiopharmacy Department at the Bristol General
Hospital. All reagents used were sterilised either by
autoclaving at 115°C 151b/square inch for 30 minutes
(P.B.S. and Sephadex G50), heat sterilisation at 2000°C
for 2 hours (glassware), ultrafiltration (P.B.S., sodium
phosphate, saturated tyrosine and Chloramine T solutions,
ND0G2 antibody) or supplied sterile by the manufacturers
(Human plasma protein fraction (H.P.P.F.), Bijoux, syringes
and needles).
The 10ml fractionating column was made from a glass pipette
with the top removed and a cotton wool plug firmed down
with the tip. Sephadex G50 was swollen overnight with
excess P.B.S., which was subsequently decanted and a further
20-30ml P.B.S. added. The resultant mixture was pipetted
into the column, without the inclusion of any air, to the
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10ml mark. 1ml H.P.P.F. was added to block any non¬
specific protein binding to the column. The column,
which has a capacity of 3ml, was washed with 3ml P.B.S.
to remove free H.P.P.F. and kept topped up with P.B.S.
to avoid any drying out of the column.
500mBq of dry sodium 123-iodine (Harwell) with carrier
sodium hydroxide were dissolved in 0.2ml of 0.3M sodium
phosphate pH 7.2 (BDH, Analar) and 0.3ml P.B.S.. lOOul of
NDOG2 antibody at a concentration of 2.6mg/ml in P.B.S.
were then added, followed by lOOul Chloramine T solution
(2mg/ml in 0.3M sodium phosphate). The iodination was
allowed to proceed for 5 minutes with intermittent mixing
and the reaction halted by the addition of lOOul of satur¬
ated L-tyrosine in 0.3M sodium phosphate. lOOul of H.P.P.F.
was added as a carrier and the whole separated on the
sephadex column. 3ml of P.B.S. (the capacity of the
column) was then added and the first P.B.S. is added and
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the next fraction containing I labelled NDOG2
(123I NDOG2) collected.
Sephadex G50 excludes molecules with a molecular weight
greater than 50,000; thus high molecular weight substances
123
such as I NDOG2 pass rapidly down the column whereas
123
those of low molecular weight (i.e. I tyrosine) pass more
slowly and may be discarded with the column.
123
A 20-30% yield of radioactivity was obtained in the I
NDOG2 fraction giving a specific activity of 4-8M-^C/mg of
NDOG2. The preparation was made up to a convenient
injection volume with normal saline and filtered through
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a 0.2uM filter into the injection vial and transferred to




The percentage of free I in the preparation was assessed
prior to injection by paper chromatography. An aliquot of
the radiopharmaceutical was placed at the bottom of a 2
inch long strip of Whatmans 3 chromatography paper. This
was suspended so that the base was in contact with a
solution of trichloracetic acid (T.C.A.) which will
123
precipitate protein and only allow free I to travel to
the top of the paper. The paper was cut in half and each
123
counted; the percentage of free I in the preparations
used in this study varied between 1 and 10%.
q qth t
5.2.6 Preparation of Tc Human Serum Albumin
This was prepared using the T.C.K.-2 kit for labelling
human albumin (International C.I.S.).
5.2.7 Equipment used and Data acquisition
Data was acquired by collecting images of the biodistribu-
tion of the radiopharmaceutical over a 20 hour period.
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Between 40-70mBq of I ND0G2 was injected intravenously
and three sets of sequential images of head and neck-, chest,
abdomen and pelvis obtained at approximately 10 minutes
(early) 4 hours (intermediate) and 20 hours (late) after
injection. In the breast carcinoma group images of the
femora were obtained in certain cases. The patient was
asked to empty her bladder prior to imaging on each occasion.
The equipment used was an International General Electric
Maxicamera 400T and a link systems data processor; the data
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was collected on a 64 x 64 matrix, with a total number of
counts for each image between 300,000 and 600,000.
By computer aided subtraction of early from later images,
an attempt was made to enhance the visualisation of areas
of increased radioactivity. In order to minimise the
generation of artefacts and to improve the accuracy of
subtraction images, the patient was repositioned before
each image by the use of radioactive skin markers placed
over the anterior superior iliac crests (Granowska et al
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1984). Account of the short radioactive half life of I
and of the biological half life of the radiopharmaceutical,
was taken by measuring the activity in serial serum samples
taken at the time of each imaging sequence. The ratio
between plasma radioactivity at 4 hour and 20 hour after
injection was calculated relative to the initial (10 min)
radioactivity by Dr P Jackson and Mr G Staddon, of the
department of Medical Physics, Bristol General Hospital.
These values were 0.79 and 0.48 respectively and were
incorporated into the subtraction technique.
5.3 Hazards
5.3.1 Allergic Reactions
A hypersensitivity reaction could occur from an allergy to
either iodine or to the ND0G2 antibody. Patients were
questioned about any known allergies prior to injection of
123
I ND0G2. Skin testing was not performed because of the
theoretical risk of sensitising the patient to mouse
protein. One patient, with an unsuspected allergy to iodine,
did develop a mild allergic skin reaction after oral
potassium iodide which responded to oral antihistamine
therapy. Imaging was not performed in this case.
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As P.L.A.P. is present in the circulation there is a
theoretical risk of antibody/antigen complex formation
and subsequent serum sickness. Other workers (Bagshawe
et al 1980, Goldenberg et al 1980 and Halsall et al 1981)
using antibodies to circulating antigens have not reported
any such reaction and none occured during this study,




I is unlikely to prevent a significant radiation hazard
because of its short half life (13 hours) and the low
dosage injected. Although P.L.A.P. is expressed by
fallopian tube, endometrial and cervical columnar epithelium,
this should not pose any hazard as these tussues had been
or were to be removed during primary surgery. Despite
trace amounts of P.L.A.P. in normal lung and thymus no
specific accumulation of activity was demonstrated'in
these tissues in any patient imaged. The risks of accumu-
123
lation of free I in thyroid and in gut mucosa have
already been discussed (5.2.1.).
503.3 Myeloma Virus
Mouse myeloma cell lines contain oncorna viruses (Types C
and A) which would be removed by affinity chromatography
and gel filtration. Moreover there is no evidence that
these viruses react with human cells.
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5.4 Results with ovarian tumours
5.4.1 The effect of iodination on the specific activity
of the ND0G2 antibody
Iodination can result in the loss of some specific activity
by an antibody. In order to assess this both iodinated and
non-iodinated ND0G2 were compared in an enzyme immunoassay
initially described by McLaughlin et al (1983) and
discussed in Chapter 4. There was a small (less than 10%)
loss of activity in the iodinated antibody (fig 5.1).
5.4.2 Demonstration of in vivo specificity
Because of their increased vascularity and the greater
permeability of their capillaries, tumours will accumulate
foreign proteins to a greater degree than normal organs.
In order to demonstrate that the images obtained were not
Q Qrfl t
solely due to a blood pool effect, 70mBq of• Tc albumin
was injected intravenously and sequential images of pelvis
and abdomen obtained in 3 patients prior to the injection,
2 days later, of 123I ND0G2. In one patient no tumour
could be demonstrated by either method or by conventional
imaging techniques but in the other 2 minimal uptake by
pelvic tumours could be seen with ^Tc albumin and this
was much less than with ND0G2 (fig 5.2 a & b).
A further patient (No. 11) whose tumour did not express
P.L.A.P. and who had residual tumour was imaged using
123I NDOG2. None of her known tumour deposits were
visualised although the stomach was clearly visualised,
due to uptake of free 123I bY gastric mucosa (fig 5.3).
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5.4.3 Normal Images
R.I.S. was not performed, for ethical reasons, on patients
who did not have actual or suspected cancer. Therefore,
normal imaging criteria were inferred from:
a) The images obtained from 2 patients (No. 7 and 19) who
were in remission at the time of imaging as judged by-
clinical examination, U.S.S. and a second look laparoscopy
(patient 7).
b) The images of 2 patients (No. 4 and 17) who had positive
pelvic images from a full bladder and a fibroid uterus
respectively but who were otherwise well gave information
about normal abdominal, chest, head and neck images.
c) The images of 3 patients (C, E and G) with breast
carcinomas, without any evidence of pelvic metastases
showed normal pelvic images.
A normal image reflects the blood pool distribution, thus
the major blood vessels, heart, liver aid spleen are
clearly shown (fig 5.4 A, B, C and D). On subsequent
images there are only changes of degree in this distri¬
bution with additional minor activity in the skeleton.
5.4.4 False Positive Results
The cells of the reticulo-endothelial system will break down
the injected radiopharmaceutical resulting in the presence
1 23
of free I in the circulation. This can be taken up by
the thyroid gland and gut mucosa as well as being excreted
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in urine, giving rise to potentially misleading areas of
high activity. Methods of suppressing uptake of by
the thyroid gland have already been discussed (5.2.1.).
In one case (patient 6), who was imaged because of elevated
serum P.L.A.P. levels following radiotherapy, high activity
was noted in the right iliac fossa in the intermediate
(Fig 5.5) but not the early or late images. This activity
123
was ascribed to the transient accumulation of I by caecal
mucosa. The absence of any tumour detectable by C.T., the
presence of activity in only one image and the patients
continued long term good health make a recurrence of her
tumour highly unlikely. This patient's serum P.L.A.P. was
elevated and was secondary to cigarette smoking, this
phenomenon has been discussed earlier (section 4.4.5 e (ii)
123
and 1.3.8. f). Caecal uptake of free I was seen in
one other case (patient 15).
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Intense uptake of I by gut mucosa produced an area of
high activity outlining the stomach in patient 11 (fig 5.3).
This patient's tumour did not express P.L.A.P. and non¬
specific uptake by tumour was excluded as there was no
tumour in this region at laparotomy.
Overall potassium iodide failed to prevent mucosal uptake
123
of I in 2 from 18 patients (11%) and potassium perchlorate




123I is cleared predominantly by the renal tract, therefore
any obstruction can lead to an area of high activity. The
bladder presents the greatest difficulty in interpreting
pelvic images, because unless it is virtually empty during
each imaging not only may genuine metastases be masked,
but also false positive results generated particularly if
a subtraction technique is used.
In one case (patient 4) chronic retention of urine gave a
clinical impression, supported by evidence from a barium
enema and ultrasound scan of an ovarian tumour. Failure
to completely empty the bladder on early scan resulted
in a region of apparent increased radioactivity to be
generated when this was subtracted from a slightly radio¬
active but still fullbLadder on the intermediate image
(fig 5.6 a, b and c).
Subtraction techniques in themselves have a potential for
generating artefacts. The method used in this study
involved the subtraction of the bLood pool (early) image
from the later images and this involves accurate realign¬
ment of the patient for each image, aided by the positioning
of radioactive skin markers over the anterior superior
iliac spines (A.S.I.S.). However, particularly if the
patient is obese, the skin can move relative to the
A.S.I.S. and incorrect alignment can occur with resultant
subtraction artefacts.
There was a positive image in one case (patient 17) due to
a fibroid uterus (fig 5.7). This was due, either to uptake
of -l-23I ND0G2 by endometrium or, more likely, to the blood
pool.
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5.4.5 Images obtained in patients with actual or
suspected ovarian tumours
A comparison between the results of R.I.S. and the opera¬
tive distribution of tumour is summarised in Table 5.3.
These 13 patients were imaged prior to or shortly following
surgery and 5 patients in this group had a second imaging
procedure performed as well (Table 5.4). A further 6
patients were imaged following a course of chemotherapy or
radiotherapy or when a change of chemotherapy was
considered and the findings compared with either C.T. or
U.S.S.. A final patient (No. 15) was imaged 6 weeks after
macroscopic clearance of a stage lc ovarian adenocarcinoma.
This patient's serum P.L.A.P. levels were noted to have
risen and her recurrent tumour was visualised both by C.T.
and R.I.S..
Two groups of abnormal features were seen on the pelvic
and abdominal images:
a) Focal abnormalities
These were seen in 12 patients, being most commonly present
in the pelvis and numerous in one instance (patient 12).
Subtraction was not usually necessary to demonstrate tumour
(5.8) but in one instance the visualisation of the
abnormality was enhanced by this technique (5.9 a, b and c).
These abnormalities correlated well with surgical, U.S.S.
or C.T. findings (Tables 5.3 and 5.4). A diffuse abnorma¬
lity was also seen in two instances (patients 8 and 14).
A focal lesion due to the probable blood pool image of a




These were present in 3 patients and two of these also had
a focal abnormality. In one case (patient 14) who had
extensive intraperitoneal seedlings, probably in asso¬
ciation with some ascites the diffuse activity was intense
enough to mask the iliac vessels (fig 5.10).
The patients imaged with actual or suspected ovarian tumours
are discussed in more detail below:
Patient 1
• This 19 year old girl presented with what proved to be a
stage 3 serous cystadenocarcinoma, which showed grade 4
reactive staining with NDOG2. Some residual tumour, which
had spread directly from the primary, was known to be
left in the pelvis after operation. She was followed up
by serial serum P.L.A.P. estimations (patient 6, chapter 4)
and was imaged after 4 courses of cisplatinum, to which
she had failed to respond. A pelvic mass was visualised
at R.I.S. and confirmed by U.S.S.. No other lesion was
demonstrable by either imaging technique.
Patient 2
A 76 year old lady who was imaged prior to surgery for
a stage 3 serous cystadenocarcinoma. The primary ovarian
tumour and the single, large omental secondary were
clearly visualised by R.I.S.. Both tumours showed grade 2




This 59 year old lady was imaged 8 days after surgery for
a stage 3 serous cystadenocarcinoma. The tumour showed
grade 3 reactive staining with ND0G2. Residual pelvic
trumour was visualised by R.I.S. but secondary seedling
deposits on colon and involved para-aortic nodes were not.
C.T. failed to demonstrate any tumour deposits in this
case. This patient has been followed up with serial serum
P.L.A.P. estimations (patient 10 in chapter 4) and is at
present in remission.
Patient 4
This 70 year old lady was admitted in sub-acute obstruction.
A mass was noted to be arising from the pelvis on abdominal
examination. A barium enema showed extensive bowel
compression and U.S.S. suggested the presence of a pelvic
tumour. No preoperative serum P.L.A.P. levels were
available, and the patient's obstruction settled after an
enema. The 10 minute pelvic image showed a central cold
area (fig 5.6 a) which at 4 hours appeared more active
than the surrounding tissues (fig 5.6 b). Subtraction
revealed an intensely active area (fig 5.6 c) which proved
to be bladder. This patient did not have a pelvic tumour
at E.U.A. and laparoscopy. Her symptoms and signs were
due to constipation and chromic retention of urine.
Patient 5
This 61 year old lady underwent a laparotomy one week prior
to imaging. A large right sided serous cystadenocarcinoma
with multiple intraperitoneal seedlings, ascites and a
liver secondary were noted. Total abdominal hysterectomy
with bilateral salpingo-oophorectomy and omentectomy was
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performed. This tumour showed grade 4 reactive staining
with ND0G2 and a diffuse abdomino-pelvic abnormality-
demonstrated at R.I.S.. The liver secondary was not
visualised but the clearance time of the radiopharma¬
ceutical from the liver was over twice that for the mean
for this group of patients. This patient died within 2
months of surgery.
Patient 6
This 48 year old lady was imaged 21 months after primary
surgery and subsequent radiotherapy for a stage la (ii)
serous cystadenocarcinoma of the ovary. This tumour had
shown grade 3 reactive staining with NDOG2 and serum
P.L.A.P. levels were noted to be elevated. R.I.S. showed
an area of increased activity in the right iliac fossa at
4 hours (fig 5.3) but not at 20 hours. A C.T. scan was
normal and the patient remains well (patient 18 chapter 4).
Her elevated P.L.A.P. levels were secondary to cigarette
smoking and the abnormality demonstrated at R.I.S. was
123
probably due to caecal uptake of free I.
Patient 7
This 33 year old patient had a laparotomy performed for a
stage 3 serous cystadenocarcinoma. The primary and
secondary tumours showed respectively grade 4 and grade 2
reactive staining with NDOG2. Residual intraperitoneal
seedlings remained after surgery and the patient was imaged
after a course of chemotherapy when in apparent remission.
No abnormality was demonstrated at R.I.S. and a second
look laparoscopy showed no bulk disease but positive
washings were obtained. The patient (No. 19 in chapter 4)
ultimately died of her disease.
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Patient 8
This 74 year old patient was left with residual disease
on bowel, bladder surface and liver edge after primary
surgery for a grade 3 staining serous cystadenocarcinoma.
R.I.S. was performed 2 months after surgery and following
2 courses of treosulphan. Focal pelvic lesions were
demonstrated as well as diffuse abdomino-pelvic activity.
The pelvic tumours were demonstrated by U.S.S. but the
abdominal deposits were not.
Patient 9
This 53 year old lady presented with a pelvic mass 3% years
after total abdominal hysterectomy and bilateral salpingo-
oophorectomy for menorrhagia. At that time a surprise
histological diagnosis of a stage lb serous cystadenocar¬
cinoma was made. Unaccountably this patient received no
further therapy and presented with a pelvic mass.
Laparotomy revealed a plaque of tumour adherent to the
pelvic sidewall and surrounding the sigmoid colon,.intra¬
abdominal seedlings and omental secondaries. Omentectomy
was performed; the tumour showed grade 1 reactive staining
with ND0G2. Serum P.L.A.P. was elevated (patient 22 in
chapter 4) and R.I.S. performed 2 weeks later visualised
the pelvic mass.
Patient 10
This 46 year old patient underwent a laparotomy which showed
a serous cystadenocarcinoma of the ovary with peritoneal
and omental secondaries. Biopsy alone was performed.
Immunohistology of a paraffin section of this showed grade 1
reactive staining with NDOG2; however, as the dewaxing of
paraffin sections causes denaturing of some of the ND0G2
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determinant it was likely that this tumour expressed
P.L.A.P. more strongly. This was born out by this
patient's high serum P.L.A.P. levels (patient 25 in
chapter 4). R.I.S. was performed 2 months after surgery
following 1 pulse of chemotherapy and demonstrated the
abdominal and pelvic tumour deposits. These were
enhanced by subtraction (fig 5.8 a, b and c) and were
also visualised by C.T..
Patient 11
This 22 year old patient with a stage 3 serous cystadeno-
carcinoma was imaged 2 months after primary surgery.
There were residual intra-abdominal and pelvic tumour
deposits although none were noted in the region of the
stomach. Imaging showed a stomach shaped area of activity
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in the upper abdomen alone, thought to be due to I
uptake by the gastric mucosa (fig 5.5). This patient's
serum P.L.A.P. levels were normal, even in the presence
of bulk disease (patient 31 in chapter 4).
Patient 12
This 25 year old patient was imaged 1 month after primary
surgery for a stage 3 serous cystadenocarcinoma, which
showed grade 4 reactive staining with ND0G2. Readual
tumour on the rectum was demonstrated by R.I.S.
Patient 13
This 36 year old patient underwent total abdominal hyster¬
ectomy, bilateral salpingo-oophorectomy and omentectomy for
an anaplastic stage 2b serous cystadenocarcinoma. Macro¬
scopic tumour clearance was obtained but pelvic wall
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peritoneal biopsies showed tumour involvement. The tumour
showed grade 2 reactive staining and R.I.S. performed 2
months later after 1 course of chemotherapy showed
recurrent pelvic tumour confirmed by C.T.. In addition an
area of increased activity was demonstrated in the upper
abdomen, possibly due to activity in stomach mucosa or
to a liver secondary. C.T. of this area failed to detect
any abnormality. This patient (No. 35 in chapter 4) contin¬
ued to deteriorate despite chemotherapy.
Patient 14
This 73 year old patient was found, at laparotomy, to have
massive intra-abdominal tumour secondaries arising from an
ovarian adenocarcinoma. This tumour was biopsied only and
showed grade 2 reactive staining with ND0G2. Imaging 3
weeks after operation and prior to chemotherapy, showed
both diffuse and focal activity corresponding to metastases
and primary tumours respectively. This patient was
followed up with serial serum P.L.A.P. estimations (patient
43 in chapter 4).
Patient 15
This 43 year old patient underwent laparotomy with macro¬
scopic clearance of her stage lc poorly differentiated
ovarian adenocarcinoma. She presented 6 weeks later with
abdominal pain and elevated serum P.L.A.P. (patient 44 in
chapter 4). R.I.S. demonstrated a pelvic recurrence
(confirmed by C.T.) as well as an area of increased




This 60 year old patient was imaged 8 months after surgery
and following a course of chemotherapy for a stage 3
ovarian adenocarcinoma. Focal pelvic lesions were demon¬
strated by R.I.S. and confirmed by U.S.S. following elevated
serum P.L.A.P. (patient 15 in chapter 4).
Patient 17
This 62 year old patient presented with a pelvic mass and
was imaged preoperatively, without knowing serum P.L.A.P.
levels. A focal abnormality (fig 5.7) was demonstrated in
the pelvis and at operation this was found to be a fibroid
uterus. The image obtained was due either to the blood pool
within the enlarged uterus or due to uptake by endometrium.
This patient's P.L.A.P. levels were later noted to be
normal.
Patient 18
This 62 year old patient was imaged 4 weeks after surgery
for a stage 3 serous cystadenocarcinoma of the ovary. This
tumour showed grade 4 reactive staining. Residual pelvic
tumour was demonstrated, by R.I.S. but intra-abdominal
peritoneal seedlings were not visualised by this technique
or U.S.S.. This patient (No 32 in chapter 4) has been
followed up with serial serum P.L.A.P. estimations, and her
subsequent deterioration predicted by assay 3.
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Patient 19
This 44 year old patient was imaged after a 6 month course
of chemotherapy following total abdominal hysterectomy and
omentectomy for a stage 3 serous cystadenocarcinoma. Small
(less than 5mm diameter) deposits were left after surgery
and her tumour showed grade 4 reactive staining with
ND0G2. No abnormality was demonstrated by either R.I.S. or
U.S.S. and the patient remains well with normal serum
P.L.A.P. levels (patient 24 in chapter 4).
Patient 20
This 49 year old patient was imaged after four pulses of
adjuvent chemotherapy following macroscopic clearance of a
stage 3 ovarian adenocarcinoma. Serum P.L.A.P. was noted
to be elevated (patient 14 in chapter 4) and R.I.S. showed
a focal pelvic lesion that was also visualised by U.S.S..
5.4.6 Demonstration of antibody on resected tumour
after R.I.S.
Frozen sections of tumour, resected 24 hours after the
123
injection of I NDOG2, of 6u thickness were cut, air
dried and fixed in acetone. They were incubated for 30
minutes with peroxidase conjugated rabbit anti mouse
immunoglobulin and then with DAB (chapter 3).
Positive reactive staining was demonstrated on the resected
tumour (fig 5.11) demonstrating the presence of NDOG2.
5.4.7 Comparison with other imaging techniques
In 12 patients with actual or suspected ovarian cancer
C.T. or U.S.S. was performed within 1 week of R.I.S. and
the results compared (Table 5.4). In 5 of these patients
the extent of the tumour had been mapped out by recent
surgery (patients 3, 4, 8, 10 and 13).
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No tumour deposit detectable by C.T. or U.S.S. was missed
by R.I.S. and in one instance (patient 3) R.I.S. detected
a focal tumour deposit that was not visualised by C.T..
In addition there were seedling tumour deposits on the
surface of the colon and spread to the para-aortic nodes.
Neither of these sites of metastasis were detected by
either imaging technique. In a further case (patient 8)
although both U.S.S. and R.I.S. detected a pelvic tumour
only R.I.S. identified this patient's widespread peri¬
toneal seedlings. In two cases (patients 7 and 19)
neither imaging technique detected any tumour. One of these
(patient 7) positive peritoneal washings only at second
look laparoscopy. Both patients were clinically in remission
at the time of imaging although patient 7 subsequently
developed intra-abdominal secondary tumour and died.
A chronically distended bladder gave a false positive
image (patient 4) but interestingly both barium enema and
an U.S.S. suggested the possible presence of an ovarian
tumour.
In two patients (No. 6 and 15) an area of increased activity
was noted in the right iliac fossa at 4 hours in both
cases. C.T. did not show a tumour in this region, although
patient 15 did have a pelvic recurrence of her tumour
from which she rapidly died, despite chemotherapy. The
area of increased activity disappeared on the 20 hour
scan in patient 6, who remains well some 11 months later
and it is unlikely that this represented anything other
123
than uptake by caecal mucosa of free I.
200
5.5 Results of R.I.S. performed on patients with breast,
endometrial and testicular tumours
5 patients with metastatic breast cancer, all of whom had
the primary tumour resected, 1 patient with a stage 4
endometrial carcinoma and 1 patient with a disseminated
seminoma were all imaged using an identical imaging
technique to that used for patients with ovarian cancer.
The results of imaging in this group of patients is
summarised in Table 5.5.
Patient A
This 45 year old man, who was a heavy cigarette smoker,
developed mediastinal, anterior chest wall and neck
metastases from his seminoma. His serum P.L.A.P. levels
were elevated but none of his known metastases were visible
at imaging.
Patient B
This 64 year old lady, who did not smoke, had a stage 4
endometrial carcinoma (invading the bladder but with no
obvious distant metastases) which showed grade 3 reactive
staining with NDOG2. Serum P.L.A.P. was elevated and
imaging demonstrated a large pelvic tumour.
Patient C
This 70 year old patient had lumbar spine metastases of
her breast carcinoma which were not visualised at R.I.S..
20 1
Patient D
This 55 year old lady developed a metastasis in her right
lung 4 years after a right mastectomy. This metastasis
was clearly visualised on both the 4 hour and 20 hour
image, being mbst clearly visualised on the latter.
Patient E
This 82 year old patient had both right femoral and left
neck nodal breast metastases which were not visible at
imaging.
Patient F
This patient aged 64, had widely disseminated tumour
present in both lumbar and sacral spine and right hip.
Only her lumbar metastasis was visualised at R.I.S..
Patient G
This patient with skull and left chest wall breast
metastases was imaged, but neither tumour deposit was
visualised.
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Overall, imaging patients with breast cancer using I
NDOG2 proved disappointing, with only 2 from 9 known sites
of secondary tumour being visualised. None of the sites of
metastatic seminoma were visualised. This patient's high
serum levels of P.L.A.P. could well have been secondary to
cigarette smoking. It is also possible that this tumour
expressed a form of P.L.A.P. not recognised by NDOG2.




The dosimetry for this antibody was calculated by
Dr P Jackson of the Department of Medical Physics,
Bristol General Hospital (Jackson et al 1985).
123I ND0G2 was cleared from the blood pool by the redistri¬
bution of the radiopharmaceutical into other compartments
123
and the excretion of free I by the kidneys. The mean
plasma clearance time of the compound was 20.8 hours and
79% of the injected activity (correcting for radioactive
decay) was present in urine after 48 hours. The amount of
123
free I present in serum, at any one time, was low and
varied between 1.3% and 7.3% (mean 3.7%). The tumour to
background (thigh) ratios varied from 1.4:1 and 4.8:1
(mean 2.95:1) and these figures are comparable to other
studies (Goldenberg et al 1980, Kim et al 1980, Bagshawe
et al 1980).
The whole body dose of radioactivity received by the
patient was 60mrem/mCi (16.3uSv/mBq).
5.7 Conclusions and Discussions
This chapter describes the preparation of radiolabelled
ND0G2 and its use in a variety of tumours, predominantly
123
ovarian carcinomas. I was used as the radiolabel in
this study as it is a pure gamma emitter, has an energy
range ideally suited to the modern gamma camera and can be
easily linked to proteins. However, it has a short half
life and is only produced weekly but is considerably
cheaper than li:LIn. Uptake of free 123I by gut mucosa and
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thyroid can, in theory, be blocked using potassium iodide
or perchlorate. In this study potassium iodide proved to
be the more effective thyroid blocking agent although
neither compound totally prevented uptake by gut mucosa.
This latter was a significant cause of false positive
images.
The chloramine T method was used to iodinate NDOG2 and
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this is a simple technique and I NDOG2 retains upwards
of 90% of the specific activity of the unlableed form.
There is a theoretical risk of serum sickness when an
antibody directed against a circulating antigen is injected
intravenously. Only a small quantity (260ug) of antibody
was used in this study and no such reactions were seen.
Indeed other workers have used up to 20mg of antibody
without ill effect (S. Larson - personal communication).
No animal models were available but the in vivo specifi-
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city of I NDOG2 has been demonstrated in humans
(section 5.4.2.).
Two forms of abnormality due to ovarian cancer were demon¬
strated with R.I.S. using NDOG2, focal and diffuse, and
these have been described already (section 5.4.5). The
R.I.S. findings correlated well with images obtained at
U.S.S. or C.T. and with the operative findings. However,
in certain situations it was difficult to visualise ovarian
tumour deposits particularly when they are in, or close
to, areas of high background activity i.e. liver and the
para-aortic region. This is due to a high proportion of
the injected activity remaining in the circulation and this
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can mask specific tumour uptake. Overall tumour to back¬
ground ratios were low (mean 2.95:1) and so methods of
subtracting the early from later images were explored to
try and eliminate the background activity. However, even
123
when the biological half life of I NDOG2 was taken into
account this method did create artefacts. It proved
impossible to be completely accurate in repositioning the
patient prior to each imaging sequence and so the early
and later images were not always perfectly superimposed.
Other causes of areas of high activity, not due to tumour
uptake of the radiopharmaceutical were the accumulation of
123
I in gut mucosa and bladder. Potassium iodide and
perchlorate never proved totally effective in eliminating
123
this and in one case (patient 6) caecal uptake of I
at 4 hours and raised serum P.L.A.P. (due to cigarette
smoking) raised the suspicion of a tumour recurrence.
However, a normal C.T. scan and the transient nature of
the uptake suggested otherwise. The patient has subsequently
remained well with no evidence of tumour recurrence.
It is vital that the bladder is completely empty before
imaging the pelvis as in one case (patient 4) chronic
retention of urine gave a clinical and R.I.S. impression
of a tumour. Conversely a full bladder may also mask
1 o o
specific uptake of NDOG2 by a pelvic tumour deposit.
The results of imaging patients with breast cancer or
seminoma were disappointing. In the latter case the
patient's elevated serum P.L.A.P. was most likely due to
cigarette smoking. Only 2 from 9 known sites of breast
metastasis were detected by this method; other workers
(McDicken et al 1983) have reported reactive staining
with the H317 anti P.L.A.P. antibody but have failed to
detect raised serum levels in these patients. As no
fresh tumour was available from patients with breast
cancer who were imaged it is possible that many did not
express P.L.A.P..
206
5.7 Tables, Charts and Figures
Legends for figures
5.1 Comparison of NDOG2 and 123I NDOG2 specific binding
capacities using assay 1.
5.2 a) Pelvic image using "mTc human serum albumin at
4 hours.
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b) Pelvic image in the same patient using I NDOG2
at 4 hours.
5.3 Abdominal image showing stomach mucosal uptake of
123
_L •
5.4 Normal late images of a) pelvis
b) Abdomen
c) Chest
d) Head and Neck.
5.5 Pelvic image at 4 hours showing caecal uptake of
123
1 •
5.6 Pelvic images, to demonstrate bladder artefact
generated by subtraction at a) 10 minutes
b) 4 hours
c) subtracted image.
5.7 Intermediate pelvic image of a patient with a
fibroid uterus.
5.8 Late pelvic image demonstrating a focal lesion.
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5.9 Series of pelvic images, to demonstrate enhanced




5.10 Late abdominal image showing a diffuse abnormality.
5.11 Demonstration of NDOG2 on resected tumour.
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Table 5.2 Comparison of results with I ND0G2
9 9m
and Tc H.S.A.
Patient Site of tumour
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20 Pelvic mass +
+
21 1
Table 5.3 Comparison of operative and radioimmunoscinti-
graphy findings in ovarian carcinoma
Patient Operative Findings R.I.S. findings













































b) No obvious liver
metastasis
a) + (focal)
b) Focal in liver
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Table 5.4 Comparison of radioimmunoscintiqraphy and
U.S.S. or C.T. findings in ovarian carcinoma
Patient C.T. or U.S.S. R.I.S.
6 No tumour (C.T.)
Uptake by caecum
at 4 hours.
None at 20 hours
7 No tumour (U.S.S.) Normal
16 Pelvic mass (C.T.) + (focal)




19 No tumour (U.S.S.) Normal
20 Pelvic mass (U.S.S.) + (focal)
1 Pelvic mass (U.S.S.) + (focal)






















Table 5.5 The results of R.I.S. in patients with breast,








































The suggestion that ND0G2 fixes a P.L.A.P. determinant
arose from the study of normal placentae of varying
gestational ages. The ND0G2 determinant first appeared
on placentae at 10 weeks gestation and was present on all
placentae examined from 16 weeks to term. This is in line
with the autogeny of P.L.A.P.. The further experimental
work performed to show that the placental isoenzyme alone
is recognised has been described in sections 2.3 and 3.3.1
Dr J Millan of Umea University, Stockholm, independently
confirmed these findings and showed that NDOG2 reacted
with the three common allelic forms (F, I and S) of
P.L.A.P..
The possibility that NDOG2 recognises something other than
enzymically active P.L.A.P. came from the comparison of
the results obtained with assays 1 and 3. The first assay
measured active enzyme only whereas assay 3 measured
the total protein captured by NDOG2. There were many
similarities between the two assays (section 4.7) but the
most striking difference was noted in the wide range of
results obtained in the normal population using assay 3.
An attempt was made to identify this antigen by affinity
chromatography and immunoblotting (section 4.8). A band,
at 67,000 Daltons was identified in "high normal' and
malignancy sera and in addition several lower molecular
weight proteins were detected in the sigma P.L.A.P. prepar¬
ation, using the polyclonal preparation, in the blotting
experiments. However, the second antigen was not clearly
identified. This proposed second antigen would need to
have one determinant recognised by ND0G2 and at least one
other recognised by the polyclonal antiserum, for assay 3
to work. Therefore assay 3 measures both enzymically active
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P.L.A.P. and either an inactive form of this enzyme or a
similar tumour associated antigen. The nature of this is
uncertain but it may be a hybrid alkaline phosphatase
molecule. Because the polyclonal antibody cross reacts
with intestinal alkaline phosphatase (Dako Data Sheet),
assay 3 could measure a hybrid consisting of one subunit
P.L.A.P. and a second subunit of intestinal alkaline
phosphatase. Such molecules have been described (Warnock
and Reisman 1969, Higashino et al 1972).
Immunohistological examination of normal tissues were
performed to assess the distribution of the NDOG2 deter¬
minant in health. This distribution corresponds to that
reported for P.L.A.P. with the exception of testis. No
reactive staining was seen with ND0G2 in this organ but
the form of P.L.A.P. reported in testis was similar to
the rare placental D variant (Goldstein et al 1982), a type
not recognised by NDOG2.
Epithelial cancers of the ovary, cervix and endometrium
all arise from structures that have a close embryological
origin and all express P.L.A.P. to some degree. Cervical
carcinomas showed the weakest degree of reactive staining
with ND0G2 with only 16% showing greater than grade 1"
staining, a figure similar to that reported in the
literature for P.L.A.P. (Cadeau et al 1974). A much
greater percentage (65%) of endometrial cancers show
positive staining (58% greater than grade 1) which is
higher than described by many workers for P.L.A.P. (Cadeau
et al 1974, Van Nagell et al 1981 and Nozawa et al 1981)
but is in accord with the findings of Doellgast and
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Homesley (1984). Expression of the ND0G2 determinant by
these tumours is not affected by their stage or differnen-
tiation as suggested by Kellen et al (1976) who found
that only stage la tumours produced P.L.A.P.. Interestingly
both samples of adenosquamous endometrial cancers showed
no reactive staining.
Relatively effective methods exist to follow up patients
with endometrial and cervical cancers, however, as had
been discussed in chapter 1, the situation is different
with ovarian cancer. This thesis has concentrated on methods,
based on the ND0G2 antibody, to assess the response of a
patient with ovarian cancer to therapy. Positive reactive
staining with ND0G2 was found in 65% of 56 malignant
ovarian tumours. This was noted predominantly in serous
cystadenocarcinomas and serous cystadenomas. The degree
of staining was not affected by the differentiation of the
tumour but heterogenicity of expression was noted between
primary and secondary tumours in the same patient. In
general, secondary tumours expressed this antigen to a
lesser degree than their primary and those cells that were
positive were present in clumps suggesting an origin from
a single cell (fig 3.9). This points to the presence of
more than one cell line in these tumours. The distribution
of the ND0G2 determinant has a very similar distribution,
in both normal and malignant gynaecological organs, to
that of another tumour associated antigen, CA 125 (Davies
et al 1985). However, this latter does not fix a P.L.A.P.
determinant (Bast et al 1985).
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From the distribution of the ND0G2 determinant in both
normal organs and ovarian cancer, P.L.A.P. would seem to
be a suitable potential tumour marker for this disease.
It is not truly tumour specific but a number of the normal
tissues that express it are either irrelevant (placenta)
or will usually have been removed at primary surgery
(fallopian tube, endometrium and cervix). Expression by
the thymus is minute which leaves the lung as the only
significant source of this antigen in healthy tissue.
Unfortunately this source proved to be a cause of false
positive results in the serum assays as cigarette smoking,
by a direct effect on lung, results in elevated serum
P.L.A.P..
Two workable assays were used to follow up patients with
ovarian cancer and of these assay 1 was the better
understood. This assay measured active P.L.A.P. and a
definite upper limit of normal was determined for this in
the healthy, non-smoking population. Assay 3 was less
satisfactory in that there was a huge variation of
expression between healthy individuals. The significance
of this has been discussed earlier and in section 4.6.4.
,e (ii). The lung was the most likely source of this
antigen as individual variation in reactive staining was
seen in the different samples examined.
Assay 3 proved the better assay in accurately predicting
the course of the disease, but there were 2 cases where
assay 2 proved superior (patients 22 and 23). In these
cases both of the assays initially agreed with each other
219
and the course of the disease, but then assay 3 fell
inappropriately. The reverse situation occured in 3 cases
(patients 12, 15 and 44), however, in these the rate of
increase of assay 3 slowed after the fall in assay 1
(fig 4.7). This, I think, tends to suggest the presence
of at least 2 separate cell lines in these cases, one
expressing active P.L.A.P. and the other expressing the
antigen referred to earlier.
Inappropriate falls in either or both assays were seen in
a total of 10 patients. In all cases an initially
increasing level reflecting tumour growth was followed by
a fall, although the tumour continued to grow. This could
be due to a changing cell population, perhaps reflecting
different sensitivities to chemotherapy.
In general the immunohistology of the tumour gave a good
guide as to who should be followed using these assays.
There were however exceptions. In one case (patient 2)
with a tumour of borderline malignancy, levels were never
elevated although this tumour showed grade 3 reactive
staining with NDOG2. This may be due to a property of
such tumours and in this context it is interesting to note
the normal levels of P.L.A.P. in preoperative serum samples
of patients with benign ovarian tumours. Pre and post
operative levels in assay 3 were the same in these cases
but all of these tumours had positive reactive staining
with ND0G2. In another 6 cases the immunohistology of
the tumour was a poor guide. In 2 such cases (patients 19
and 34) the assays were of poorer predictive value than
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might have been expected, possibly reflecting a changing
cell population or the lower potential for metastasis of
P.L.A.P. producing cells. The reverse situation occurred
in 3 cases (patients 21, 30 and 36),perhaps reflecting
unrepresentative tumour sampling as one or both assays
accurately reflected tumour load from before operation to
death.
R.I.S. was the other method of using NDOG2 to assess the
extent of this disease. In patients with ovarian cancer,
this technique appeared safe and at least as accurate as
C.T. or U.S.S. in detecting tumour deposits. The success
of R.I.S. depended firstly on the tumour expressing the
NDOG2 dterminant but also on a number of other factors.
Those tumour deposits in or close to areas of high
background activity, such as the para-aortic nodes and
liver, were not visualised; however in the latter case a
prolonged clearance time was noted. In order to remove
this background activity a subtraction technique was
performed as described in section 5.2.7. However, this
did not improve the sensitivity of the technique although
it did clarify areas of increased activity seen in the
unsubtracted images. It frequently proved impossible to
totally accurately reposition the patient for each set of
images and thus subtraction artefacts were generated.
Small intra-abdominal deposits were not visualised
(e.g. patient 9) unless numerous.
There were a number of false positive results which have
already been described (section 5.4.4), however two of
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these warrant further discussion. Uptake of free I
by gut mucosa occurred in 3 cases and proved impossible to
o o -1
stop regardless of which blocking agent was used. As
ovarian cancer frequently metastasises to the surface of
gut a situation could arise that would make the interpre¬
tation of some images difficult. A full bladder gave rise
to a false positive result in one case (patient 4) but
equally this could have masked a genuine deposit. It is
essential to ensure that the bladder is definitely empty
prior to each set of images.
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R.I.S. with I ND0G2 was a poor imaging technique in
the small number of patients imaged with disseminated
breast cancer. This is a tumour that expresses P.L.A.P.
but whose serum levels are often normal (McDicken et al
1983); in these cases there was no way of ensuring that
the tumours did express the ND0G2 determinant, perhaps
a reason for the disappointing results.
This thesis has described 2 methods of using the NDOG2
antibody to assess the response of a patient, with
ovarian cancer, to therapy. Both methods have their
share of false positive and false negative results but
there are many advantages in using ND0G2 in a serum assay
compared to its use in R.I.S.. The serum assays are less
time consuming for both operator and patient, cheap and
a large number of patients can be screened in a day. In
addition there are no potential hazards (e.g. allergic
reaction) to the patient. Admittedly the serum assay will
not localise the position of the tumour recurrence, but
in the case of ovarian cancer, this is largely irrelevant
to the patient's prognosis.
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However, R.I.S. does give information about the biodistri-
bution and tumour uptake of the antibody in vivo, which is
essential before antibody directed therapy can be considered.
This has not been performed using ND0G2 but some workers
have claimed at least short term success, using this treat¬
ment modality in ovarian cancer (Hammersmith Oncology
Group 1984).
The ND0G2 antibody only recognises a subpopulation of
cells in any one tumour and the response of this population
to chemotherapy may not be representative of the tumour
as a whole. Further work is being directed to the develop¬
ment of a panel of monoclonal antibodies in an attempt to
identify the various cell lines present in ovarian cancer
and to subsequently use these in antibodies serum assays
to follow up patients with this disease.
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